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Foreword 
 
 
 
Variability is probably the single word which better characterizes papillary thyroid carcinoma (PTC). 
Diagnostic subtleties in PTC and the multiple morphological variants of PTC can be a challenge to the 
Pathologist but can also constitute a source of confusion for the Clinician and his Patient whose expectations 
can be flawed by an unpredictable course of the disease.  
To avoid disproportionate treatments and surprising outcomes, an extra effort has been made to search for 
personalized management and treatment of patients with thyroid cancer, often based upon molecular findings 
frequently lacking a precise morphological and topographical characterization. The growing knowledge on 
the molecular profile of tumours has contributed to a deeper understanding of cancer biology; despite this, 
we disagree with those who announce the end of Surgical Pathology, relaying their faith into sophisticated 
molecular technologies with little or no input from the histopathological standpoint. 
Taking this into consideration, and using PTC as a model, we decided to characterize exhaustively from the 
clinico-pathological standpoint a series of cases with long term follow up which were screened for molecular 
alterations in the elements of the pro-proliferative mitogen-activated protein kinase pathway and for 
topographic differences in the expression of the elements of the growth suppressive Transforming growth 
factor-beta/Smad-dependent pathway. The series of PTCs was composed by cases of classic and follicular 
variant of PTC. The restriction of the analysis to these two variants, the most frequent after papillary 
microcarcinoma, was forced by the low number of available cases of less frequent variants, assuring also that 
the conclusions of the study would not be limited in their application to a marginal group of rare cases. In 
addition, we decided to consider tumour size as a continuous variable, without separating papillary 
microcarcinoma into a distinct category. This latter decision reflects the acknowledgment of the influence of 
time over cancer progression: the evaluation of the time factor and the disclosure of the hidden natural 
history configure, nowadays, major problems in cancer research. 
As a consequence of the limitations imposed by the availability of cases, our series of PTC included cases 
with lymph node metastases and cases without metastatic disease or recurrence, lacking a significant 
representation of cases with distant metastases and fatal cases. The evaluation of aggressiveness based upon 
lymph node metastases is debatable as lymph node metastases do not have an important impact over 
patients’ survival. Despite this, the occurrence of lymph node metastases is, beyond any doubt, a 
manifestation of malignancy (a condition that sometimes is not very obvious in PTC), an important cause of 
morbidity and a determinant of additional treatment. 
The series of PTC cases was selected from the Cancer Registry of the Pathology Department of Centro 
Hospitalar de São João after reviewing all filed cases of thyroid tumours. The results of this review allowed 
also the identification of a set of problems that may provide clues to future studies oriented to the 
understanding of PTC biology. Part of this series and some of the identified problems are being studied by 
the Consortium composed by Centro Hospitalar de São João, IPATIMUP and Instituto Português de 
Oncologia Francisco Gentil do Porto within the project “Identificação de fatores prognósticos e de seleção 
terapêutica em carcinomas diferenciados da tireoide” sponsored by Calouste Gulbenkian Foundation. 
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I.1 Thyroid: from the first stages of development until the senescent morphological and functional 
tissue 
 
The thyroid gland is an endocrine organ located in the neck that is responsible for the production and 
controlled release of thyroid hormones. The thyroid hormones are essential to fetal development and 
regulation of many metabolic processes. 
The thyroid median primordium derives from the endoderm and appears at the foramen cecum of the tongue 
by the 26th day of fetal life [1]. From this cephalic location, the median primordium, descends to its final 
position anteriorly to the 2nd- 4th traqueal ring and expands laterally to form the lateral lobes [2]. At this 
stage, by the 9th- 10th week of fetal life, the thyroid parenchyma is organized into solid and trabecular 
structures with small lumina where thyroglobulin positive colloid starts to be produced [2]. The well-formed 
follicles that constitute the functional units of the thyroid appear two weeks later [2]. The follicles are 
composed by cuboid follicular cells that face a colloid filled lumen and are surrounded by a basement 
membrane. 
Concurrently, at 6th-7th week of fetal life, the two thyroid lateral primordia derived from the ultimobranchial 
bodies (IVth -Vth branchial pouch complex) are integrated in the lateral lobes of the thyroid carrying the 
neural crest derived C cells and the endoderm derived main cells [1,2]. The C cells are neuroendocrine cells 
responsible for the production of calcitonin – a protein involved in the phospho-calcium homeostasis – and 
are difficult to distinguish from follicular cells as they often integrate the follicles. The main cells can be 
detected in nearly 78% of fetal thyroids, under the appearance of isolated cells or nests [3] – the so called 
solid cell nests. The solid cell nests are normal elements of the adult thyroid occurring in up to 68% of adult 
thyroids [4] that can harbor C cells together with the main cells. The solid cell nests can become hyperplastic 
[5] and are thought to represent nests of putative thyroid stem cells [6]. Other intra-thyroid tissues, 
presumably of branchial pouch origin, include islands of mature cartilage and ectopic thymus, parathyroid 
and salivary gland [7-9]. 
The normal adult thyroid with all its components is organized in lobules separated by fibrous septa 
conveying nervous bundles and vessels, including a rich lymphatic network that coalesce in the peri-thyroid 
soft tissue condensation and drain to cervical and mediastinic lymph nodes. 
The follicular cell, under a hostile environment like a chronic inflammatory setting, and/or in senescent 
status, may acquire particular phenotypes. Examples of these particular phenotypes include the oncocytic 
transformation and the squamous and ductal metaplasia of the follicular epithelium [10]. The oncocytic 
phenotype results from the accumulation of cytoplasmatic mitochondria and can occur in benign and 
malignant tumour cells [11]. Similarly, with age, the colloid tends to coalesce in globular formations and to 
accumulate calcium oxalate crystals. 
 
 
I.2 Papillary thyroid carcinoma (PTC) and related thyroid diseases  
I.2.1 PTC 
 
Only a small percentage of the very common thyroid diseases are malignant. Clinically evident thyroid 
cancer accounts for approximately 1% of all malignant tumours in developed countries [12] and for about 
2% in Portugal [13, 14]. In the USA, for instance, the incidence of thyroid cancer is ~9/100 000 per year 
[15]. The incidence rate of thyroid cancer have been increasing over the last years in most countries 
including Portugal (TableI.1), while the mortality rates due to these tumours has decreased [12, 14]. 
The number of new cases of papillary thyroid carcinoma (PTC) per year increased 56% in Portugal, from 
2001 to 2005 [13, 14, 16, 17] and, nowadays, represents 80 to 90% of all thyroid cancers [14].  PTC is the 
most frequent endocrine malignancy, even in the pediatric group [12].  
Although it can occur in a wide range of ages, PTC is more frequent in women in the 5th-6th decade of life 
[12], predominantly as a sporadic disease, with only 5% of cases developing in a familial setting [18]. 
Linkage studies suggest that familial PTC is a heterogeneous disorder caused by more than one susceptibility 
gene [19, 20]. Regarding the influence of environmental factors, the exposure to radiation in general and to 
radioactive iodine in particular appears to be the most closely related to the occurrence of PTC, as it is 
illustrated by the striking incidence in children exposed to radioactive fallout [21]. The relative frequency of 
 26 
 
PTC is also greater in regions of adequate or high dietary iodine intake compared to regions of iodine 
deficiency [12]. 
 
 
 
 
 
 
 
 
 
PTC usually presents as a cold nodule or mass in the thyroid or as a cervical adenopathy. Additionally, 
numerous clinically silent, incidentally found PTCs are detected in image studies of the neck performed by 
other reasons, at autopsy and in surgically removed glands for benign conditions [12, 22]. 
In the preoperative setting, the ultrasound examination of the thyroid nodule followed by fine-needle 
aspiration biopsy (FNAB) constitute the most effective procedure to diagnose PTC and to separate it from 
benign thyroid nodules which do not need surgery [23]. In reference centers, the diagnostic accuracy of 
FNAB reaches 90% [24]. 
In the surgical specimen, PTC may assume the appearance of an infiltrative whitish mass or mimic a 
follicular adenoma (FA) with a well circumscribed, often encapsulated, periphery. Moreover, PTCs can be 
multicentric and are often very small, becoming difficult to identify. 
Together with follicular thyroid carcinoma (FTC), PTC forms the group of the well differentiated thyroid 
carcinomas disclosing follicular cell differentiation [12]. The diagnosis of PTC relies on the distinctive 
nuclear features of tumour cells that include enlargement, elongation and overlapping, clear-empty 
appearance, contours irregularity, prominence of grooves and nuclear pseudo-inclusions. The determinant 
nature of these nuclear features underlies the success of the cytological diagnosis in FNAB.  
The architectural organization of PTC is variable as is illustrated by the 16 variants recognized by the World 
Health Organization (WHO) in 2004 [12]. If one excludes the incidentally found papillary microcarcinomas 
which by definition measures less than 1cm, the classic PTC (CPTC) and the follicular variant of PTC 
(FVPTC) are the most frequently diagnosed variants [12]. CPTC and FVPTC present distinct cyto-
architectural features [12], distinct molecular alterations [25-27] and distinct biological/clinical behaviour 
[25, 28, 29] (see below). CPTC discloses, predominantly, an infiltrative often multicentric growth pattern, a 
papillary or mixed papillary/follicular architecture together with occasional cystic formations and 
psammoma bodies, while FVPTC presents a variable growth pattern and a monotonous follicular/trabecular 
architecture that may be composed by medium or large size follicles (see below). 
The majority of CPTC and FVPTC cases evolve favourably, and the patients have a 10-year survival up to 
98% [1, 30]. Despite the generally good prognosis, PTCs may give rise to recurrences as well as to lymph 
node and distant metastases, sometimes many years after diagnosis [31]. 
The most frequent molecular alterations detected in PTC occur in mitogenic-activated protein kinase 
(MAPK) pathway elements and include BRAF and RAS mutations, and RET/PTC and NTRK rearrangements 
[12, 32]. 
 
I.2.2 Benign and malignant diseases related to PTC 
 
PTC related inflammatory diseases include Hashimoto thyroiditis and Graves’ disease that are autoimmune 
disorders afflicting predominantly middle age women. 
Hashimoto thyroiditis is a disease characterized by the production of auto-antibodies against thyroglobulin 
and other follicular cell antigens [1]. Morphological features of Hashimoto thyroiditis include extensive 
lymphocytic infiltration of the thyroid with germinal center formation and oncocytic transformation of the 
follicular epithelium. “Complications” of Hashimoto thyroiditis include lymphoma [33] and PTC [34]. It has 
been suggested that Hashimoto thyroiditis represents a precursor stage of PTC [35] due to the occurrence of 
scattered PTC-type nuclei and RET/PTC translocations in Hashimoto thyroiditis [36]. The probable 
passenger nature of RET/PTC translocations [37] and the absence of BRAF mutations in Hashimoto 
thyroiditis [38] argue against the possibility of Hashimoto thyroiditis play a major role in PTC occurrence. 
Graves’ disease is characterized by the production of auto-antibodies against specific domains of the thyroid 
Table I.1 Incidence rates of thyroid cancer per 100 000 habitants in Portugal (A) and , specifically, in the 
North of Portugal (B)[13, 14, 16, 17] 
 
Year 2001 Year 2005 
Males Females Total Males Females Total 
A 2.5 10.5 6.6 4.0 15.4 9.9 
B 2.7 14.4 8.8 5.7 24.1 15.2 
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stimulating hormone receptor [1]. Morphologic features of Graves’ disease include hyperplastic follicles 
with prominent papillary formations that may be difficult to distinguish from PTC.  Although well 
established in Hashimoto thyroiditis, the increased incidence of PTC in patients with Graves’ disease is still 
debatable [1].  
The papillary aspect of the follicular epithelium can also occur in nodular goiter and be confused with 
concurrent and incidental PTC. 
Follicular adenoma (FA) is defined as a benign encapsulated tumour that shows evidence of follicular 
differentiation and lacks capsular and/or vascular invasion and nuclear features typical of PTC [12]. If PTC 
nuclear features occur focally or are doubtful, the differential diagnosis between benign and malignant 
tumour can be very difficult. In this situation, it may be advisable to classify the lesion as well differentiated 
tumour of uncertain malignant potential [12, 39]. The FA diagnostic is one of exclusion and therefore it is 
difficult to make in a precise manner without the recommended complete analysis of the tumour capsule. 
This turns impossible its diagnosis at the preoperative setting (FNAB) and very difficult in most frozen 
section examinations. An encapsulated follicular tumour with images of capsular and/or vascular invasion 
but without nuclear features typical of PTC is a follicular carcinoma (FTC) [12]. Whenever the PTC 
nuclear features are focal or doubtful in an encapsulated and clearly invasive tumour, the designation of well 
differentiated carcinoma - not otherwise specified is advised [12, 39]. Nowadays, FTC accounts for less 
than 5-10% of the clinically evident thyroid carcinomas [40, 41], occurring mainly in females at the 5th-6th 
decades of life and rarely in childhood. FTC may be associated to low iodine intake [42] or to a history of 
nodular goiter, in some cases developed under a genetic background [43]. In FTC, the development of 
multicentricity and regional lymph node metastases are much less frequent than in PTC, while blood borne 
metastases to lungs and bones occur mainly in widely invasive and angio-invasive FTC [44]. Widely 
invasive FTC may be morphologically difficult to distinguish from poorly differentiated thyroid carcinoma 
(PDTC), both carrying a long term mortality approaching 50%. On the other hand, minimally invasive, non 
angio-invasive FTC may be difficult to distinguish from FA and carries very low long term mortality [12, 
45]. If one cannot separate FTC from FA, the use of the follicular tumour of uncertain malignant 
potential designation is advisable [12, 39].  It is useless to search for molecular biomarkers in this setting, as 
some molecular features such as chromosome instability [46, 47], RAS mutations [48] and 
PAX8/PPARgamma [49] can be detected in both FTC and FA. Most of these molecular alterations are also 
shared by the FVPTC [48, 50]. As stated above, whenever encapsulated, the FVPTC can also be very 
difficult to distinguish from minimally invasive FTC, as the morphologic criteria depend only in the 
appreciation of the subjective PTC nuclear features [12]. The widespread and occasionally not precise 
utilization of the so-called nuclear criteria for diagnosing PTC is contributing to the decreasing incidence of 
FTC and to the increased incidence of FVPTC since it’s the recognition as an entity [1, 12, 41]. 
Poorly differentiated carcinoma (PDTC) and anaplastic/undifferentiated thyroid carcinoma 
(ATC/UTC) are tumours with a poor and very poor prognosis, respectively. These carcinomas are thought to 
arise from well differentiated carcinomas, PTC and FTC [12, 51]. This assumption is based upon the 
frequent recognition of a well differentiated tumour component within or in contiguity with PDTC and 
ATC/UTC. ATC/UTC tends to occur in old patients and typically have p53 mutations. Both PDTC and 
ATC/UTC share molecular alterations with PTC (e.g BRAF and RAS mutations) and with FTC (e.g RAS 
mutations)[51,52]. 
PTC can exceptionally coexist with other common and rare tumours of the thyroid, including medullary 
thyroid carcinoma (the malignant C cell neoplasm) [53], mucoepidermoid carcinoma [54] and squamous 
cell carcinoma [55]. 
 
I.3 PTC: in the limits of morphology 
 
I.3.1 Clinico-pathological features related to aggressiveness 
 
There are several clinical and/or morphological features of PTC that have been frequently, though not 
always, associated to a less favourable prognosis, namely advanced age at time of diagnosis [29, 31, 56], 
male gender [31], tumour size above 1 cm [29, 57], extra-thyroid extension [29, 56, 58, 59], multicentricity 
[29], absence of total encapsulation [29, 58, 60], vascular invasion [29] and distant metastases [29, 56]. The 
presence of lymph node metastases is not fully accepted as a prognostic factor, and it is not associated to an 
increased mortality rate despite being determinant for the type of surgical approach and radioactive iodine 
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therapy [29, 56]. Whenever lymph node metastases are found at presentation they are predictive of an 
increased risk of subsequent loco-regional recurrence [61]. 
The acknowledgement of the aforementioned clinico-pathological prognostic factors led to several staging or 
scoring systems. These systems provide good, and frequently, quite equivalent prognostic information [62] 
(Table I.2). Unfortunately, based upon the scores built with these systems, 15% of tumour recurrences and 
over 10% of cancer deaths occur in patients with carcinomas initially classified as low risk [63, 64]. 
One of the most controversial items considered in some of these systems is tumour grading. Akslen and 
LiVolsi [65, 66] have established a grading score for PTC that highlighted, for the first time, the importance 
of vascular invasion together with nuclear atypia and tumour necrosis [65, 66]. Nowadays, the tumour 
grading is epitomized by the recognition that many high grade carcinomas actually correspond to PDTCs 
[51, 67].  
 
 
Part of the controversies on the prognostic value of the above mentioned features reflects the variable 
composition of the different series. This holds particularly true regarding the relative proportion of CPTC 
and FVPTC in general, and of the encapsulated subtype of FVPTC in particular [60, 74].Most cases of CPTC 
are poorly circumscribed, display a peripheral invasive front and give frequently rise to lymph node 
metastases, whereas cases of FVPTC are frequently encapsulated [12]. In the absence of unequivocal signs 
of capsular or vascular invasion, encapsulated FVPTCs follow an extremely benign course [60].  There is 
also a relatively frequent poorly circumscribed/ infiltrative subtype of FVPTC that, like CPTC, is prone to 
give rise to lymph node metastases [25, 75] (see below). 
It is also acknowledged that other histological variants of PTC display relative specific patterns of 
invasiveness and metastisation [12]. For instance, the diffuse sclerosing variant and the diffuse/multinodular 
subtype of FVPTC that occur in young patients, frequently metastasize both to regional lymph vessels and to 
distant organs, and respond to radioactive iodine therapy [76-79]. These variants should be separated, for 
prognosis and therapy prediction, from the locally aggressive tall cell and columnar cell variants of PTC 
which occur in elderly patients and respond poorly to radioactive iodine therapy [76, 77, 80, 81]. 
 
I.3.2 Vessels and metastatic pattern 
 
One of the reasons that justify the attempts to distinguish PTC from FTC relies on the different preferential 
routes of metastatic spread associated with these two thyroid cancer histotypes [12]. While PTC have a 
tendency to give rise to lymph node metastases via lymphatic vessels, FTC metastasize mainly via blood 
vessels to lungs and bones [1, 12, 82]. 
Although traditionally included in the PTC group [12], the FVPTC encompasses a subtype of encapsulated 
tumours which tend to share features with both CPTC and FTC [25, 28, 75]. Besides the rare and aggressive 
diffuse/multinodular subtype of FVPTC [79], cases of FVPTC may be classified according to their peripheral 
Table I.2 Some of the clinico-pathological staging/scoring systems used in the evaluation of PTC prognosis. 
Prognostic variable 
Patient factors Tumour factors Surgical factors 
Age Gender Size Grade DNA 
ploidy 
Extra-thyroid 
extension 
Distant 
metastases 
Incomplete 
resection 
Staging/scoring system 
EORTC[68] 
Byar et al, 1979 + + - - - + + - 
AGES[69] 
Hay et al, 1987 + - + + - + + - 
AMES[70] 
Cady et al, 1988 + + + - - + + - 
DAMES[71] 
Pasieka et al, 1992 + + + - + + + - 
MACIS[72] 
Hay et al, 1993 + - + - - + + + 
SAG[65] 
Akslen, 1993 + + - + - - - - 
TNM 7th edition[73] 
Brierley et al, 2009 + - + - - + + - 
+ factor included in the score, - factor not included in the score 
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growth pattern in two categories: infiltrative (or poorly circumscribed) subtype (PC-FVPTC) and 
encapsulated subtype (E-FVPTC) [75]. The PC-FVPTCs share most of the morphological features of CPTC, 
give frequently rise to lymph node metastases and disclose BRAF V600E mutation in 26% of the cases [26, 
75], whereas the E-FVPTCs seem morphologically related to FA and minimally invasive FTC, often disclose 
RAS mutations and PAX8/PPARgama rearrangements [26, 48, 83] and follow an extremely benign course in 
the absence of unequivocal signs of capsular or vascular invasion [45, 60]. In the presence of vascular 
invasion, the E-FVPTCs tend to give rise, like FTC, to blood borne metastases [75, 79, 84]. 
The peculiar metastatic properties of the FVPTC subtypes are not fully understood and may be related to 
angiogenesis. Several groups have reported an increased expression of factors promoting the formation of 
new blood vessels (hemangiogenesis) in PTC in comparison with normal thyroid tissue [85, 86]; such factors 
are variably correlated with tumour size [86, 87], increased microvessel count using CD31 [88], increased 
risk of recurrence and decreased disease free survival [87, 89]. 
The expression of lymphangiogenic factors (vascular endothelial growth factor-C and vascular endothelial 
growth factor-D) appears to be increased in PTC in comparison with normal thyroid tissue [85, 86, 90, 91], 
benign lesions [85, 86, 90, 91] and FTC [92]. The increased expression of lymphangiogenic factors in PTC is 
related with increased intratumoural and peritumoural lymph vessel density (LVD) [90, 91, 93]. The 
association between the expression of lymphangiogenic factors in PTC and the occurrence of lymph node 
metastases was observed by some groups [86, 91, 93-95] whereas others did not detect such association [85, 
90]. 
In the past, the endothelial markers used to identify vessels, like factor VIII, CD31, CD34 and von 
Willebrand factor, highlighted both lymphatic and blood vessels [87, 88, 96-99]. The situation has changed 
with the finding of lymphatic vessel specific immunomarkers [100, 101], that have been used to determine 
the intratumoural and the peritumoural LVD in several thyroid tumour types. The best known of these 
lymphatic endothelium specific markers are the D2-40 (podoplanin) [81, 90, 102, 103], the LYVE-1 (lymph 
vessel endothelial hyaluronan receptor) [85, 102, 104] and the VEGFR-3 (Vascular endothelial growth factor 
receptor-3) [91, 93, 94].  
Intratumoural LVD has been found to be higher in PTC than in FA [85, 90], and higher in FVPTC than in 
FA or FTC [103]. Some authors reported an association between increased PTC intratumoural LVD and 
male gender [104], multifocal disease [104], invasiveness [94] and occurrence of lymph node metastases [91, 
93, 94, 104], in contrast to other groups that did not find any association between PTC intratumoural LVD 
and the above mentioned features [85, 90]. 
The values for peritumoural LVD were similar in PTC, FTC and FA in the series of Giorgadze et al [103], 
while in the series of Garcia et al [90] FTC cases disclosed higher peritumoural LVD than PTC. There are 
also conflicting results regarding the association between PTC peritumoural LVD and the occurrence of 
lymph node metastases [90, 93]. 
 
I.4 PTC: beyond morphology 
 
I.4.1 Transforming growth factor-beta (TGF-beta) and the Smad-dependent pathway 
 
The infiltrative growth pattern of most non encapsulated forms of PTC is mainly the result of increased 
motility and tumour cells’ invasiveness [105, 106, 107], which are features related to the so called epithelial-
to-mesenchymal transition (EMT). At PTC´s infiltrative periphery, the neoplastic cells display loss of 
polarity/cohesiveness [107], decreased expression of beta-catenin and E-cadherin at the cell membrane 
[108], increased nuclear expression of STAT3 [Couto et al, unpublished results], increased cytoplasmatic 
expression of vimentin [107], fibronectin 1[105], met [109], ret [110], cytokeratin 5/6 [111] and of galectin-3 
[112], and increased nuclear expression of cyclin D1[113]. 
The above mentioned alterations at the infiltrative edge of the tumours reflect probably the cross-talk 
between tumour cells and cellular and non-cellular elements of the stroma, in part mediated by integrin-
related epithelial-to-stromal connections which are enhanced at PTC´s periphery [114]. Dendritic cells were 
found to be located at the tumour´s invasion edge in a small series of PTC [115] and, together with 
lymphocytes, appear to be decreased in PTCs with distant metastases [116], while increased density of 
tumour-associated macrophages in poorly differentiated carcinomas correlate with invasion and decreased 
survival [117]. 
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EMT is partially regulated by Transforming growth factor-beta (TGF-beta) in PTC cell lines [118-121] 
and in animal models [122]. TGF-beta is one of the members of the TGF-beta superfamily and occurs in 3 
isoforms – TGF-beta1, TGF-beta2 and TGF-beta3 – that function via the same membrane receptor signaling 
system [123].  In TGF-beta/Smad-dependent pathway, the activated TGF-beta receptor complex propagates 
the signal inside the cell through the phosphorylation of receptor regulated Smad2 and Smad3 downstream 
proteins localized in the cytoplasm [123-125]. Phosphorylated Smad2 and Smad3 form heteromeric 
complexes with Smad4 and re-localize to the nucleus where they regulate gene transcription [123-125]. 
Inhibitory Smad7 acts in an opposite manner and antagonizes TGF-beta/Smad-dependent signaling, 
inducing TGF-beta receptor degradation and thus preventing Smad2 and Smad3 phosphorylation [124, 125]. 
TGF-beta/Smad-dependent pathway activation induces major growth suppressive effects on epithelial cells 
in general [125], and on animal [126-128] and human [129, 130] thyroid cell lines, as well as on some PTC 
cell lines [118, 121], in particular. TGF-beta is also related with inhibition of migration and invasiveness in 
some PTC cell lines [118].  
The expression of TGF-beta, Smad2, Smad3, and Smad7 has been detected in multinodular goiters [131-133] 
and in FAs of some series [133, 134], but not in other series of thyroid lesions where TGF-beta was the only 
element searched for [135].  
In tumours, TGF-beta expression has been detected in 52-100% of PTC cases [131, 133-136] and, whenever 
specifically studied at the tumour´s periphery, was associated to the occurrence of extra-thyroid extension 
and lymph node metastases [119]. Similarly, phosphorylated Smad2/Smad3 (P-Smad2/3), has been detected 
in every case of PTC [133], while Smad4 is expressed in 75% of PTC cases [133] and in every PTC cell line 
[137, 138]. Smad7 expression has been detected in 80% of PTCs and in PTC cell lines [133, 137] 
In tumour cells, particularly when exhibiting an EMT phenotype characterized by prominent mesenchymal-
type features [105], the response to TGF-beta growth suppressive effect can be partially or totally abrogated 
via interferences in the signaling pathways that mediate its action [119, 122, 105, 139-141]. TGF-beta anti-
proliferative effects were reported as attenuated in cases of multinodular goiter [141] and ATC/UTC cell 
lines [142], as well as in rat thyroid cell lines [143]. At the EMT, the TGF-beta altered cell response has been 
associated to the development of pro-oncogenic effects, namely through the inhibition of cell adhesion and 
enhancement of motility [125, 144].  
Besides playing a functional role in tumour cell migration, invasion and EMT in vitro, TGF-beta and high 
TGF-beta/Smad-dependent pathway activity are associated with invasion, nodal metastization and BRAF 
mutation in PTCs [119].  
It has been reported that oncogenic BRAF stimulates TGF-beta secretion in vitro [119]. BRAF is thought to 
play a major role in extracellular matrix remodeling [144] and is required for TGF-beta-induced EMT during 
progression from PTC to poorly differentiated carcinoma in an animal model [122]. It has also been shown 
that BRAF suppresses the expression of E-cadherin, which is a typical finding at the infiltrative edge of 
poorly circumscribed PTCs, and that this effect can be abrogated with both TGF-beta and MAPK inhibitors 
[119]. 
 
I.4.2 BRAF, RAS and the mitogen-activated protein kinase (MAPK) pathway  
 
BRAF and RAS proto-oncogene point mutations are two of the most common structural genetic alterations in 
PTC. Other genetic alterations also leading to activation of the intra-cellular mitogen-activated protein kinase 
(MAPK) pathway are the chromosomal rearrangements of receptor tyrosine kinase genes (RET and 
NTRK)[12].  
The activation of the MAPK pathway has been implicated in the regulation of transcription factors that 
control genes related to cell proliferation, differentiation and survival [145]. 
The BRAF gene codifies a protein from the serine-treonin family that is a critical effector of the MAPK 
pathway [32]. The most frequent activating BRAF mutation results from the transversion of a thymine to an 
adenine at nucleotide 1799 in exon 15, substituting a valine for a glutamic acid at codon 600 
(V600E)[146, 147]. Besides V600E which occurs in nearly 90% of BRAF mutated thyroid cancers, other rare 
mutations and even some rare rearrangements have been described [147].  
BRAF mutations have been detected in 7% to 83% of PTC [26, 27, 32, 48, 52, 56, 58, 74, 146-153]. 
The detection of the V600E mutation in FNAB specimens is a powerful adjunct for the diagnosis of PTC and 
has increased the specificity of PTC cytological diagnosis to almost 100% [154-156]  but, unfortunately, the 
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sensitivity of such detection remains low due to the high percentage of non BRAF mutated PTCs [59, 147, 
157].  
The preoperative prognostic value of BRAF mutation detection in PTC remains controversial [58, 155, 158] 
partly reflecting the variable composition of the different series. BRAF mutations are present in 40-54% of 
CPTC [52, 74, 146, 151, 153] and in 7-29% of FVPTC [26, 48, 52, 74, 151, 153]. 
BRAF mutations have been associated to the classic PTC phenotype [52, 74, 151], advanced age at time of 
diagnosis [52, 56, 74], male gender[152], tumour size above 1cm [153], extra-thyroid extension[52, 154, 
159], absence of total encapsulation [26, 154], vascular invasion[56], lymph node metastases [58, 149, 150], 
distant metastases [150], recurrence [154] and higher tumour stages [56, 150]. Basolo et al [59] have shown 
that in small PTC´s there is a significant association between the presence of BRAF mutation and tumour 
invasiveness and nodal metastization [59]. 
The most important argument against the value of the preoperative detection of the BRAF mutation stems 
from the relative high percentage of mutated papillary microcarcinomas that have an excellent prognosis [57, 
58, 158] even if some of them tend to be locally infiltrative and carry a high rate of lymph node metastases 
[58, 59, 155, 160].   
The practical value of the BRAF V600E detection for therapeutic purposes in metastatic follicular cell 
derived carcinomas with down regulation of sodium-iodine symporter and thyroid peroxidase that frequently 
cease to respond to radioactive iodine is very promising[156, 158, 161].  
RAS proto-oncogenes (H-RAS, K-RAS and N-RAS) are key regulators of growth and differentiation that also 
play a role in the canonic MAPK pathway [32]. Point mutations of the GTP domain are the most frequent 
mechanism of oncogenic activation of RAS. In the setting of PTC, the most frequent alteration of this group 
of proto-oncogenes is the activating N-RAS mutation at codon 61 of exon 2 (Q61R) [162, 163]. 
In thyroid tumours, RAS mutations are more frequent in FA and FTC [1] and occur in 0 to 43% of PTC [26, 
27, 32, 48, 83, 162, 163], more often in FVPTC (25-43%) [26, 27, 48, 83] than in CPTC (0-23%) [27, 48, 83, 
162]. 
RAS mutations have been associated to large tumour size [48], encapsulation [26, 84, 159], vascular invasion 
[83], extra-thyroid extension [159], poorly differentiated areas [83] and low rate of lymph node metastases 
[83, 159]. BRAF and RAS mutations appear to be alternative events in PTC [148]. 
The proto-oncogene RET codifies a tyrosine-kinase receptor that is located at the cell membrane and is also 
implicated in the activation of the MAPK pathway [32]. The oncogenic rearrangements RET/PTC (more 
often RET/PTC1 and RET/PTC3) are the result of double stands breaks in DNA of chromosome 10. The 
incidence of RET/PTC rearrangements is 60% in PTCs of children and young patients (much higher than in 
adults), reaching 80% in patients with PTC developed in the setting of nuclear fallout [164]. 
The NTRK gene codifies a high affinity receptor that triggers the activation of MAPK pathway and can be 
constitutively activated after rearrangements with other genes. NTRK rearrangements occur in less than 10% 
of PTCs [12]. 
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The biological and clinical behaviour of PTC is extremely variable and is still difficult to predict. The 
numerous clinico-pathological and molecular factors with putative but not definitive interest to the 
management of patients with PTC is one of the two reasons that justify the difficulties of the Pathologist for 
writing a pathological report and the doubts of the Clinician about its interpretation. The second reason 
emerges from the impact of immunohistochemical and molecular factors over the fragile diagnostic criteria 
of malignancy, which are starting to interfere with the established classification of thyroid tumours. 
The aims of this Thesis reflect the clinico-pathological inspiration of the work and spring from the two 
reasons mentioned above. 
 
 
Structural aim 
 
 To review all cases of thyroid tumours filed in the Cancer Registry of the Pathology 
Department of Centro Hospitalar de São João. 
 
 
Specific aims 
 
First specific aim  To evaluate the relative contribution of the clinico-pathological features of 
the tumours and of their molecular profiles to the development of PTC 
aggressive behaviour. 
 
Second specific aim To identify genetic and epigenetic alterations of PTC that may be used as 
biomarkers of invasion and metastization in the daily practice of diagnostic 
Anatomic Pathology. 
 
 
To achieve the structural aim we addressed the following problems:  
 
 
1. Selection of a representative series of PTC cases. 
 
2. Identification of problems in thyroid cancer diagnosis and prognosis that should be approached in 
future studies. A particular interest was devoted to the neoplastic components coexistent with PTC 
with influence over the patients’ outcome. 
 
 
To achieve the first specific aim we addressed the following problems:  
 
 
1. Clarification of the differential contribution of the clinico-pathological features to the development 
of lymph node metastases in classic PTC (CPTC) and follicular variant of PTC (FVPTC). The role 
played by intratumoural and peritumoural lymph vessel density was particularly addressed. 
 
2. Clarification of the differential contribution of BRAF (V600E) and N-RAS (Q61R) mutations to the 
development of lymph node metastases in CPTC and FVPTC, and of the association of such 
mutations to other clinico-pathological features. 
 
3. Clarification of the morphological and molecular basis underlying the differences in the biological 
and clinical behaviour of encapsulated FVPTC (E-FVPTC) and poorly circumscribed FVPTC (PC-
FVPTC).   
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To achieve the second specific aim we addressed the following problems: 
 
 
1. Disclosure of the relationship between the expressions of TGF-beta, phosphorylated Smad2/Smad3, 
Smad4 and inhibitory Smad7 and some clinico-pathological features associated to PTC 
aggressiveness. 
 
2. Disclosure of the topographic differences of TGF-beta expression in CPTC and FVPTC cases with 
and without genetic alterations. 
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III.1 Identification of the thyroid tumours filed in the Cancer Registry of the Pathology Department of 
Centro Hospitalar de São João 
 
The first step in the identification of all cases of thyroid tumours (malignant tumours and tumours of 
uncertain malignant potential) filed in the Cancer Registry of the Pathology Department of Centro Hospitalar 
de São João, was the gathering of the pathology reports and the slides of the cases. All thyroid tumours 
submitted to histological examination were identified from 1978 to 2006 (29 years). Clinical data were 
collected from the reports and further complemented with the available follow up data retrieved from the 
clinical files of each patient. The available survival data were unfortunately, largely incomplete. All available 
slides, corresponding to 75% of the recorded cases, were reviewed and the major tumour of each case was 
classified according to the 2004 WHO criteria [12]. 
 
III.2 Selection of a representative series of PTC cases 
 
A representative series of 75 PTC cases, including a group of 42 CPTCs and a group of 33 FVPTCs, was 
selected from the cases previously retrieved from the Cancer Registry of the Pathology Department of Centro 
Hospitalar de São João.  
All recorded PTCs with papillary and/or follicular architecture and available filed material were considered 
for selection. The slides were reviewed independently by two pathologists (CE and MSS) and the tumours 
were classified as CPTC and FVPTC, irrespective of size. The cases with doubtful PTC features, with 
features typical of other PTC variants and/or with unknown follow up were excluded.  
Both groups integrated cases with lymph node metastases (+M), together or not with distant metastases, and 
cases without metastases and long term follow up (-M). The PTC-M subgroup included all the CPTC and 
FVPTC cases with at least 10 years of follow up and image examination and/or cytological data confirmative 
of the absence of metastases in the lymph nodes, lungs and bones. The PTC+M subgroup included more 
recent cases of CPTC and FVPTC with available material representative of the tumour and of its lymph node 
metastases that were either present at the time of surgery or developed during follow up. Three cases 
disclosed, together with lymph node metastases, lung metastases detected in image studies.   
None of the patients of the PTC+M subgroup died from the disease (this information has limited value due to 
the short follow up of most of the cases).  
 
III.2.1 Tumour samples and pathological classification 
 
All samples had been fixed in formalin and included in paraffin. A paraffin block representative of the 
tumour and adjacent non tumoural tissue of each case was selected. 
All the tumours with papillary pattern in over 5% of the tumour sampled area were classified as CPTC, 
whereas those tumours with a predominant follicular pattern and papillary pattern in 5% or less of the tumour 
sampled area were classified as FVPTC. Small tumours with 1cm or less in diameter were also classified 
according to their growth pattern as CPTC or FVPTC.  
Well circumscribed tumours (WC-PTC) were those with expansive growth pattern without a well formed 
capsule or limited by a capsule with no or minimal invasion, and infiltrative/poorly circumscribed tumours 
(PC-PTC) were those with infiltrative growth pattern or with a widely invaded capsule. The designation of 
encapsulated tumour was exclusively applied to FVPTCs totally limited by a usually thin capsule with no or 
minimal invasion (E-FVPTC). Under the designation of multicentricity, all multifocal lesions, regardless of 
representing multicentric tumours or intra-thyroidal disseminated carcinomas, were included. Extra-thyroid 
extension was considered to be present whenever macroscopic extra-thyroid extension was observed. Lymph 
vessel invasion was considered to be present whenever at least one image of unequivocal invasion of a 
lymph vessel was observed. Venous invasion, from here foreword designated vascular invasion, was 
considered to be present whenever at least one image of unequivocal venous vessel invasion was observed. 
The presence of oncocytic cells was considered whenever they accounted for more than 10% of the tumour 
cells.  
The clinical and available follow up data, together with the pathological features of the tumoural and non 
tumoural thyroid tissue of each case, were registered in an informatic supported database. 
The analyses of the tumour samples performed in this study were authorized by the Ethics Committee of 
Centro Hospitalar de São João. 
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III.3 Immunohistochemical analysis 
 
The selected series of 75 PTC cases was studied by immunohistochemistry. 
Immunohistochemical staining was performed using streptovidin-biotin technique. Sections of 2µm 
thickness were cut from the selected paraffin blocks and placed on coated slides. The slides were dried, 
deparaffinized in Clear Rite (Richard - Allan, Thermo Scientific) and hydrated in sequential gradients of 
ethanol. For antigen retrieval, sections were immersed in 10mM sodium citrate buffer, pH 6.0 and then 
heated for 15 minutes. Endogenous peroxidase was blocked with 3% hydrogen peroxidase in methanol 
(Panreac) for 10 minutes in humid chamber and then Avidin blocking and Biotin blocking was performed 
(Lab Vision, Thermo Scientific). In order to block unspecific bounding to hydrophobic epitopes, the sections 
were immersed in Ultra V Block (Lab Vision, Thermo Scientific) for 10 minutes at room temperature. Slides 
were incubated overnight at 4ºC with the following primary antibodies: 
 
• D2-40 monoclonal antibody in a 1:25 dilution (D2-40, Signet Laboratories, Dedham, MA, USA) 
• TGF-beta1/2 rabbit polyclonal antibody (from here foreword designated as TGF-beta) in a 1:50 
dilution (TGF-beta1(V), Santa Cruz Biotechnology, CA) against a peptide in the C-terminus of 
precursor and mature human TGF-beta1 and TGF-beta2 ligands 
• P-Smad2/3 rabbit polyclonal antibody in a 1:100 dilution (P-Smad2/3 (Ser 423/425), Santa Cruz 
Biotechnology, CA) against C-terminus of both phosphorylated Smad2 and Smad3 
• Smad4 monoclonal mouse antibody in a 1:100 dilution (Smad4 (B-8), Santa Cruz Biotechnology, CA) 
• Smad7 mouse monoclonal antibody in a 1.100 dilution (Smad7 (Z8-B), Santa Cruz Biotechnology, CA) 
 
Then, slides were incubated with biotinylated secondary goat antibody and streptavidin-peroxidase complex 
(Lab Vision, Thermo Scientific) for 10 minutes at room temperature. The sections were developed with DAB 
solution (DAKO Corporation) according to the manufacturer’s instructions, counterstained with hematoxylin 
(J.T.Baker, Deventer, Holland) for 2 minutes, dehydrated in sequential gradients of ethanol, immersed in 
Clear Rite solution, mounted with Mounting medium (Richard - Allan, Thermo Scientific) and coverslipped 
with Entellan (Merck). Adequate positive and negative controls in tissue microarrays were used. 
 
III.3.1 Assessment of the immunohistochemical expression of D2-40 and determination of 
lymph vessel density (LVD) 
 
The expression of D2-40 was searched in 61 tumours of the series including E-FVPTCs (n=14) and PC-
PTCs (n=49). The remaining cases (n=14) had either insufficient representation of tumour or the tumour 
comprised post fine-needle aspiration tracts, previously associated to an increased LVD [103]).  
D2-40 expression was considered positive whenever cytoplasmatic staining of endothelial cells of lymphatic 
vessels was observed. The evaluation of D2-40 expression was performed by counting positive D2-40 
structures with morphological features of lymphatic vessels that were clearly separated from adjacent vessels 
and from other soft tissue components, as previously described [165]. Packed vessels were assumed as 
constituting one lymphatic unit. Analysis was performed at x200 magnification in the areas of highest 
vascularity (hot spots). The LVD of each case corresponds to the average obtained in counting 10 hot spot 
fields. The evaluation of D2-40 expression and lymph vessel counting was performed blindly in 
intratumoural and peritumoural areas of all 61 cases, except in 3 FVPTC cases in which the remaining non 
neoplastic thyroid tissue was insufficiently represented. The intratumoural lymph vessels were defined as 
vessels within the tumour area, whereas the peritumoural lymph vessels included vessels both in the capsule 
and in the remaining non tumoural thyroid tissue.  
 
III.3.2 Assessment of the immunohistochemical expression of TGF-beta 
 
The TGF-beta expression in the tumour cells was evaluated in the center and in the periphery of all 
carcinomas (CPTC and FVPTC) and in the respective remaining thyroid tissue, which was used as an 
internal control tissue, in order to reduce the influence of fluctuations of the physiological expression in each 
case. TGF-beta expression detected in cells of the control tissue was considered as the basal expression.  
TGF-beta expression in the tumour cells located in the center of each tumour was compared with the 
expression in the respective control tissue and the TGF-beta expression in the tumour cells located in the 
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periphery of each tumour was compared with the expression in the respective center of the tumour. The 
mean expressions observed in each location were also compared. The center of the tumour comprised the 
bulk of the tumour, i.e., the whole neoplastic tissue except the subcapsular areas and/or the invasive front. 
The periphery of the tumour comprised the rim of tumour cells underneath the capsule or at the expansive 
periphery in WC-PTC, and in the rim of tumour cells in the invasive front in PC-PTC.  TGF-beta expression 
was cytoplasmatic and was graded in 4 categories that were considered to represent a sort of semi-
quantitative steps of number of positive cells and immunostaining intensity: 
 
• Negative 0 (weak staining in less than 25% of cells) 
• Positive 1 (weak staining in at least 25% of cells or moderate intensity in less than 25% of cells) 
• Positive 2 (moderate intensity in at least 25% of cells or intense staining in less than 25% of cells)  
• Positive 3 (intense staining in at least 25% of cells) 
 
III.3.3 Assessment of the immunohistochemical expression of Smad2/3, Smad4 and Smad7 
 
The expression of phosphorylated Smad2/3 (P-Smad2/3), Smad4 and Smad7 was both nuclear and 
cytoplasmatic and was evaluated in all CPTC and FVPTC tumours and in the respective remaining thyroid 
tissue, which was used as an internal control tissue and considered as the basal expression. The expression of 
P-Smad2/3, Smad4 and Smad7 in the center of the tumour and at the periphery were considered too difficult 
to distinguish and, therefore, assumed as similar.  The expression was graded in 2 categories regarding each 
sub-cellular location (cytoplasmatic or nuclear) separately:  
 
• Negative (weak staining in less than 25% of cells) 
• Positive (weak, moderate or intense staining in at least 25% of cells)  
 
III.4 Molecular analysis 
 
All but 10 cases of the selected PTCs were screened for BRAF and N-RAS mutations.  
Genomic DNA was extracted from 10µm sections of 65 tumours, including 34 CPTC and 31 FVPTC (the 
remaining 10 cases had insufficient or inadequate available material). Slides were microscopically examined, 
marked and dissected under microscopic observation. The obtained material was deparaffinized in xylene, 
washed in ethanol and rehydrated. DNA extraction was performed using the Genomic DNA Purification Kit 
(Gentra Systems, Inc., Minneapolis, MN) according to the manufacturer’s instructions. Sequences of BRAF 
(exon 15) and N-RAS (exon 2) genes were amplified using primer pairs listed in the Table III.1, using a 
programmable thermocycler (MyCycler, Bio-Rad,USA). The PCR mixture (25µl) contained 2.5µl x10 PCR 
Buffer, 0.8mM dNTPs (Fermentas), 0.07µg each primer, 0.1-0.2 µg genomic DNA, 0.5 UTaq DNA 
Polymerase (Go Taq Flexi DNA Polymerase, Promega Corporation) and 2.5mM magnesium chloride 
(Promega Corporation). After 10 minutes of initial denaturation, the PCR mixtures were subjected to 35 
cycles of denaturation for 30 seconds at 95ºC, annealing according to the amplicon and extension for 45 
(BRAF) and 40 (N-RAS) seconds at 72ºC. A final extension period of 10 minutes at 72ºC was performed. 
PCR products were submitted to electrophoresis in agarose gel and purified by enzymatic treatment. Purified 
samples were sequenced on both strands as follows: 3µl purified PCR product was added to 7µl sequencing 
reaction containing 3.4µl Sequencing Buffer (Applied Biosystems, Forester City, CA), 30ng primer and 
0.6µl Big Dye Terminator (Applied Biosystems). Sequencing was performed in an ABI Prism 3100 Genetic 
Analyser (Applied Biosysytems). Mutated samples were re-extracted, re-amplified and re-sequenced to 
confirm the result.  
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Table III.1 Primers and PCR conditions. 
Gene Exon Primer sequence Length (bp) 
PCR annealing 
temperature (ºC) 
PCR annealing time 
(seconds) 
BRAF 15 F: TCATAATGCTTGCTCTGATAGGA R: GGCCAAAAATTTAATCAGTGGA 224 58 40 
N-RAS 2 F: GATTCTTACAGAAAACAAGT R: CCTTCGCCTGTCCTCATGTATT 119 57 35 
 
III.5 Statistical analysis 
 
The χ2 test with Yates’ correction and the Students’t test (unpaired) were used in the statistical analysis. Two 
values were considered significantly different when p<0.05 and suggestively different when p<0.1. 
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IV.1 Identification of the thyroid tumours filed in the Cancer Registry of the Pathology Department of 
Centro Hospitalar de São João 
 
In the 29-year period covered by this study, 1237 cases of primary thyroid tumours were identified in the 
Cancer Registry of the Pathology Department of Centro Hospitalar de São João.  
Table IV.1 summarizes the distribution of the cases per tumour histotype. 
 
Table IV.1 Distribution of the 1237 cases of primary thyroid tumours per each tumour histotype 
Diagnosis     %(n) Representative image of the histotype 
Well differentiated carcinoma and well differentiated tumour  94.4(1168) 
Papillary thyroid carcinoma 89.3(1043) 
Follicular thyroid carcinoma 10.4(122) 
WDTUMP   0.3(3) 
Poorly differentiated carcinoma 1.2(15) 
Undifferentiated carcinoma  0.8(10) 
Medullary carcinoma  3.1(38) 
Lymphoma 0.4(5) 
Mucoepidermoid carcinoma 0.1(1) 
           WDTUMP – well differentiated tumour of uncertain malignant potential 
 
The number of cases with a well differentiated carcinoma diagnosis has increased over the years, particularly 
due to an increased number of PTC cases, both of PTCs larger than 1cm and of PTCs with 1cm or less in 
their largest dimension, while the number of FTC cases remained persistently low over the years. 
The overall percentage of PTC cases with tumour size (largest dimension of the largest tumour) above 1.0cm 
(56.8%) was slightly higher than the percentage of cases with 1.0cm or less (43.2%) (Table IV.2).  
Of the 1043 PTC cases, 86.9% (n=906) were diagnosed in women and 13.1% (n=137) in men, with a mean 
age at the diagnosis of 46.4 years (median 47.0 years, range 12 – 85 years) and of 47.5 years (median 49 
years, range 11 – 84 years), respectively. The 1043 PTC cases were sub-classified irrespective of size, 
according to the WHO criteria [12]. The FVPTC (n=411) was the most frequent variant followed by CPTC 
(n=377); the remaining tumours (n=255) belonged to other variant categories, were not classified with 
precision or were not classified due to absence of respective filed material (Table IV.2).  
From the CPTC cases, 23.1% (87 out of 377) developed lymph node metastases and 2.3% (9 out of 377) 
developed distant metastases to the lungs and/or bones at the time of diagnosis or later. One or more 
recurrences were identified in 6.1% (23 out of 377) of CPTC. From the FVPTC cases, 2.9% (12 out of 411) 
developed lymph node metastases and 1.0% (4 out of 411) developed distant metastases to the lungs and/or 
bones at the time of diagnosis or later. One or more recurrences were identified in 2.7% (11 out of 411) of 
FVPTC. The development of distant metastases and recurrences was similar in CPTC and FVPTC cases, and 
the occurrence of lymph node metastases was more frequent in CPTC cases than in FVPTC cases (p<0.001). 
In the group of cases displaying lymph node and/or blood borne metastases there was not a single case of 
well differentiated tumour of uncertain malignant potential, nor any case of minimally invasive, non angio-
invasive FTC or encapsulated, noninvasive FVPTC (see Paper 5 for further details). 
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Table IV.2  Sub-classification of the 1043 PTCs 
PTC variants* % (n) Representative image of the PTC variant 
Classic (CPTC) 36.1(377) 
Follicular (FVPTC) 39.4(411) 
Diffuse sclerosing  1.1(11) 
Tall cell 0.6(6) 
Columnar cell 0.2(2) 
Solid 4.0(42) 
Oncocytic 5.2(54) 
Unclassified/unknown 13.4(140) 
 
         *In 435 cases the largest tumour measured 1cm or less in their largest dimension 
 
In the 29 year period of the study, 5 cases of PTC with a poorly differentiated carcinoma component were 
identified and included in the 15 cases of poorly differentiated carcinoma discriminated in Table IV.1. Out 
of the five patients, two developed recurrences (40%), one had distant metastases (20%), one died from the 
disease (20%) and the remaining patient was lost for follow up. 
 
Besides the thyroid tumours listed in Table IV.1, it was also possible to identify two cases of PTC coexisting 
with particular basaloid neoplasms (see Papers 6 and 7 for further details), one of which was seen in 
consultation. Finally, we have also reviewed a case of metastases from ductal breast carcinoma within a pre-
existing PTC.  
 
IV.2 Clinico-pathological features of the selected series of PTC cases 
 
The clinico-pathological features of the 75 selected cases, including 42 CPTCs and 33 FVPTCs, are 
summarized in Tables IV.3 and IV.4, respectively.  
CPTC and FVPTC cases had similar clinico-pathological features except different frequencies of poorly 
circumscribed growth pattern (83.3% of CPTC and 54.5% of FVPTC; p=0.010) and vascular invasion 
(28.6% of CPTC and 57.6% of FVPTC; p=0.018).  
 
IV.2.1 Classic PTC (CPTC) 
 
The 42 CPTC cases were 23 CPTC-M (54.8%) with a mean follow up time of 19.9±2.5 years and 19 
CPTC+M (45.2%) with a mean follow up time of 5.5±3.2 years. The CPTC-M cases included 20 females 
(87.0%) with a mean age of 41.5±15.7 years and 3 males (13.0%) with a mean age of 49.3±21.4 years. The 
patients with CPTC-M underwent partial thyroidectomy (lobectomy or lobectomy plus isthmectomy) in 
60.9% of cases and total thyroidectomy in 34.8% of cases; in 4.3% of the cases the precise extension of the 
surgery was not known. The CPTC+M cases included 15 females (78.9%) with a mean age of 38.1±19.1 
years and 4 males (21.1%) with a mean age of 22.3±14.0 years. The patients with CPTC+M underwent total 
thyroidectomy with or without lymph node dissection in 73.7% and 26.3% of cases, respectively. 
CPTC-M tumours presented less often poorly circumscribed growth pattern (69.6% of CPTC-M and 100.0% 
of CPTC+M; p=0.010), extra-thyroid extension (13.0% of CPTC-M and 47.4% of CPTC+M; p=0.020) and 
multicentricity (26.1% of CPTC-M and 63.2% of CPTC+M; p=0.028) than CPTC+M (Table IV.5).  
 47 
 
CPTC-M and CPTC+M tumours were not significantly different concerning gender, age, size, presence of 
capsule or capsular invasion, vascular invasion (Table IV.5) and not also concerning necrosis (21.7% and 
21.1%, respectively), intra-tumoural inflammation (60.9% and 63.2%, respectively), oncocytic cells (43.5% 
and 26.3%, respectively) and mitotic index (0.70 and 0.53 mitoses per 10 high power fields, respectively). 
The lymphocytic-rich stroma was detected only in two CPTC-M tumours (Table IV.3). In the adjacent 
thyroid parenchyma there were no significantly different frequencies of focal or diffuse Hashimoto type 
thyroiditis in CPTC-M and CPTC+M cases (47.8% and 57.9%, respectively), nor of benign follicular 
pathology (30.4% and 15.8%, respectively) (Table IV.3). 
Table IV.3 Clinico-pathological features of the CPTC cases 
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1 M 58 17 0.8 + + PC - - - - 1 - C - f - PT T1aN0M0 I - 
2 F 66 19 1.5 + + WC - - - - 1 - C + - NG T T1bN0M0 I - 
3 F 31 21 3.5 + + PC + - - + 0 - P - - FA PT T2N0M0 I - 
4 F 59 21 0.6 + + PC + - - + 1 + - - - NG PT T1aN0M0 I - 
5 F 37 21 1.0 + - WC + - - - 1 + L + f - T T1aN0M0 I - 
6 F 35 18 0.3 + + PC - - - - 0 - P - - NG PT T1aN0M0 I - 
7 F 40 18 1.5 - NA PC - - - - 0 + L + + - T T1bN0M0 I - 
8 F 38 18 0.5 - NA PC - - - - 0 - C - - NG PT T1aN0M0 I - 
9 M 25 20 1.2 - NA PC - - + + 0 - C - - - PT T1bN0M0 I - 
10 F 30 21 0.6 - NA PC + - - - 2 + C + f - PT T1aN0M0 I - 
11 F 40 20 2.2 - NA WC - - - - 0 + - + f - T T2N0M0 I - 
12 F 50 20 3.0 + + WC - - - + 0 - C + f - PT T2N0M0 II - 
13 F 25 17 2.1 + + WC - - - + 0 - P + - - T T2N0M0 I - 
14 F 45 22 4.5 + - WC + - - - 1 + - - - - PT T3N0M0 III - 
15 F 23 24 2.5 - NA PC - - - - 1 - P + - NG ND T2N0M0 I - 
16 M 65 24 2.3 - NA PC - - - - 0 - C + f - PT T2N0M0 II - 
17 F 21 19 2.0 - NA PC - - + - 3 - C + f - PT T1bN0M0 I - 
18 F 79 23 2.8 + + PC - + - - 0 - C + f - PT T3N0M0 III - 
19 F 65 16 3.5 - NA PC - + - - 1 + P + f NG T T3N0M0 III - 
20 F 28 24 2.5 - NA PC - - + - 2 + C - - - T T2N0M0 I - 
21 F 28 20 2.0 - NA PC - - + - 1 - C - - - PT T1bN0M0 I - 
22 F 43 18 1.5 + + WC + - + - 0 + C + - - PT T1bN0M0 I - 
23 F 47 16 4.5 - NA PC - + + - 1 + P + f - T T3N0M0 III - 
24 F 28 5 0.9 + + PC - - - - 0 + - - - - T T1aN1M0 I + 
25 F 21 6 1.2 + + PC - - - + 0 + C + + NG TL T1bN1M0 I + 
26 F 22 14 1.9 - NA PC + - - - 1 - - - - - TL T1bN1M0 I + 
27 F 30 3 1.3 + + PC - + + - 0 - P + + - TL T3N1M0 I + 
28 F 56 3 0.7 - NA PC + - - - 0 - - + - NG TL T1aN1M0 III + 
29 F 18 3 1.5 - NA PC + + + - 1 - C + f - T T3N1M0 I + 
30 M 22 4 1.1 - NA PC + - - - 1 - P - + - TL T1bN1M0 I + 
31 F 22 6 0.8 - NA PC - - - + 0 - C + - - TL T1aN1M0 I + 
32 F 56 3 0.8 - NA PC + - - - 0 - P - - - TL T1aN1M0 III + 
33 M 42 5 1.6 - NA PC + + - + 0 + P + f - TL T3N1M0 I + 
34 F 38 7 3.0 + + PC + - + - 1 - P + + - T T2N1M0 I + 
35 F 35 5 1.7 + + PC - - + - 0 - C + f - TL T1bN1M0 I + 
36 c,d M 11 9 6.0 - NA PC + + + - 0 - C + f - TL T4aN1M0 II + 
37 c,d F 56 4 2.4 - NA PC - + - - 1 + C + - - TL T3N1M0 IVC + 
38 F 83 1 7.5 - NA PC - + - + 1 + - + - - T T4aN1M0 IVA + 
39 F 18 4 3.6 - NA PC + - + - 0 - C - - - TL T2N1M0 I + 
40 M 14 4 2.5 - NA PC + + - - 1 - P - f - TL T3N1M0 I + 
41 F 32 9 1.1 - NA PC - + - - 1 - C - f NG T T3N1M0 I + 
42 F 56 10 7.5 - NA PC + + - - 2 - C + f - TL T3N1M0 III + 
N number, M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, EE extra-thyroid extension, C cellular, P 
poorly cellular, L lymphocyte rich, II intra-tumoural inflammation, f focal, BFP benign follicular pathology in the adjacent thyroid tissue, NG 
nodular goiter, FA follicular adenoma, LNM lymph node metastases, PT partial thyroidectomy, T total thyroidectomy, TL total thyroidectomy with 
lymph node dissection, ND not determined, NA not applicable. 
a
 Number of mitoses per 10 high power fields (400x),b Thyroiditis was considered + whenever Hashimoto thyroiditis features were present, c Cases 
with concurrent distant metastases, d Cases with recurrence(s). 
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 IV.2.2 Follicular variant of PTC (FVPTC) 
 
The 33 FVPTC cases were 25 FVPTC-M (75.8%) with a mean follow up time of 17.7±3.7 years and 8 
FVPTC+M (24.2%) with a mean follow up time of 6.9±4.1 years. The FVPTC-M cases included 22 females 
(88.0%) with a mean age of 41.7±12.2 years and 3 males (12.0%) with a mean age of 47.0±13.1 years. The 
patients with FVPTC-M underwent partial thyroidectomy (lobectomy or lobectomy plus isthmectomy) in 
60.0% of cases or total thyroidectomy in 40.0% of cases. The FVPTC+M cases included 5 females (62.5%) 
with a mean age of 42.2±13.5 years and 3 males (37.5%) with a mean age of 47.0±22.7 years. The patients 
with FVPTC+M underwent total thyroidectomy with or without lymph node dissection in 75.0% and 25.0% 
of cases, respectively. 
FVPTC-M tumours were significantly less often poorly circumscribed than FVPTC+M (40.0% of FVPTC-
M and 100.0% of FVPTC+M; p=0.004), presented significantly less often extra-thyroid extension (0.0% of 
FVPTC-M and 50.0% of FVPTC+M; p=0.002) and vascular invasion (44.0% of FVPTC-M and 100.0% of 
FVPTC+M; p=0.010).  
Table IV.4 Clinico-pathological features of the FVPTC cases 
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1 F 32 22 2.0 + + WC - - + - 2 + P + f - PT T1bN0M0 I - 
2 F 26 21 1.8 - NA PC + - + - 0 - P - - - PT T1bN0M0 I - 
3 F 59 19 0.5 + - WC - - - + 0 + - + - NG T T1aN0M0 I - 
4 F 51 18 1.4 + - WC - - - - 0 + C + - NG T T1bN0M0 I - 
5 F 36 18 0.5 - NA PC - - - - 0 - C + - NG PT T1aN0M0 I - 
6 F 39 15 1.0 - NA WC + - - - 1 - - - - NG PT T1aN0M0 I - 
7 F 48 13 0.6 + - WC - - - - 0 - P - + NG PT T1aN0M0 I - 
8 F 33 20 0.2 - NA PC - - - - 0 - C + + FA T T1aN0M0 I - 
9 F 30 15 0.5 - NA WC - - - - 0 - - - - NG PT T1aN0M0 I - 
10 F 21 21 0.6 - NA PC - - - - 0 - - - f NG T T1aN0M0 I - 
11 F 37 18 0.3 - NA PC - - + - 0 - P - - NG PT T1aN0M0 I - 
12 F 28 21 2.8 - NA WC + - + - 0 - P - - - T T2N0M0 I - 
13 F 34 20 3.5 + - WC - - - - 0 - P - f - PT T2N0M0 I - 
14 M 61 22 4.0 + + WC - - + - 0 - - - - - T T2N0M0 II - 
15 M 35 20 3.5 + + WC - - + - 0 - - - - - PT T2N0M0 I - 
16 F 50 20 2.5 + + WC - - - - 1 - - - - - PT T2N0M0 II - 
17 F 47 23 3.0 - NA PC - - - - 0 + - - - - PT T2N0M0 II - 
18 F 49 14 3.0 + + WC + - + - 0 - - - f NG T T2N0M0 II - 
19 F 35 21 1.7 - NA PC + - + - 1 - P + f NG PT T1bN0M0 I - 
20 F 32 13 4.7 - NA PC + - + - 0 + - - - - T T3N0M0 I - 
21 F 52 13 2.5 + + WC + - - - 1 - P - - NG T T2N0M0 II - 
22 F 66 13 2.5 + + WC + - - + 0 + P - f - PT T2N0M0 II - 
23 F 58 13 1.5 - NA PC + - + - 1 + C + - NG PT T1bN0M0 I - 
24 F 54 10 1.8 - NA PC + - + - 0 + P + f NG PT T1bN0M0 I - 
25 M 45 20 4.0 + + WC - - - - 0 + - - - - T T2N0M0 II - 
26 d M 57 3 9.5 + + PC - + + - 6 - - - - - TL T3N0M0 III + 
27 F 56 3 0.8 + + PC + - + - 0 - P + - - TL T1aN1M0 III + 
28 M 21 4 2.5 - NA PC - + + - 1 - C + - - TL T4aN1M0 I + 
29 F 20 14 1.0 - NA PC + - + - 1 - - + + - TL T1aN1M0 I + 
30 F 49 4 2.2 + + PC - - + - 1 - - - - - T T2N1M0 III + 
31 F 43 10 4.0 - NA PC + + + - 1 - - + f - TL T4aN1M0 I + 
32 F 43 10 1.5 - NA PC + + + - 0 - C + - - TL T3N1M0 I + 
33c,d M 63 7 1.8 + + PC - - + - 0 - - - - FA T T1bN0M0 I + 
N number, M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, EE extra-thyroid extension, C cellular, P 
poorly cellular, L lymphocyte rich, II intra-tumoural inflammation, f focal, BFP benign follicular pathology in the adjacent thyroid tissue, NG 
nodular goiter, FA follicular adenoma, LNM lymph node metastases, PT partial thyroidectomy, T total thyroidectomy, TL total thyroidectomy with 
lymph node dissection, ND not determined, NA not applicable. 
a
 Number of mitoses per 10 high power fields (400x), b Thyroiditis was considered + whenever Hashimoto thyroiditis features were present, 
c
 Cases with concurrent distant metastases, d Cases with recurrence(s). 
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FVPTC-M and FVPTC+M displayed different mean mitotic indexes (0.28 and 1.25 mitoses/10 high power 
fields, respectively; p=0.031). FVPTC-M cases presented significantly more often (56.0%) benign follicular 
pathology in the adjacent thyroid parenchyma than FVPTC+M tumours (12.5%)(p=0.046). In the subgroup 
of tumours with 1 cm or less, all the FVPTC-M had associated benign follicular pathology (8 out of 8), while 
none of the FVPTC+M had associated benign follicular pathology (0 out of 2). A similar difference was 
observed in the subgroup of tumours larger than 1cm (14 out of 25 and 1 out of 8, respectively)(p=0.022). 
FVPTC-M and FVPTC+M were not significantly different concerning gender, age, presence of capsule or 
capsular invasion, multicentricity (Table IV.5), nor necrosis (8.0% and 0.0%, respectively), intra-tumoural 
inflammation (32.0% and 62.5%, respectively), presence of oncocytic cells (36.0% and 0.0%, respectively), 
focal or diffuse Hashimoto type thyroiditis (36.0% and 25.0%, respectively) and stroma types (Table IV.4). 
 
IV.2.3 PTC cases with lymph node metastases (PTC+M) versus PTC cases without lymph node 
metastases (PTC-M) 
 
Table IV.5 summarizes the differences between the 27 PTC+M and the 48 PTC-M. 
PTC+M cases presented more often a poorly circumscribed growth pattern (p<0.0001), extra-thyroid 
extension (p<0.0001) and larger size of the tumours in the group with 1cm or less (p=0.019) than PTC-M 
tumours. PTC+M tumours tended to be more often multicentric than PTC-M tumours (p=0.051).  
When comparing poorly circumscribed CPTC+M and CPTC-M tumours the former were more often 
multicentric than the latter (57.9% and 18.8%, respectively; p=0.036) (Table IV.6).  Similarly, poorly 
circumscribed FVPTC+M tumours displayed more often extra-thyroid extension than FVPTC-M (50.0% and 
0.0%, respectively; p=0.023) (Table IV.6). 
 
Table IV.5. Comparison of  clinico-pathological features of CPTC and FVPTC cases with and without lymph node metastases 
(LNM) 
PTC Variant Features With  LNM Without  LNM p value 
CPTC 
Gender (Female:Male) 15:4 20:3 
>0.1 
Age, years(mean±sd) 34.7±19.0 42.5±16.2 
Tumour size of tumours >1,cm (mean±sd)  
Tumour size of tumours ≤1,cm (mean±sd)  
2.9±2.3 
0.8±0.1 
2.5±1.0 
0.6±0.2 
Capsule (absence/total) 0.74 0.52 
Capsule invasion (presence/total) 1.00 0.82 
Vascular invasion (presence /total) 0.32 0.26 
Multicentricity (presence/total) 0.63 0.26 
<0.05 Growth pattern (poorly circumscribed/total) 1.00 0.70 
Extra-thyroid extension (presence/total) 0.47 0.13 
FVPTC 
Gender (Female:Male) 5:3 22:3 
>0.1 
Age, years (mean±sd) 44.0±16.1 42.3±12.1 
Tumour size of tumours >1,cm (mean±sd) 3.6±3.0 2.7±1.0 
Capsule (absence/total) 0.50 0.52 
Capsule invasion (presence/total) 1.00 0.67 
Multicentricity (presence/total) 0.50 0.40 
Tumour size of tumours ≤1,cm (mean±sd) 0.9±0.1 0.5±0.2 0.1-0.05 
Vascular invasion (presence /total) 1.00 0.44 
<0.05 Growth pattern (poorly circumscribed/total) 1.00 0.40 
Extra-thyroid extension (presence/total) 0.50 0.00 
CPTC 
+ 
FVPTC 
Gender (Female:Male) 20:7 42:6 
 
>0.1 
 
 
Age, years (mean±sd) 37.5±18.4 42.4±14.1 
Tumour size of tumours >1,cm (mean±sd) 3.1±2.4 2.6±1.0 
Capsule (absence/total) 0.67 0.52 
Capsule invasion (presence/total) 1.00 0.74 
Vascular invasion (presence /total) 0.52 0.35 
Multicentricity (presence/total) 0.59 0.33 0.1-0.05 
Tumour size of tumours ≤1,cm (mean±sd) 0.8±0.1 0.6±0.2 
<0.05 Growth pattern (poorly circumscribed/total) 1.00 0.51 
Extra-thyroid extension (presence/total) 0.48 0.06 
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Table IV.6 Comparison of  clinico-pathological features of poorly circumscribed CPTC and poorly circumscribed FVPTC cases 
with and without lymph node metastases (LNM) 
PTC Subtype Features With  LNM Without LNM p value 
PC-CPTC 
Multicentricity (presence/total) 0.58 0.19 0.036 
Extra-thyroid extension (presence/total) 0.47 0.19 0.152 
Vascular invasion (presence /total) 0.32 0.31 >0.999 
PC-FVPTC 
Multicentricity (presence/total) 0.50 0.50 >0.999 
Extra-thyroid extension (presence/total) 0.50 0.00 0.023 
Vascular invasion (presence /total) 1.00 0.67 0.206 
 
 
 
IV.3 D2-40 expression in lymph vessels and evaluation of lymph vessel invasion and LVD in the 
selected series of PTC cases 
 
The clinico-pathological features and the LVD data on the 29 cases of FVPTC separated into E-FVPTC 
(n=12) and PC-FVPTC (n=17) are summarized in Table IV.7. The respective data on the 32 cases of CPTC 
are summarized in Table IV.8. 
 
 
TableIV.7 Clinico-pathological features of the 29 cases of FVPTC (12 cases of E-FVPTC and 17 cases of PC-FVPTC) and 
respective intratumoural and peritumoural LVD 
Case Gender Age (years) Tumour size (cm) M EE LI VI LNM I-LVD P-LVD 
E-
FV
PT
C
 
1 F 32 2.0 - - - + - 0.0 8.1 
4a F 51 1.4 - - - - - 0.0 15.4 
6 b F 39 1.0 + - - - - 0.6 11.5 
7a F 48 0.6 - - - - - 0.0 14.1 
9 b F 30 0.5 - - - - - 0.0 14.2 
12 b F 28 2.8 + - - + - 0.0 6.8 
13a F 34 3.5 - - - - - 0.0 9.8 
14 M 61 4.0 - - - + - 0.0 12.7 
15 M 35 3.5 - - - + - 0.0 18.0 
16 F 50 2.5 - - - - - 0.0 10.3 
21 F 52 2.5 + - - - - 0.0 14.2 
22 F 66 2.5 + - - - - 0.0 18.2 
PC
-
FV
PT
C
 
2 F 26 1.8 + - - + - 0.0 11.5 
5 F 36 0.5 - - - - - 0.5 10.1 
10 F 21 0.6 - - - - - 4.8 9.7 
11 F 37 0.3 - - - + - 0.0 8.6 
17 F 47 3.0 - - - - - 0.0 9.8 
20 F 32 4.7 + - - + - 1.0 21.0 
23 F 58 1.5 + - + + - 0.3 9.8 
24 F 54 1.8 + - + + - 0.2 10.0 
25 M 45 4.0 - - - - - 0.1 9.4 
26 M 57 9.5 - + + + + 4.4 14.0 
27 F 56 0.8 + - + + + 1.3 1.5 
28 M 21 2.5 - + - + + 2.0 ND 
29 F 20 1.0 + - - + + 6.0 21.0 
30 F 49 2.2 - - - + + 3.9 15.0 
31 F 43 4.0 + + - + + 0.1 ND 
32 F 43 1.5 + + - + + 4.3 ND 
33c M 63 1.8 - - - + + 0.0 10.8 
M male, F female, + presence, - absence, M multicentricity, EE extra-thyroid extension, LI lymph vessel invasion, VI vascular invasion, LNM 
lymph node metastases, I intratumoural, P peritumoural, ND not determined. a Cases without capsular invasion, b Cases with a very thin and 
irregular capsule, c Case with concomitant distant metastases.  
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IV.3.1 Clinico-pathological features, including lymph vessel invasion, of encapsulated FVPTC 
(E-FVPTC) cases versus poorly circumscribed FVPTC (PC-FVPTC) and CPTC cases 
 
E-FVPTC cases presented significantly less often vascular invasion (p=0.029) and lymph node metastases 
(p=0.009) than PC-FVPTC cases (Table IV.9). None of the E-FVPTC cases presented extra-thyroid 
extension, lymph vessel invasion or lymph node metastases while in cases with infiltrative growth pattern 
(PC-FVPTC plus CPTC), occurrence of extra-thyroid extension was observed in 32.7% of the cases, lymph 
vessel invasion was also observed in 32.7% of the cases, and lymph node metastases were detected in 75.0% 
of the cases (p=0.026, p=0.014 and p=0.0006, respectively) (Tables IV.7, IV.8 and IV.9). 
 
TableIV.9 Clinico-pathological features, including lymph vessel invasion, of PTC cases 
Features E-FVPTC 
n(%) 
PC-FVPTC 
n(%) 
CPTC 
n(%) 
FVPTC 
vs 
CPTC (p) 
E-FVPTC 
vs 
PC-FVPTC (p) 
E-FVPTC 
vs 
PC-FVPTC+CPTC (p) 
Gender             Female 
                          Male 
10 (83.3) 
2 (16.7) 
13 (76.5) 
4 (23.5) 
26 (81.3) 
6 (18.7) >0.999 >0.999 >0.999 
Age                   >45 years 
                          ≤45 years 
6 (50.0) 
6 (50.0) 
7(41.2) 
10 (58.8) 
10 (31.3) 
22 (68.7) 0.302 0.716 0.342 
Tumour size     >1.0 cm 
                          ≤1.0 cm 
9 (75.0) 
12 (25.0) 
12 (70.6) 
5  (29.4) 
25 (78.1) 
7 (21.9) 0.767 >0.999 >0.999 
M  4 (33.3) 8 (47.1) 12 (37.5) 0.798 0.703 0.749 
EE 0 (0.0) 4 (23.5) 12 (37.5) 0.045 0.121 0.026 
LI 0 (0.0) 4 (23.5) 12 (37.5) 0.094 0.059 0.014 
VI  4 (33.3) 13 (76.5) 11 (34.4) 0.075 0.029 0.520 
LNM 0 (0.0) 8 (47.1) 18 (56.3) 0.038 0.009 0.0006 
M multicentricity, EE extra-thyroid extension, LI lymph vessel invasion, VI  vascular invasion, LNM lymph node metastases 
TableIV.8 Clinico-pathological features of the 32 cases of CPTC and respective intratumoural and peritumoural LVD 
Case Gender Age (years) Tumour size (cm) M EE LI VI LNM I-LVD P-LVD 
1 M 58 0.8 - - - - - 0.0 7.0 
3 F 31 3.5 + - - - - 0.2 9.8 
6 F 35 0.3 - - + - - 0.3 8.1 
7 F 40 1.5 - - - - - 0.4 8.7 
9 M 25 1.2 - - - + - 2.0 10.9 
10 F 30 0.6 + - - - - 0.0 7.9 
15 F 23 2.5 - - + - - 0.9 15.8 
16 M 65 2.3 - - - - - 0.0 16.5 
17 F 21 2.0 - - + + - 0.0 14.1 
18 F 79 2.8 - + - - - 0.0 16.0 
19 F 65 3.5 - + + - - 0.0 8.3 
20 F 28 2.5 - - - + - 0.0 12.0 
21 F 28 2.0 - - - + - 0.0 14.1 
23 F 47 4.5 - + + + - 5.1 9.3 
24 F 28 0.9 - - - - + 0.2 13.0 
25 F 21 1.2 - - + - + 0.1 19.3 
26 F 22 1.9 + - + - + 0.7 18.0 
27 F 30 1.3 - + - + + 0.5 14.7 
28 F 56 0.7 + - + - + 1.0 10.3 
29 F 18 1.5 + + - + + 0.0 12.0 
30 F 22 0.8 - - - - + 0.2 12.5 
32 F 56 0.8 + - + - + 0.7 13.4 
33 M 42 1.6 + + - - + 2.2 3.7 
34 F 38 3.0 + - - + + 0.0 14.3 
35 F 35 1.7 - - - + + 1.4 11.7 
36a M 11 6.0 + + + + + 0.4 14.3 
37 a F 56 2.4 - + - - + 1.5 11.5 
38 F 83 7.5 - + - - + 1.0 11.3 
39 F 18 3.6 + - + + + 3.1 13.3 
40 M 14 2.5 + + + - + 2.0 14.0 
41 F 32 1.1 - + - - + 0.4 7.3 
42 F 56 7.5 + + - - + 0.6 20.0 
M male, F female, + presence, - absence, M multicentricity, EE extra-thyroid extension, LI lymph vessel invasion, VI vascular invasion, LNM 
lymph node metastases, I intratumoural, P peritumoural, ND not determined.   a Cases with concomitant distant metastases.  
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In cases without extra-thyroid extension, the occurrence of lymph vessel invasion was related to lymph node 
metastases (p=0.022). 
 
IV.3.2 D2-40 expression in lymph vessels 
 
The D2-40 expression in the endothelial cells in intratumoural location highlighted small thin-walled lymph 
vessels with tiny lumina located in the dependence of fibrous septa arising from the tumour capsule 
(FigureIV.1A) or amongst tumour cells (FigureIV.1B). The D2-40 positive lymph vessels were found less 
often in the center of the tumours than in the periphery, particularly at the invasive front of the infiltrative 
tumours. 
In both FVPTC subgroups and in the CPTC group, there was, besides the subset of lymph vessels with D2-
40 expression, a majority of small thin-walled, D2-40 negative, nearly collapsed capillary vessels of 
uncertain origin, and ectatic lymph vessels in the remaining thyroid tissue. Such D2-40 negative capillary 
vessels were morphologically indistinguishable from vessels with D2-40 expression (FigureIV.1C and D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D2-40 expression in the peritumoural thyroid 
tissue highlighted thin-walled ectatic lymph 
vessels (FigureIV.1E) in all cases. 
Peritumoural lymph vessels with D2-40 
expression showed, in some cases displaying 
infiltrative growth, neoplastic thrombi within 
their lumina (FigureIV.1F). Neoplastic thrombi 
were not observed within the intratumoural thin-
walled vessels without D2-40 expression.  
All the blood vessels with an organized wall 
surrounded by a smooth muscle layer in which 
the presence of vascular invasion was searched, 
did not disclose D2-40 expression in the 
endothelial cells (FigureIV.1G). Neoplastic 
thrombi were also detected in peritumoural 
thick walled vessels (FigureIV.1H). 
Complex networks of lymph vessels expressing 
D2-40 were detected in the peritumoural tissue 
in association with lymphoid aggregates and in 
perithyroidal lymph nodes with and without 
metastases (FigureIV.1I and J). 
 Figure IV.1  
 
D2-40 expression in the endothelial cells.  
A – D2-40 positive intratumoural lymph vessels in a 
fibrous septum (case23 CPTC, 400x); B – D2-40 positive 
intratumoural lymph vessels between tumour cells at the 
invasive front (case39 CPTC, 100x); C – Intratumoural 
lymph vessels D2-40 expression and thin walled vessels 
without D2-40 expression(arrow) (case39 CPTC, 400x); 
D – Intratumoural thin walled vessels without D2-40 
expression (arrows) (case39 CPTC, 200x); E – D2-40 
positive peritumoural lymph vessels (case16 FVPTC, 
100x); F – D2-40 positive intratumoural lymph vessel 
with neoplastic thrombus (case26 FVPTC, 200x); G – 
Peritumoural medium sized vein without D2-40 
expression surrounded by D2-40 positive small lymph 
vessels (case13 FVPTC, 200x); H – D2-40 negative 
peritumoural vein with neoplastic thrombus (case24 
FVPTC, 200x); I – Complex network of D2-40 positive 
lymph vessels in the peritumoural tissue associated with a 
lymphoid aggregate (case16 FVPTC, 100x) and J – 
Complex network of D2-40 positive lymph vessels in a 
perithyroidal lymph node with PTC metastases (case37 
CPTC, 100x). 
 53 
 
 
 
IV.3.3 Intratumoural LVD 
 
In 11 out of 12 cases of E-FVPTC (91.7%) not a single intratumoural D2-40 stained vessel was observed 
(Table IV.7). Case 6 of the E-FVPTC subgroup was the only one with D2-40 positive intratumoural lymph 
vessels and did not show signs of extra-thyroid extension, lymph vessel invasion or vascular invasion, nor 
had given rise to lymph node metastases (Table IV.7). At variance with E-FVPTC, the majority of PC-
FVPTC cases (76.5%) had intratumoural D2-40 positive lymph vessels. The mean intratumoural LVD was 
significantly higher in PC-FVPTC (1.7±2.1) and in CPTC (0.8±1.1) than in E-FVPTC (0.05) (p=0.020 and 
p=0.030, respectively) (Figure IV.2A). It was also higher in PC-FVPTC than in CPTC (p=0.049) (Figure 
IV.2A). 
The mean intratumoural LVD was significantly higher in tumours with extra-thyroid extension (p=0.041), 
lymph vessel invasion (p=0.026) and lymph node metastases (p=0.008) (TableIV.10). In FVPTC cases, the 
mean intratumoural LVD was significantly higher in PC-FVPTC cases with lymph node metastases 
(p=0.047) (TableIV.10). 
 
 
IV.3.4 Peritumoural LVD 
 
The mean peritumoural LVD was similar in FVPTC (E-FVPTC: 12.8±3.6 and PC-FVPTC: 11.6±5.0, 
p=0.501) and in CPTC (12.3±3.7)(p=0.888) (Figure IV.2B). In all PTC groups, the mean peritumoural LVD 
was significantly higher than the mean intratumoural LVD (p<0.0001), and it was not significantly 
associated with any clinico-pathological or molecular feature, namely lymph vessel invasion (p=0.626) or 
lymph node metastases (p=0.288).  
 
TableIV.10 Relationship between the intratumoural LVD and the morphological features of FVPTC (E-FVPTC and PC-FVPTC) 
and CPTC cases 
Features E-FVPTC PC-FVPTC CPTC PC-FVPTC+CPTC PTC 
   mean±sd p mean±sd p mean±sd p mean±sd p mean±sd p 
M   Present 
Absent 
0.2±0.3 
0.0±0.0 0.170 
1.7±2.3 
1.7±2.1 0.930 
0.9±1.0 
0.7±1.2 0.616 
1.2±1.6 
1.0±1.6 0.696 
1.0±1.5 
0.8±1.4 0.560 
EE  Present 
Absent 
- 
0.1±0.2 - 
2.7±2.1 
1.4±2.1 0.289 
1.1±1.5 
0.6±0.8 0.156 
1.5±1.7 
0.9±1.5 0.181 
1.5±1.7 
0.7±1.3 0.041 
LI   Present 
Absent 
- 
0.1±0.2 - 
2.4±2.6 
1.4±1.9 0.363 
1.2±1.5 
0.5±0.7 0.104 
1.6±1.9 
0.6±1.3 0.135 
1.6±1.9 
0.6±1.2 0.026 
VI   Present 
Absent 
0.0±0.0 
0.1±0.2 0.506 
1.8±2.1 
1.4±2.3 0.715 
1.1±1.7 
0.6±0.7 0.192 
1.5±1.9 
0.7±1.0 0.078 
1.3±1.8 
0.6±1.0 0.052 
LNM  Present 
Absent 
- 
0.1±0.2 - 
2.8±2.2 
0.8±1.5 0.047 
0.9±0.9 
0.6±1.4 0.532 
1.5±1.6 
0.7±1.4 0.084 
1.5±1.6 
0.5±1.2 0.008 
M  multicentricity, EE extra-thyroid extension, LI  lymph vessel invasion, VI  vascular invasion, LNM lymph node metastases 
 
 
 
Figure IV.2 
 
Comparison between the 
LVD in the FVPTC 
group (E-FVPTC and 
PC-FVPTC) and in the 
CPTC group.   
A – Graphic representing 
the mean intratumoural 
LVD in the three PTC 
groups; B – Graphic 
representing the mean 
peritumoural LVD in the 
three PTC groups. A B 
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IV.4 Immunohistochemical expression of elements of the TGF-beta/Smad-dependent pathway in 
the selected series of PTC cases 
 
Tables IV.11 and IV.12 summarize the immunohistochemical expression of TGF-beta, P-Smad2/3, Smad4 
and Smad7 in the 42 CPTC cases and in the 33 FVPTC, respectively. 
 
 
 
TableIV.11. Clinico-pathological and immunohistochemical features of the CPTC cases 
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1 M 58 0.8 PC - C - - - - - 0.0 3 2 1 +/- -/+ -/+ -/+ +/+ -/+ - 
2 F 66 1.5 WC - C + - - - ND ND 2 2 1 +/+ +/- -/+ +/+ +/+ +/- - 
3 F 31 3.5 PC - P - + - - - 0.2 3 3 2 +/+ +/- -/+ +/+ +/+ +/- - 
4 F 59 0.6 PC + - - + - - ND ND 2 2 1 +/+ +/- -/+ +/+ +/+ +/- - 
5 F 37 1.0 WC + L + + - - ND ND 3 3 2 +/- +/+ -/+ -/+ +/+ +/+ - 
6 F 35 0.3 PC - P - - - - + 0.3 2 3 0 +/- +/- +/+ +/+ +/- +/- - 
7 F 40 1.5 PC + L + - - - - 0.4 3 3 1 +/+ +/- -/+ -/+ +/- +/- - 
8 F 38 0.5 PC - C - - - - ND ND 2 2 0 +/+ +/+ -/+ -/+ +/+ +/- - 
9 M 25 1.2 PC - C - - - + - 2.0 2 1 1 +/+ +/- -/+ -/+ +/+ +/- - 
10 F 30 0.6 PC + C + + - - - 0.0 2 3 2 +/+ +/- -/+ +/+ -/+ -/+ - 
11 F 40 2.2 WC + - + - - - ND ND 1 2 2 +/+ +/- -/+ -/+ +/+ +/+ - 
12 F 50 3.0 WC - C + - - - ND ND 1 1 0 +/- +/- -/+ -/+ +/- +/- - 
13 F 25 2.1 WC - P + - - - ND ND 1 1 1 +/+ +/- -/+ +/+ +/+ +/- - 
14 F 45 4.5 WC + - - + - - ND ND 2 3 2 +/- +/+ +/+ -/+ +/+ +/- - 
15 F 23 2.5 PC - P + - - - + 0.9 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - 
16 M 65 2.3 PC - C + - - - - 0.0 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - 
17 F 21 2.0 PC - C + - - + + 0.0 1 2 0 +/+ +/- -/+ +/+ +/+ +/- - 
18 F 79 2.8 PC - C + - + - - 0.0 3 3 1 +/+ -/- -/+ -/+ +/+ +/- - 
19 F 65 3.5 PC + P + - + - + 0.0 1 2 0 +/+ +/- -/+ +/- +/- +/- - 
20 F 28 2.5 PC + C - - - + - 0.0 3 3 0 +/+ +/+ -/+ +/+ +/+ +/- - 
21 F 28 2.0 PC - C - - - + - 0.0 3 3 0 +/+ +/- -/+ +/+ +/+ +/+ - 
22 F 43 1.5 WC + C + + - + ND ND 1 1 0 +/+ +/- -/+ +/+ +/+ +/+ - 
23 F 47 4.5 PC + P + - + + + 5.1 1 3 1 +/+ +/- -/+ +/+ +/+ +/- - 
24 F 28 0.9 PC + - - - - - - 0.2 1 2 1 +/+ +/- +/+ +/+ +/+ +/- + 
25 F 21 1.2 PC + C + - - - + 0.1 1 2 2 +/+ +/+ +/+ +/+ -/+ +/- + 
26 F 22 1.9 PC - - - + - - + 0.7 1 1 1 +/+ +/- -/+ +/+ +/+ +/- + 
27 F 30 1.3 PC - P + - + + - 0.5 2 3 2 +/+ +/- -/+ +/+ -/+ +/- + 
28 F 56 0.7 PC - - + + - - + 1.0 3 3 2 +/+ +/- -/+ +/+ -/+ +/- + 
29 F 18 1.5 PC - C + + + + - 0.0 3 3 2 +/+ +/- +/+ +/+ -/+ +/- + 
30 M 22 1.1 PC - P - + - - - 0.2 2 3 2 +/- +/- +/+ +/+ -/- +/- + 
31 F 22 0.8 PC - C + - - - ND ND 1 2 2 +/+ +/- -/+ +/+ -/+ +/- + 
32 F 56 0.8 PC - P - + - - + 0.7 1 2 1 +/+ +/- -/+ +/+ -/+ +/+ + 
33 M 42 1.6 PC + P + + + - - 2.2 2 3 3 +/+ +/- -/+ +/+ -/+ +/- + 
34 F 38 3.0 PC - P + + - + - 0.0 1 1 2 +/+ +/- -/+ +/+ -/+ +/- + 
35 F 35 1.7 PC - C + - - + - 1.4 0 2 2 +/+ +/- -/+ +/+ -/+ +/- + 
36a,b M 11 6.0 PC - C + + + + + 0.4 1 2 0 +/+ +/- -/+ +/+ +/- +/- + 
37a,b F 56 2.4 PC + C + - + - - 1.5 1 2 2 +/+ +/- -/+ +/+ -/+ +/- + 
38 F 83 7.5 PC + - + - + - - 1.0 0 3 ND +/+ ND -/+ ND -/+ ND + 
39 F 18 3.6 PC - C - + - + + 3.1 2 2 1 +/+ +/- +/+ +/+ -/+ +/- + 
40 M 14 2.5 PC - P - + + - + 2.0 1 2 1 +/+ +/- +/+ +/+ -/- +/- + 
41 F 32 1.1 PC - C - - + - - 0.4 0 2 1 +/- +/- -/+ +/+ +/- +/- + 
42 F 56 7.5 PC - C + + + - - 0.6 1 2 1 +/+ +/- -/+ +/+ -/+ +/- + 
M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, C cellular, P poorly cellular, L lymphocyte rich, II intra-
tumoural inflammation, EE extra-thyroid extension, I-LVD intratumoural lymph vessel density,C expression in the center of the tumour, P expression 
in the tumour periphery, CT expression in the control tissue, n nuclear expression, c cytoplasmatic expression, LNM lymph node metastases,  ND not 
determined. a Cases with concurrent distant metastases,  b Cases with recurrence(s). 
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Table IV.12. Clinico-pathological and immunohistochemical features of the FVPTC cases 
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1 F 32 2.0 WC + P + - - + - 0.0 2 0 2 +/+ +/- -/+ +/+ +/+ +/- - 
2 F 26 1.8 PC - P - + - + - 0.0 2 3 1 +/+ +/- -/+ +/+ +/+ +/+ - 
3 F 59 0.5 WC + - + - - - ND ND 0 0 0 +/- +/- -/+ +/- +/- +/- - 
4 F 51 1.4 WC + C + - - - - 0.0 2 3 1 +/+ +/- +/+ +/+ +/+ +/- - 
5 F 36 0.5 PC - C + - - - - 0.5 1 1 1 +/+ +/- +/+ +/+ +/- +/- - 
6 F 39 1.0 WC - - - + - - - 0.6 1 1 0 +/- +/- +/+ +/+ +/+ +/- - 
7 F 48 0.6 WC - P - - - - - 0.0 1 0 0 +/+ +/+ +/+ +/+ +/- +/- - 
8 F 33 0.2 PC - C + - - - ND ND 3 3 0 +/+ +/+ +/+ +/+ +/+ +/- - 
9 F 30 0.5 WC - - - - - - - 0.0 1 1 0 +/+ +/+ -/+ +/+ +/- +/- - 
10 F 21 0.6 PC - - - - - - - 4.8 1 3 1 +/- +/- -/+ +/+ +/- +/- - 
11 F 37 0.3 PC - P - - - + - 0.0 1 1 1 +/- +/- -/+ +/+ +/- +/- - 
12 F 28 2.8 WC - P - + - + - 0.0 2 3 0 +/+ +/- -/+ +/+ +/+ +/+ - 
13 F 34 3.5 WC - P - - - - - 0.0 0 0 0 +/- +/- +/+ -/+ +/- +/- - 
14 M 61 4.0 WC - - - - - + - 0.0 2 2 2 +/+ +/- -/+ +/+ +/+ +/- - 
15 M 35 3.5 WC - - - - - + - 0.0 1 1 1 +/+ +/- -/+ +/+ +/- +/- - 
16 F 50 2.5 WC - - - - - - - 0.0 1 1 1 +/- +/- -/+ -/+ +/- +/- - 
17 F 47 3.0 PC + - - - - - - 0.0 2 3 0 +/- +/- +/+ +/+ +/+ +/- - 
18 F 49 3.0 WC - - - + - + ND ND 2 1 1 +/+ +/+ -/+ +/+ +/+ +/- - 
19 F 35 1.7 PC - P + + - + ND ND 3 3 1 +/+ +/- -/+ +/+ +/+ +/- - 
20 F 32 4.7 PC + - - + - + - 1.0 2 3 2 +/+ +/- +/+ +/+ +/+ +/- - 
21 F 52 2.5 WC - P - + - - - 0.0 1 1 2 +/- +/- +/+ +/+ +/- +/- - 
22 F 66 2.5 WC + P - + - - - 0.0 1 1 0 +/+ +/- +/+ +/+ +/- +/- - 
23 F 58 1.5 PC + C + + - + + 0.3 0 1 1 +/+ +/- -/+ +/+ +/+ +/- - 
24 F 54 1.8 PC + P + + - + + 0.2 1 2 1 +/+ +/+ -/+ +/+ +/+ +/- - 
25 M 45 4.0 WC + - - - - - - 0.1 1 1 1 +/- +/- -/+ +/+ +/- +/- - 
26b M 57 9.5 PC - - - - + + + 4.4 2 2 1 +/+ +/+ +/+ +/+ -/+ +/- + 
27 F 56 0.8 PC - P + + - + + 1.3 1 2 2 +/+ +/- +/+ +/+ -/- +/- + 
28 M 21 2.5 PC - C + - + + - 2.0 1 2 0 +/+ +/- -/+ +/+ -/+ +/- + 
29 F 20 1.0 PC - - + + - + - 6.0 0 1 2 +/- +/- -/+ +/+ -/- +/- + 
30 F 49 2.2 PC - - - - - + - 3.9 0 1 0 +/- +/- -/+ +/+ -/- +/- + 
31 F 43 4.0 PC - - + + + + - 0.1 0 1 0 +/- +/- -/+ +/+ -/- +/- + 
32 F 43 1.5 PC - C + + + + - 4.3 1 3 1 +/- +/- -/+ +/+ +/- +/- + 
33a,b M 63 1.8 PC - - - - - + - 0.0 1 3 1 +/- +/- -/+ +/+ -/+ +/- + 
M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, C cellular, P poorly cellular,  EE extra-thyroid 
extension, I-LVD intratumoural lymph vessel density, C expression at  the center of the tumour, P expression at the tumour periphery, CT expression 
in the control tissue, n nuclear expression, c cytoplasmatic expression, LNM lymph node metastases,  ND not determined. a Cases with concurrent 
distant metastases,  b Cases with recurrence(s). 
 
IV.4.1 CPTC versus FVPTC 
 
           IV.4.1.1 TGF-beta expression  
 
TGF-beta expression was observed in all but two FVPTC-M cases and was detected in the center of 88.0% 
of tumours (95.2% of CPTC and 81.8% of FVPTC), at the periphery of 94.7% of tumours (100% of CPTC 
and 87.9% of FVPTC) and in the control tissues in 73.0% of cases (78.6% of CPTC and 63.3% of FVPTC). 
In comparison with the respective control tissue, the center of the carcinomas disclosed basal or 
overexpression of TGF-beta in 83.8% of cases.  The TGF-beta expression at the periphery of each tumour 
was similar or higher than the TGF-beta expression in the center in all but one CPTC-M and three FVPTC-
M cases (94.7%) (Tables IV.11 and IV.12) (Figure IV.3). 
The mean intensity of TGF-beta expression in the center of the tumours, in comparison with the respective 
control tissue, was much higher in PTC-M than in PTC+M (p<0.0001).The mean intensity of TGF-beta 
expression at the periphery, compared with the respective center of the tumours, was significantly higher in 
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PTC+M than in PTC-M (p=0.0001) and was also significantly higher in tumours with poorly circumscribed 
growth pattern (p<0.0007) and extra-thyroid extension (p=0.002) (Table IV.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IV.4.1.2 Smad 2/3 expression  
 
P-Smad2/3 nuclear expression was observed in all tumours (Figure IV.4A and B) and in all but two control 
tissues of the CPTC-M group (97.3%) (Figure IV.4C).  
P-Smad2/3 cytoplasmatic expression was observed in 72.0% of tumours and in 18.9% of control tissues. In 
comparison to the respective control tissue, P-Smad2/3 had a basal level or was underexpressed in the 
cytoplasm of tumour cells in 43.2% of the cases. Tumours with basal or underexpression of cytoplasmatic P-
Smad2/3 belonged more frequently to the group of FVPTC than to the CPTC group (60.6% and 29.3%, 
respectively; p=0.010) (Tables IV.11 and IV.12).  
          IV.4.1.3 Smad4 expression  
 
Smad4 nuclear expression was observed in 26.7% of tumours and 85.1% of control tissues (Figure IV.4D, E 
and F). Smad4 had a basal level or was overexpressed in the nuclei of tumour cells in 39.2% 
of the cases in comparison with the respective control tissue. Vascular invasion was significantly less 
frequent in tumours with basal or overexpressed nuclear Smad4 (p=0.004), particularly in the FVPTC group 
(p=0.003) (Table IV.13).  
Smad4 cytoplasmatic expression was observed in all tumours and in all but two control tissues of the PTC-M 
group (97.3%) and was not significantly associated to any clinical or pathological feature. 
Figure IV.3  
 
TGF-beta expression at the center and at the 
periphery of the tumours.  
A- Well circumscribed FVPTC-M with similar 
expression at the center and at the periphery (case 
14; 200x); B – Well circumscribed FVPTC-M 
with increased expression at the periphery (case12, 
200x); C – Poorly circumscribed FVPTC+M with 
lung metastases and increased expression at the 
periphery (case 33, 200x); D – Well circumscribed 
FVPTC-M with decreased expression at the 
periphery (case18, 200x); E – Poorly 
circumscribed CPTC+M with increased expression 
at the periphery (case33, 40x) and F – Poorly 
circumscribed CPTC-M with increased expression 
at the periphery  (case17,40x). 
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IV.4.1.4 Smad7 expression  
 
Smad7 nuclear expression was observed in 69.3% of tumours and in all but two control tissues of the CPTC-
M group (97.3%) (Figure IV.4G, H and I). 
Smad7 had a basal level or was overexpressed in the nuclei of the tumour cells in 71.6% of tumours in 
comparison with the respective control tissue. There was a significant association between basal to 
overexpressed Smad7 in the nuclei of the tumour cells and well circumscribed growth pattern (p=0.0001), 
unicentric CPTC (p=0.048), absence of vascular invasion in FVPTC (p=0.013), absence of extra-thyroid 
extension in FVPTC (p=0.023) and absence of lymph node metastases in both CPTC and FVPTC (p<0.0001) 
(Table IV.13).   
Smad7 cytoplasmatic expression was observed in 66.7% of tumours and in 14.9% of the control tissues. 
Smad7 had a basal level or was underexpressed in the cytoplasm of the tumour cells in 48.6% of cases in 
comparison with the respective control tissue, both in CPTC and FVPTC. Smad7 cytoplasmatic expression 
was not significantly associated to any clinical or pathological feature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.4 
 
Expression of P-Smad2/3: A – Papillary areas of the center of the tumour (case 26 of CPTC 
group, 200x), B –Follicular areas of the center of the tumour (case 28 of FVPTC group, 400x) 
and C – Control tissue (case 2 of CPTC group, 400x). 
Expression of Smad4: D – Papillary areas of the center of the tumour (case 39 of CPTC group, 
200x), E – Follicular areas of the center of the tumour (case 27 of FVPTC group, 200x) and F– 
Control tissue (case 27 of FVPTC group, 200x).  
Expression of Smad7: G – Papillary areas of the center of the tumour (case 9 of CPTC group, 
400x), H – Follicular areas of the periphery of the tumour (case 1 of FVPTC group, 100x) and I 
– Control tissue (case 1 of FVPTC group; 200x).  
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Table IV.13 Comparison between the immunohistochemical patterns of and the PTC features. 
 Features TGF-beta intensity of expression (mean±sd) Overexpression or basal nuclear expression (%) C-CT p P-C p   Smad4 p Smad7 p 
CP
TC
+
FV
PT
C 
GP     PC 
         WC 
0.5±1.2 
0.4±0.7 0.839 
0.7±0.7 
0.1±0.5 0.0007 
33.3 
52.2 0.198 
58.8 
100.0 0.0001 
M      Present  
          Absent 
0.3±0.9 
0.6±1.2 0.217 
0.5±0.6 
0.5±0.8 0.630 
35.5 
41.8 0.635 
61.3 
79.1 0.120 
EE     Present  
          Absent 
0.3±0.9 
0.5±1.1 0.409 
1.0±0.7 
0.4±0.7 0.002 
26.7 
42.4 0.377 
40.0 
79.7 0.008 
VI      Present  
          Absent 
0.4±1.2 
0.5±1.0 0.719 
0.6±0.8 
0.4±0.7 0.259 
19.4 
53.5 0.004 
61.3 
79.1 0.120 
LNM  Present  
          Absent             
-0.2±0.9 
0.8±1.0 <0.0001 
0.9±0.6 
0.3±0.7 0.0001 
30.8 
43.8 0.325 
19.2 
100.0 <0.0001 
CP
TC
 
GP     PC 
         WC 
0.6±1.2 
0.5±0.8 0.787 
0.6±0.7 
0.3±0.5 0.362 
35.3 
57.1 0.401 
58.8 
100.0 0.075 
M      Present  
          Absent 
0.4±0.7 
0.7±1.3 0.393 
0.5±0.5 
0.5±0.8 0.757 
35.3 
31.7 0.753 
47.1 
79.2 0.048 
EE     Present  
          Absent 
0.2±1.0 
0.7±1.2 0.233 
1.0±0.6 
0.3±0.7 0.006 
27.3 
43.3 0.478 
45.5 
73.3 0.140 
VI      Present  
          Absent 
0.8±1.4 
0.4±1.0 0.449 
0.5±0.9 
0.5±0.6 0.945 
25.0 
44.8 0.305 
58.3 
69.0 0.719 
LNM  Present  
          Absent             
-0.2±0.9 
1.1±1.0 <0.0001 
0.8±0.6 
0.3±0.7 0.009 
33.3 
43.5 0.540 
22.2 
100.0 <0.0001 
FV
PT
C 
GP     PC 
         WC 
0.4±1.2 
0.4±0.7 0.812 
0.9±0.7 
0.0±0.5 <0.0001 
29.4 
50.0 0.296 
58.8 
100.0 0.007 
M      Present  
          Absent 
0.2±1.2 
0.5±0.8 0.383 
0.6±0.7 
0.4±0.8 0.310 
35.7 
42.1 >0.999 
78.6 
78.9 >0.999 
EE     Present  
          Absent 
0.5±0.6 
0.4±1.0 0.824 
1.0±0.8 
0.4±0.7 0.148 
25.0 
41.4 >0.999 
25.0 
86.2 0.023 
VI      Present  
          Absent 
0.2±1.0 
0.6±1.0 0.224 
0.7±0.7 
0.2±0.7 0.077 
15.8 
71.4 0.003 
63.2 
100.0 0.013 
LNM  Present  
          Absent             
0.1±1.0 
0.6±1.0 0.091 
1.1±0.6 
0.3±0.7 0.004 
25.0 
44.0 0.431 
12.5 
100.0 <0.0001 
GP Growth pattern, M multicentricity, EE extra-thyroid extension, VI vascular invasion, LNM lymph node metastases, C expression at the 
center of the tumour, P expression at the tumour periphery, CT expression in  the control tissue. 
 
IV.4.2 Well circumscribed PTC (WC-PTC) versus poorly circumscribed PTC (PC-PTC) 
Globally, the difference between the mean TGF-beta expression in the center of the tumours and in the 
control tissue was similar in WC-PTC and in PC-PTC (p=0.839) whereas the difference between the mean 
TGF-beta expression in the periphery of the tumours and in the center of the tumours was much higher in 
PC-PTC than in WC-PTC (p=0.0007) (Table IV.13).  
In 63.6% of WC-PTC cases (14 out of 22) the TGF-beta expression was nearly homogeneous, absent or 
low/moderate, throughout the tumour. In PC-PTC, the PTC-M cases disclosed a significantly more intense 
expression of TGF-beta in the center of the tumours than in the control tissue (p<0.0001), whereas in 
PTC+M cases the cells in the periphery of the tumours presented a significantly more intense expression of 
TGF-beta than those in the center of the tumours (p=0.017) (Table IV.14).  
Smad4 nuclear expression in WC-PTC subgroup was detected only in tumours without vascular invasion 
(p=0.005) (Table IV.14), whereas in PC-PTC, Smad4 nuclear expression was not significantly associated to 
any clinical, pathological or molecular features. 
 
Table IV.14 Comparison between the immunohistochemical patterns of expression in well and poorly circumscribed PTCs. 
                    
Features 
Increment in TGF-beta intensity of 
expression (mean±sd) 
Overexpression or basal nuclear 
expression (%) 
Underexpression or basal 
cytoplasmatic  expression (%) 
T p P p  Smad4     p   Smad7 p P-Smad2/3 p 
W
C
 
PT
C VI         Present 
             Absent 
0.7±0.8 
0.4±0.7 0.376 
0.0±0.6 
0.1±0.5 0.641 
0.0 
70.6 0.005 
100.0 
100.0 >0.999 
16.7 
64.7 0.069 
PC
 
PT
C 
M          Present 
             Absent       
0.1±0.9 
0.8±1.3 0.053 
0.7±0.6 
0.7±0.9 0.935 
26.1 
39.3 0.381 
47.8 
67.9 0.167 
21.7 
53.6 0.025 
EE        Present 
             Absent       
0.3±0.9 
0.6±1.3 0.398 
1.0±0.7 
0.6±0.7 0.048 
26.7 
50.0 0.746 
40.0 
66.7 0.119 
26.7 
44.4 0.348 
LNM    Present 
             Absent       
-0.2±0.9 
1.2±1.1 <0.0001 
0.9±0.6 
0.4±0.8 0.017 
30.8 
36.0 0.771 
19.2 
100.0 <0.0001 
34.6 
44.0 0.573 
VI vascular invasion, M Multicentricity, EE extra-thyroid extension,  LNM lymph node metastases, T expression at the center of the tumour, P expression 
at the tumour periphery,  
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IV.5 Results of the molecular analysis and correlation with the clinico-pathological and 
immunohistochemical data of the selected series of PTC cases 
 
Tables IV.15 and IV.16 summarize the result of the molecular analysis and the clinico-pathological features 
of the CPTC and of the FVPTC cases, respectively.  
 
 
 
TableIV.15 Clinico-pathological,  immunohistochemical and molecular  features of the CPTC cases 
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1 M 58 0.8 PC - - - - 0.0 - 3 2 1 +/- -/+ -/+ -/+ +/+ -/+ ND ND 
2 F 66 1.5 WC - - - ND ND - 2 2 1 +/+ +/- -/+ +/+ +/+ +/- ND ND 
3 F 31 3.5 PC + - - - 0.2 - 3 3 2 +/+ +/- -/+ +/+ +/+ +/- - - 
4 F 59 0.6 PC + - - ND ND - 2 2 1 +/+ +/- -/+ +/+ +/+ +/- - - 
5 F 37 1.0 WC + - - ND ND - 3 3 2 +/- +/+ -/+ -/+ +/+ +/+ ND ND 
6 F 35 0.3 PC - - - + 0.3 - 2 3 0 +/- +/- +/+ +/+ +/- +/- ND ND 
7 F 40 1.5 PC - - - - 0.4 - 3 3 1 +/+ +/- -/+ -/+ +/- +/- V600E - 
8 F 38 0.5 PC - - - ND ND - 2 2 0 +/+ +/+ -/+ -/+ +/+ +/- ND ND 
9 M 25 1.2 PC - - + - 2.0 - 2 1 1 +/+ +/- -/+ -/+ +/+ +/- - - 
10 F 30 0.6 PC + - - - 0.0 - 2 3 2 +/+ +/- -/+ +/+ -/+ -/+ V600E - 
11 F 40 2.2 WC - - - ND ND - 1 2 2 +/+ +/- -/+ -/+ +/+ +/+ - - 
12 F 50 3.0 WC - - - ND ND - 1 1 0 +/- +/- -/+ -/+ +/- +/- V600E - 
13 F 25 2.1 WC - - - ND ND - 1 1 1 +/+ +/- -/+ +/+ +/+ +/- V600E - 
14 F 45 4.5 WC + - - ND ND - 2 3 2 +/- +/+ +/+ -/+ +/+ +/- V600E Q61R 
15 F 23 2.5 PC - - - + 0.9 - 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - - 
16 M 65 2.3 PC - - - - 0.0 - 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - - 
17 F 21 2.0 PC - - + + 0.0 - 1 2 0 +/+ +/- -/+ +/+ +/+ +/- V600E - 
18 F 79 2.8 PC - + - - 0.0 - 3 3 1 +/+ -/- -/+ -/+ +/+ +/- - - 
19 F 65 3.5 PC - + - + 0.0 - 1 2 0 +/+ +/- -/+ +/- +/- +/- V600E - 
20 F 28 2.5 PC - - + - 0.0 - 3 3 0 +/+ +/+ -/+ +/+ +/+ +/- - - 
21 F 28 2.0 PC - - + - 0.0 - 3 3 0 +/+ +/- -/+ +/+ +/+ +/+ V600E - 
22 F 43 1.5 WC + - + ND ND - 1 1 0 +/+ +/- -/+ +/+ +/+ +/+ - - 
23 F 47 4.5 PC - + + + 5.1 - 1 3 1 +/+ +/- -/+ +/+ +/+ +/- V600E - 
24 F 28 0.9 PC - - - - 0.2 + 1 2 1 +/+ +/- +/+ +/+ +/+ +/- V600E - 
25 F 21 1.2 PC - - - + 0.1 + 1 2 2 +/+ +/+ +/+ +/+ -/+ +/- - - 
26 F 22 1.9 PC + - - + 0.7 + 1 1 1 +/+ +/- -/+ +/+ +/+ +/- - - 
27 F 30 1.3 PC - + + - 0.5 + 2 3 2 +/+ +/- -/+ +/+ -/+ +/- - - 
28 F 56 0.7 PC + - - + 1.0 + 3 3 2 +/+ +/- -/+ +/+ -/+ +/- - - 
29 F 18 1.5 PC + + + - 0.0 + 3 3 2 +/+ +/- +/+ +/+ -/+ +/- - - 
30 M 22 1.1 PC + - - - 0.2 + 2 3 2 +/- +/- +/+ +/+ -/- +/- - - 
31 F 22 0.8 PC - - - ND ND + 1 2 2 +/+ +/- -/+ +/+ -/+ +/- ND ND 
32 F 56 0.8 PC + - - + 0.7 + 1 2 1 +/+ +/- -/+ +/+ -/+ +/+ ND ND 
33 M 42 1.6 PC + + - - 2.2 + 2 3 3 +/+ +/- -/+ +/+ -/+ +/- - - 
34 F 38 3.0 PC + - + - 0.0 + 1 1 2 +/+ +/- -/+ +/+ -/+ +/- V600E - 
35 F 35 1.7 PC - - + - 1.4 + 0 2 2 +/+ +/- -/+ +/+ -/+ +/- V600E - 
36a,b M 11 6.0 PC + + + + 0.4 + 1 2 0 +/+ +/- -/+ +/+ +/- +/- - - 
37a,b F 56 2.4 PC - + - - 1.5 + 1 2 2 +/+ +/- -/+ +/+ -/+ +/- - - 
38 F 83 7.5 PC - + - - 1.0 + 0 3 ND +/+ ND -/+ ND -/+ ND V600E - 
39 F 18 3.6 PC + - + + 3.1 + 2 2 1 +/+ +/- +/+ +/+ -/+ +/- - - 
40 M 14 2.5 PC + + - + 2.0 + 1 2 1 +/+ +/- +/+ +/+ -/- +/- - - 
41 F 32 1.1 PC - + - - 0.4 + 0 2 1 +/- +/- -/+ +/+ +/- +/- V600E - 
42 F 56 7.5 PC + + - - 0.6 + 1 2 1 +/+ +/- -/+ +/+ -/+ +/- ND ND 
M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, EE extra-thyroid extension, I-LVD Intratumoural lymph vessels density,  
LNM lymph node metastases, C expression at  the center of the tumour, P expression at the tumour periphery, CT expression at the control tissue, n nuclear 
expression, c cytoplasmatic expression,  ND not determined. a Cases with concurrent distant metastases,  b Cases with recurrence(s). 
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Table IV.16 Clinico-pathological, immunohistochemical and molecular features of the FVPTC cases 
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1 F 32 22 2.0 WC - - + - 0.0  2 0 2 +/+ +/- -/+ +/+ +/+ +/- - - 
2 F 26 21 1.8 PC + - + - 0.0 - 2 3 1 +/+ +/- -/+ +/+ +/+ +/+ V600E - 
3 F 59 19 0.5 WC - - - ND ND - 0 0 0 +/- +/- -/+ +/- +/- +/- - - 
4 F 51 18 1.4 WC - - - - 0.0 - 2 3 1 +/+ +/- +/+ +/+ +/+ +/- - - 
5 F 36 18 0.5 PC - - - - 0.5 - 1 1 1 +/+ +/- +/+ +/+ +/- +/- V600E - 
6 F 39 15 1.0 WC + - - - 0.6 - 1 1 0 +/- +/- +/+ +/+ +/+ +/- - Q61R 
7 F 48 13 0.6 WC - - - - 0.0 - 1 0 0 +/+ +/+ +/+ +/+ +/- +/- - - 
8 F 33 20 0.2 PC - - - ND ND - 3 3 0 +/+ +/+ +/+ +/+ +/+ +/- - - 
9 F 30 15 0.5 WC - - - - 0.0 - 1 1 0 +/+ +/+ -/+ +/+ +/- +/- - - 
10 F 21 21 0.6 PC - - - - 4.8 - 1 3 1 +/- +/- -/+ +/+ +/- +/- - - 
11 F 37 18 0.3 PC - - + - 0.0 - 1 1 1 +/- +/- -/+ +/+ +/- +/- - - 
12 F 28 21 2.8 WC + - + - 0.0 - 2 3 0 +/+ +/- -/+ +/+ +/+ +/+ - - 
13 F 34 20 3.5 WC - - - - 0.0 - 0 0 0 +/- +/- +/+ -/+ +/- +/- - - 
14 M 61 22 4.0 WC - - + - 0.0 - 2 2 2 +/+ +/- -/+ +/+ +/+ +/- V600E - 
15 M 35 20 3.5 WC - - + - 0.0 - 1 1 1 +/+ +/- -/+ +/+ +/- +/- - Q61R 
16 F 50 20 2.5 WC - - - - 0.0 - 1 1 1 +/- +/- -/+ -/+ +/- +/- - - 
17 F 47 23 3.0 PC - - - - 0.0 - 2 3 0 +/- +/- +/+ +/+ +/+ +/- - Q61R 
18 F 49 14 3.0 WC + - + ND ND - 2 1 1 +/+ +/+ -/+ +/+ +/+ +/- - - 
19 F 35 21 1.7 PC + - + ND ND - 3 3 1 +/+ +/- -/+ +/+ +/+ +/- ND ND 
20 F 32 13 4.7 PC + - + - 1.0 - 2 3 2 +/+ +/- +/+ +/+ +/+ +/- - - 
21 F 52 13 2.5 WC + - - - 0.0 - 1 1 2 +/- +/- +/+ +/+ +/- +/- - - 
22 F 66 13 2.5 WC + - - - 0.0 - 1 1 0 +/+ +/- +/+ +/+ +/- +/- - - 
23 F 58 13 1.5 PC + - + + 0.3 - 0 1 1 +/+ +/- -/+ +/+ +/+ +/- V600E - 
24 F 54 10 1.8 PC + - + + 0.2 - 1 2 1 +/+ +/+ -/+ +/+ +/+ +/- - - 
25 M 45 20 4.0 WC - - - - 0.1 - 1 1 1 +/- +/- -/+ +/+ +/- +/- - - 
26b M 57 3 9.5 PC - + + + 4.4 - 2 2 1 +/+ +/+ +/+ +/+ -/+ +/- - - 
27 F 56 3 0.8 PC + - + + 1.3 + 1 2 2 +/+ +/- +/+ +/+ -/- +/- - - 
28 M 21 4 2.5 PC - + + - 2.0 + 1 2 0 +/+ +/- -/+ +/+ -/+ +/- - - 
29 F 20 14 1.0 PC + - + - 6.0 + 0 1 2 +/- +/- -/+ +/+ -/- +/- ND ND 
30 F 49 4 2.2 PC - - + - 3.9 + 0 1 0 +/- +/- -/+ +/+ -/- +/- - - 
31 F 43 10 4.0 PC + + + - 0.1 + 0 1 0 +/- +/- -/+ +/+ -/- +/- - - 
32 F 43 10 1.5 PC + + + - 4.3 + 1 3 1 +/- +/- -/+ +/+ +/- +/- V600E - 
33a,b M 63 7 1.8 PC - - + - 0.0 + 1 3 1 +/- +/- -/+ +/+ -/+ +/- - - 
M male, F female, + presence, - absence, WC well circumscribed, PC poorly circumscribed, EE extra-thyroid extension, I-LVD Intratumoural lymph vessels density,  
LNM lymph node metastases, C expression at  the center of the tumour, P expression at the tumour periphery, CT expression at the control tissue, n nuclear expression, 
c cytoplasmatic expression,  ND not determined. a Cases with concurrent distant metastases,  b Cases with recurrence(s). 
 
IV.5.1 Correlation between the results of the molecular analysis and the clinico-pathological 
data, including the lymph vessels profile 
 
Overall, the BRAF V600E mutation occurred in 19 out of 65 PTC cases (29.2%) and the N-RAS Q61R 
mutation occurred in 4 out of 65 PTC tumours (6.2%). 
The frequency of BRAF mutation in CPTC group was significantly higher than in FVPTC group (41.2% and 
16.1%, respectively)(p=0.032), and occurred in 13 out of 42 PTC-M tumours (31.0%) and in 6 out of 23 
PTC+M tumours (26.1%). The N-RAS mutation occurred only in PTC-M tumour (Tables IV.15 and IV.16). 
In the CPTC group, 9 out of 18 CPTC-M (50.0%) and 5 out of 16 CPTC+M (31.3%) displayed BRAF 
mutation. The BRAF V600E mutation was detected in one case of E-FVPTC (6.7%) and four cases of PC-
FVPTC (25.0%) (Table IV.16 and Figure IV.5). The N-RAS mutation was detected in 1 out of 34 CPTC 
tumours (2.9%); it was a Q61R mutation in a well circumscribed encapsulated CPTC-M tumour (1 out of 18 
– 5.6%) with a concurrent BRAF V600E mutation.  
In the FVPTC group, the BRAF V600E mutation was detected in four FVPTC-M (16.7%) and one 
FVPTC+M (14.3%).  N-RAS Q61R mutation was detected in 3 out of 31 cases (9.7%) all of which were 
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FVPTC-M tumours (3 out of 24 – 12.5%). The N-RAS Q61R mutation was detected in two cases of E-
FVPTC (13.3%) and one case of PC-FVPTC (6.3%) (Tables IV.15 and IV.16; Figure IV.5). 
The presence of BRAF mutation in CPTC was significantly associated to female gender (p=0.031)(14 
females and 0 males) (Table IV.17). In FVPTC cases, the mean intratumoural LVD was significantly lower 
in E-FVPTC cases with wild type N-RAS (p=0.016). Case 6 of the E-FVPTC subgroup was the only one with 
D2-40 positive intratumoural lymph vessels and was a N-RAS mutated tumour that did not show signs of 
extra-thyroid extension, lymph vessel invasion or vascular invasion, nor had given rise to lymph node 
metastases (Table IV.16).  
The presence of BRAF and N-RAS mutation was not significantly associated to any other clinical or 
morphological feature (Tables IV.15, IV.16 and IV.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV.17 Comparison of  molecular features of CPTC and FVPTC cases  
PTC 
Variant Features 
BRAF 
Wild type 
BRAF 
V600E p value 
CPTC 
Gender (female:male) 14:6 14:0 0.031 
Age, years(mean±sd) 35.2±19.0 40.5±16.9 0.41 
Tumour size, cm (mean±sd) 
Number of tumours (>1cm/total) 
2.2±1.2 
0.90 
2.7±1.9 
0.86 
0.294 
>0.999 
Capsule (absence/total) 0.70 0.57 0.487 
Capsule invasion (presence/total) 1.00 0.83 >0.999 
Growth pattern (poorly circumscribed/total) 0.90 0.79 0.627 
Multicentricity (presence/total) 0.55 0.29 0.079 
Extra-thyroid extension (presence/total) 0.35 0.29 >0.999 
Vascular invasion (presence /total) 0.35 0.33 >0.999 
Lymph vessels invasion (presence/total) 0.44 0.27 0.448 
Intratumoural LVD (mean±sd) 0.9±1.0 0.8±1.5 0.771 
Lymph node metastases (presence/total) 0.55 0.36 0.315 
pT (T3+T4/total) 0.35 0.36 >0.999 
Stage III+IV/total 0.15 0.29 0.410 
FVPTC 
Gender (Female:Male) 21:5 4:1 >0.999 
Age, years (mean±sd) 43.5±12.5 44.8±14.8 0.837 
Tumour size,cm (mean±sd) 
Number of tumours (>1cm/total) 
2.4±1.9 
0.62 
1.9±1.3 
0.80 
0.576 
>0.999 
Capsule (absence/total) 0.73 0.94 0.172 
Capsule invasion (presence/total) 0.73 1.00 >0.999 
Growth pattern (poorly circumscribed/total) 0.46 0.80 0.333 
Multicentricity (presence/total) 0.35 0.60 0.350 
Extra-thyroid extension (presence/total) 0.23 0.20 >0.999 
Vascular invasion (presence /total) 0.50 0.80 0.345 
Lymph vessels invasion (presence/total) 0.13 0.20 >0.999 
Intratumoural LVD (mean±sd) 0.8±1.5 1.0±1.8 0.778 
Lymph node metastases (presence/total) 0.23 0.20 >0.999 
pT (T3+T4/total) 0.15 0.20 >0.999 
Stage III+IV/total 0.12 0.00 >0.999 
CPTC 
+ 
FVPTC 
Gender (Female:Male) 35:11 18:1 0.093 
Age, years (mean±sd) 39.9±16.0 41.6±16.1 0.689 
Tumour size, cm (mean±sd) 
Number of tumours (>1cm/total) 
2.3±1.6 
0.80 
2.5±1.7 
0.84 
0.647 
0.740 
Capsule (absence/total) 0.54 0.63 0.589 
Capsule invasion (presence/total) 0.81 0.86 >0.999 
Growth pattern (poorly circumscribed/total) 0.65 0.79 0.379 
Multicentricity (presence/total) 0.43 0.32 0.418 
Extra-thyroid extension (presence/total) 0.33 0.32 >0.999 
Vascular invasion (presence /total) 0.43 0.47 0.791 
Lymph vessels invasion (presence/total) 0.26 0.25 >0.999 
Intratumoural LVD (mean±sd) 0.8±1.3 0.9±1.6 0.993 
Lymph node metastases (presence/total) 0.37 0.32 0.780 
pT (T3+T4/total) 0.24 0.32 0.547 
Stage III+IV/total 0.13 0.21 0.461 
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Figure IV.5  
 
Summary of the most impressive findings concerning the distinction between E-FVPTC (A) 
and PC-FVPTC+CPTC (B).  
Red vessels – D2-40 negative intratumoural thin walled vessels; Blue vessels – D2-40 positive 
intratumoural and peritumoural lymph vessels; Black vessels – thick walled veins; Blue thunder 
over blue vessel – collapsed D2-40 positive lymph vessel; Pink spots – neoplastic thrombi; EE – 
extra-thyroid extension; IT-LV – D2-40 positive intratumoural lymph vessels; PT-LV – 
peritumoural lymph vessels; LVinv – lymph vessel invasion; Vinv – vascular invasion, LNM – 
lymph node metastasis). 
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IV.5.2 Correlation between the results of the molecular analysis and the immunohistochemical 
expression of elements of TGF-beta/Smad-dependent pathway  
 
The BRAF V600E mutation was detected in 20.0% of WC-PTC including 4 WC-PTC cases disclosing 
similar or higher TGF-beta expression in the periphery than in the center, while none of the 3 WC-PTCs with 
a lower TGF-beta expression in the periphery than in the center were BRAF mutated tumours. The group of 
WC-PTC cases with similar or higher TGF-beta expression at the periphery than in the center had similar 
clinico-pathological features and no lymph node metastases, independently of the BRAF mutational status 
(Tables IV.15 and IV.16). 
The BRAF mutation was detected in 15 PC-PTCs (33.3%) disclosing similar or higher TGF-beta expression 
in the periphery than in the center. PC-PTC cases with similar or higher TGF-beta expression at the 
periphery than in the center disclosed lymph node metastases in 40.0% of BRAF mutated tumours and in 
56.7% of tumours with wild-type BRAF (Tables IV.15 and IV.16).  
 
The Table IV.18 summarizes the result of the molecular analysis and the immunohistochemical expression 
of elements of TGF-beta/Smad-dependent pathway in CPTC and FVPTC.  
 
 
Table IV.18 Comparison between the immunohistochemical patterns of expression of the elements of TGF-
beta/Smad-dependent pathway and the PTC molecular profile. 
 
 Features 
Increment in TGF-beta intensity of expression 
(mean±sd) 
Underexpression or basal 
cytoplasmatic expression (%) 
C-CT p P-C p P-Smad2/3 p 
CP
TC
+F
V
PT
C BRAF     V600E 
              Wild type 
0.2±1.2 
0.5±1.0 0.295 
0.8±0.8 
0.4±0.7 0.029 
22.2 
50.0 0.053 
N-RAS    Q61R  
                Wild type 
0.8±1.0 
0.5±1.0 0.532 
0.5±0.6 
0.5±0.7 0.965 
75.0 
40.0 0.302 
CP
TC
 
BRAF     V600E 
              Wild type 
0.3±1.3 
0.6±1.1 0.562 
0.8±0.8 
0.4±0.6 0.048 
23.1 
25.0 >0.999 
N-RAS    Q61R  
              Wild type 
0.0 
0.5±1.2 0.694 
1.0 
0.5±0.7 0.525 
100.0 
21.9 0.242 
FV
PT
C BRAF     V600E 
              Wild type 
0.0±0.7 
0.5±0.9 0.255 
0.8±0.8 
0.4±0.8 0.324 
20.0 
69.2 0.060 
N-RAS    Q61R  
              Wild type 
1.0±1.0 
0.4±0.9 0.239 
0.3±0.6 
0.5±0.8 0.720 
66.7 
60.7 >0.999 
C expression at  the center of the tumour, P expression at the tumour periphery, CT expression at the control tissue. 
 
 
The mean intensity of TGF-beta expression at the periphery, compared with the respective center of the 
tumours, was significantly higher in BRAF mutated PTCs when CPTC and FVPTC are considered together 
(p=0.029) or when the comparison is restricted to CPTC (p=0.048) (Table IV.18).  
Tumours with basal or underexpression of P-Smad2/3 cytoplasmatic expression tended to have more often 
wild type BRAF than mutated BRAF (p=0.053) (Table IV.18). The same trend was observed when this 
comparison was restricted to FVPTC (p=0.060) (Table IV.18). 
BRAF V600E mutation and N-RAS Q61R mutation were not significantly associated to Smad4 or Smad7 
expression in CPTC nor in FVPTC (Tables IV.15 and IV.16). 
 
 
 
 
 
 
 
 
 
 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
 
 
 
 
 
 
 
 
 
 
V Discussion 
________________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
As in other worldwide centers [41, 167-169], the number of PTC diagnosis recorded in the Cancer Registry 
of the Pathology Department of Centro Hospitalar de São João (Porto, North of Portugal) has increased over 
the last 29 years encompassing both small and large tumours, probably reflecting not only a real increment in 
the number of PTC cases but also changes in health care guidelines/politics. Such changes, like the 
widespread use of thyroid ultrasound, the preoperative cytological diagnosis and the more extensive 
sampling of the surgical specimens during pathological examination, appear to have contributed to the 
detection of asymptomatic and small PTCs [12], as expressed in the trend towards decreased mean tumour 
size of PTCs archived in our Cancer Registry.  
At variance with the increasing incidence of thyroid cancer, the mortality due to these tumours has decreased 
[12]. In our files, the large majority of PTC follows an indolent clinical behaviour and the rates of recurrence 
and distant metastases are globally low in comparison with other series on record [56]. These low rates 
probably reflect a number of facts: deficient information on the follow up of the patients, increasing number 
of incidentally found small and/or very small tumours and inclusion in the group of carcinomas of the 
encapsulated form of PTC previously diagnosed as follicular adenoma. 
The identification of areas with peculiar features topographically associated to PTC or the identification of 
metastasis into preexisting PTC appear to constitute unusual settings with putative impact in the patients’ 
outcome that justify the systematic need for an appropriate sampling of the tumours. In our series, as in 
others, the coexistence of well differentiated PTC with areas of neoplastic progression towards poorly 
differentiated carcinoma was associated to a poorer outcome in comparison to strictly well differentiated 
PTCs [62, 67]. Conversely, the coexistence of PTC and basaloid neoplasms represents a rare finding with 
unknown consequences to the natural history of PTC. The two reported cases of basaloid neoplasms 
associated to PTC expressed diffusely p63, like the main cells of solid cell nests and, in one case, the 
basaloid neoplasm shared with the PTC component the same N-RAS mutation. The morphological and 
immunophenotypic features of, at least, such basaloid neoplasms (Eloy et al, unpublished observations) are 
similar to those observed in the solid cell nests. Solid cell nests can occur in topographic continuity with 
papillary microcarcinoma sharing with it a BRAF molecular alteration [169], conveying the hypothesis of a 
histogenetic relationship between solid cell nests and PTC (see Papers 6 and 7 for further discussion). 
Besides some clinically aggressive cases of PTC with or without coexistent particular histopathologic 
components, our files also record strictly well differentiated PTCs (more frequently CPTC than FVPTC 
cases) displaying signs of clinico-pathological aggressiveness, namely lymph node metastases. 
Predictive factors of PTC metastatic capacity and of local aggressive behaviour still remain incompletely 
established.  
In the study of our series of 75 PTCs (discussed from here foreword) we found that, both in CPTC and in 
FVPTC, extra-thyroid extension and poorly circumscribed growth pattern were the clinical and 
morphological features most closely associated to lymph node metastases. In fact, all the PTCs metastatic to 
the lymph nodes were poorly circumscribed, whereas all well circumscribed PTCs did not give rise to lymph 
node metastases.  
In the CPTC group, multicentricity was significantly associated to lymph node metastases, particularly in 
subgroup of poorly circumscribed tumours. In the poorly circumscribed tumours of the FVPTC group, extra-
thyroid extension was the most important feature associated to lymph node metastases. In FVPTC cases, 
vascular invasion and mitotic index were also significantly associated to lymph node metastases, although 
the latter may reflect the existence of a single case with 6 mitoses per 10 high power fields. 
FVPTC tumours measuring 1cm or less and arising in a gland with benign pathology other than thyroiditis 
were less often associated to lymph node metastases than solitary FVPTC. This difference probably reflects 
our biased sample of small tumours that was composed by incidentally found PTCs in patients operated for 
benign pathology (nodular goiter or FA). In our series, this difference was also observed in tumours larger 
than 1cm. The low frequency of lymph node metastases from PTC arising together with concurrent benign 
pathology other than thyroiditis has not been reported before to the best of our knowledge, and needs 
confirmation in larger series. 
Our results support the assumption that encapsulated, non angio-invasive FVPTC carry an excellent 
prognosis even when the patients underwent partial thyroidectomy [27, 28, 45, 60, 170] (see Paper 4). The 
emerging importance of the growth pattern of PTC on the outcome of the patients justifies the need for a 
complete sampling of the periphery of the tumours during the pathological examination of the surgical 
specimen, as it is recommended in the setting of encapsulated follicular tumours [12].  
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The peculiar metastatic properties of the FVPTC subtypes (E-FVPTC and PC-FVPTC) are not fully 
understood and may be related to lymphangiogenesis or, at least, to the abundance of lymph vessels in both 
settings. The search for intratumoural lymph vessels disclosed a clear cut difference between E-FVPTC and 
PC-FVPTC and CPTC. D2-40 positive lymph vessels were not detected within 11 out of 12 tumours of the 
E-FVPTC group, a result that fits with the absence of lymph vessel invasion and lymph node metastases in 
E-FVPTC. A very low frequency of identifiable intratumoural lymph vessels had been previously reported 
by other groups in FA [85, 90, 103] and FTC [85, 103].  
The rarity of extra-thyroid extension, intratumoural lymph vessels, lymph vessel invasion and lymph node 
metastases in E-FVPTC, together with the differences on the molecular features i.e. the scarcity of BRAF 
V600E mutation [26] and prominence of RAS mutations [26], also confirmed in the present study (see 
below), contributes to separate E-FVPTC from PC-FVPTC and to approach the former to minimally invasive 
FTC [75, 84] (see Papers 4 and 5 for further discussion). It remains to be clarified whether the absence of 
intratumoural D2-40 positive lymph vessels in most E-FVPTCs, as well as in other follicular patterned 
tumours, reflects a low capacity of incorporation (with or without proliferation) of lymphatic vessels since 
the first steps of tumourigenesis, or their disappearance by a collapsing mechanism (or other mechanism) 
secondary to the increased intratumoural pressure that may occur during the neoplastic development of 
encapsulated tumours [100]. 
The results we have obtained contribute also to show that PC-FVPTC cases share most of the features of 
CPTC cases [75] (see Paper 4). This is particularly obvious regarding the poorly circumscribed peripheral 
growth pattern which is frequently or occasionally accompanied by vascular invasion and extra-thyroid 
extension, occurrence of BRAF V600E mutation (see below), abundance of intratumoural lymphatic vessels, 
lymph vessel invasion and lymph node metastases. 
The significant association we observed between intratumoural LVD and occurrence of lymph node 
metastases confirms the data reported by several groups [91, 93, 94, 104] and contradicts others [85, 90]. In 
our series, lymph vessel invasion appears to be the second strongest factor associated with the occurrence of 
lymph node metastases after extra-thyroid extension. The relation between high intratumoural LVD 
determined by D2-40 and lymph node metastases is indirectly confirmed by the absence of nodal metastasis 
in E-FVPTC cases that do not have intratumoural lymphatic vessels despite the abundance of peritumoural 
lymph vessels. 
The abundance of D2-40 positive peritumoural lymph vessels was similar in the three groups of PTC (E-
FVPTC, PC-FVPTC and CPTC) as it had been previously reported by Giorgadze et al [103] in a series of 
follicular patterned lesions. Peritumoural LVD was not significantly related to any clinico-pathological 
feature, namely the occurrence of lymph vessel invasion or lymph node metastasis, thus supporting the 
results of Garcia et al [90]. The mean peritumoural LVD determined by D2-40 expression was higher than 
intratumoural LVD as previously reported [90] and was similar in all groups of PTC, thus implying that such 
feature does not appear to be modulated by the tumour histotype. 
In our series, as in others [104], all lymph vessels disclosing neoplastic thrombi in their lumina expressed 
D2-40, suggesting that the intratumoural D2-40 negative vessels may constitute less efficient pathways for 
PTC dissemination. It remains to be clarified if the D2-40 expression in such cases is induced by the 
presence of the neoplastic thrombi or if intratumoural D2-40 vessels, mainly located at the invasive front, as 
observed by Hall et al [104] is the result of the invasion of peritumoural tissues with subsequent 
incorporation of the originally peritumoural D2-40 positive lymph vessels in the bulk of the tumour. The 
latter hypothesis is favoured by the association we found between extra-thyroid extension and intratumoural 
high LVD. In this scenario, the absence of an invasive front, as well as the presence of a well constituted 
capsule, could prevent the recruitment of D2-40 positive peritumoural lymph vessels and their subsequent 
invasion by the neoplastic cells, as suggested by the nearly absence of D2-40 positive intratumoural lymph 
vessels in E-FVPTC of our series. 
The prominence of peritumoural small sized veins, including capsular veins presenting luminal neoplastic 
trombi, point to the role played by vascular (venous) invasion. Vascular (venous) invasion was observed in 
26 out of 61 cases of PTC, but in such cases the invaded veins did not express D2-40 in the endothelial cells, 
arguing against the hypothesis that D2-40 expression may be induced in endothelial cells by neoplastic 
thrombi. The neoplastic thrombi seen in the thick walled veins may result from invasion of small 
intratumoural vessels or from the direct invasion of such thick walled blood vessels which present a well-
developed muscle layer probably able to resist the effect of the intratumoural pressure over the vessels of the 
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capsule [100, 171]. The increment in the intratumoural interstitial pressure is thought to be partially due to 
the functionally impaired lymphatic system in tumours, thus leading to subsequent problems of fluids and 
macromolecules [172]. In our series, the number of cases with distant metastases (n=3) is too low (data not 
shown) to allow the clarification of the role played by D2-40 positive and negative vessels in the occurrence 
of blood borne metastasization.  
Our findings highlight the role played by intratumoural lymphangiogenesis in lymph node metastization at 
variance with the well acknoledged importance of intratumoural angiogenesis in the metastatic potential of 
FTC and PTC [85, 87, 97-99]. While in CPTC the most important pathway of initial dissemination appears 
to be via intratumoural lymph vessels, in encapsulated follicular patterned tumours the invasion via veins of 
the capsule or outside the tumour is aparantly necessary to give rise to blood borne metastasis [1, 82].  
Our study highlights the role of intratumoural lymph vessels in PTC nodal metastization and reinforces the 
importance of distinguishing E-FVPTC from PC-FVPTC regarding invasiveness. 
The tumour cells’ invasiveness is a feature related to the EMT that develops at the periphery of the tumours, 
in their invasive front [105-107]. It is known that the neoplastic cells at the tumour periphery differ 
substantially from those in the bulk of the tumours regarding the expression of several structural and 
functional proteins (e.g. cytokeratins, vimentin, beta-catenin, E-cadherin, fibronectin 1, TGF-beta) [105, 
107,108,111,119].  
The role of TGF-beta in thyroid cell signaling and in thyroid carcinogenesis, like in many other models, is 
very complex and profoundly influenced by the cellular and tissue context [119], thus being better evaluated 
in tissue samples than in cell lines. In the present study, we observed signs of the dual role of TGF-beta 
regarding the co-existence in the same tumour of signs of activation and of inhibition of TGF-beta/Smad-
dependent pathway according to the location of the neoplastic cells. 
The tumour suppressive effect of TGF-beta/Smad-dependent pathway that had been firmly established in 
thyroid cell lines [126-130] and in some PTC cell lines [118,121], was found to be abrogated at the periphery 
of PTC [105, 119] where increased vimentin expression and loss of E-cadherin with increased motility and 
invasiveness configure the EMT invasive phenotype [107]. We observed, particularly in the poorly 
circumscribed tumours, that TGF-beta expression was stronger in the invasive front than in the central 
regions of the tumours, and that an increased TGF-beta expression at the periphery of the tumours was 
associated to the occurrence of extra-thyroid extension and lymph node metastases, as previously reported by 
Riesco-Eizaguirre et al [119].  
Our subdivision of PTCs into well and poorly circumscribed carcinomas (WC-PTC and PC-PTC, 
respectively) goes further than the usual division into CPTC and FVPTC and provides interesting results: in 
WC-PTC (no infiltrative features and no lymph node metastases) the mean increment of TGF-beta 
immunoexpression from the center to the periphery was very low in comparison with PC-PTC, in line with 
the above mentioned association between TGF-beta expression at the periphery and invasiveness, also 
reported by other authors [119]. 
We detected TGF-beta and P-Smad2/3 expressions in the center of all cases of WC-PTC and PC-PTC and 
control tissues (except in nine TGF-beta negative cases), as it had been reported previously [131, 133, 135, 
136], thus highlighting the existence of signs of functioning TGF-beta/Smad-dependent pathway in PTC.  
Smad4 nuclear expression is considered as indicative of functioning TGF-beta/Smad-dependent pathway 
[133,137,139] but the nuclear translocation of phosphorylated Smad2 in response to TGF-beta, does not 
require the presence of Smad4 [123], as our results also indicate. In the present study, all tumours expressed 
Smad4 in the cytoplasm of the neoplastic cells, like it had been observed by Matsuo et al [133] and Cerutti et 
al [137], whereas Smad4 nuclear expression was detected in 27% of tumours. In WC-PTC, Smad4 nuclear 
expression was detected only in cases without vascular invasion. The nuclear expression of Smad4 in PTC 
cells had not been detected previously to the best of our knowledge. The percentage of cases with Smad4 
nuclear expression may be related with an impaired nuclear translocation of Smad2/3-Smad4 complexes as a 
sort of end result of Smad4 mutations that were detected in another series in 21% of PTCs [173]. 
Unfortunately, the absence of available material for the molecular search of Smad4 mutations in the present 
series did not allow the confirmation or the rejection of this hypothesis. Whatever the mechanisms involved 
in the process, we found that signs of functioning TGF-beta/Smad-dependent pathway in the center of the 
tumours, namely basal or overexpression of TGF-beta and nuclear Smad4, were associated to low vascular 
invasiveness and absence of lymph node metastases, respectively. 
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Smad7 nuclear expression has been associated to loss of TGF-beta/Smad-dependent pathway inhibition 
[174] and was found to be at basal or overexpressed levels in 72% of the cases of the present series, a 
percentage similar to that reported in another series of PTC [133]. We found that Smad7 nuclear expression 
was associated to low neoplastic invasiveness, namely well circumscribed growth pattern and unicentricity in 
CPTC, and to absence of extra-thyroid extension and vascular invasion in FVPTC. More importantly, Smad7 
nuclear expression was associated to absence of lymph node metastases both in CPTC and FVPTC.  
The encapsulated, non-angio-invasive FVPTC is the prototype of a carcinoma with an extremely benign 
course [60]. In the present series, and in almost every series on record, most WC-PTCs display a capsule and 
are apparently protected from the cascade of TGF-beta oncogenic effects occurring at the periphery of PC-
PTC. The WC-PTC that do not disclose invasive front nor EMT features (independently of the occurrence of 
BRAF mutation), nor lymph node metastases, often present a nearly homogeneous TGF-beta expression 
throughout the tumour.  
At variance with TGF-beta, BRAF mutation has been found to promote growth and cell invasiveness [52].In 
one animal model of PTC, the oncogenic BRAF was found to cooperate with TGF-beta in the induction of 
migration and invasion, disrupting the suppressive effects of TGF-beta/Smad-dependent signaling pathway 
[122]. Basolo et al [59] have shown that in small PTCs there is a significant association between the 
presence of BRAF mutation and tumour invasiveness and nodal metastization [59]. In fact, besides the 
recognized putative contribution of the detection of BRAF mutation to the preoperative diagnosis of PTC and 
the emerging evidence of its influence over the PTC response to radioiodine therapy [161], the data on BRAF 
mutated cell lines and experimental models, as well as on the observational data on human PTC, do not 
prove that BRAF mutation per se is a major prognostic factor, remaining to be clarified how does BRAF 
mutation increases tumour cells invasiveness. Moreover, the association between BRAF mutation and some 
pathological features with clinical significance are incompletely established [27, 52, 56, 58, 74, 149-154, 
159].  
In our series, BRAF V600E mutation was less frequently detected than in most series on record [26, 27, 32, 
48, 52, 56, 58, 74, 147-153]. It was significantly more frequent in CPTC than in FVPTC cases, an 
observation consistent with the results of Trovisco et al [74], as well as those of many other series [52, 151]. 
The BRAF V600E mutation was detected in 7% of WC-FVPTC and 25% of PC-FVPTC. 
At variance with the results reported by others, we did not observe in our series a significant association 
between BRAF mutation and poor circumscription [26, 154], tumour size above 1cm [153], extra-thyroid 
extension [52, 154, 159], vascular invasion [56] and lymph node metastases [58, 149, 154]. In the present 
series, the occurrence of BRAF mutation was not also significantly associated with intratumoural LVD. None 
of the 3 patients of our series with distant metastases had a BRAF mutated tumour in contrast with the results 
of Namba et al [150].  
In our series there was not a significant association between the presence of BRAF mutation and lymph node 
metastases. This result fits with those of some studies on record [74, 147, 151] and contradicts others [56, 58, 
154]. Instead, BRAF mutation was strongly associated to the CPTC group, whose cases were more often 
poorly circumscribed than FVPTC cases. Within each group, no additional significant associations to other 
morphological features related to aggressiveness were found. 
BRAF V600E mutated CPTCs were significantly more often found in females than in males, in contrast with 
the previously observed higher frequency in males [152] or similar frequency in both genders [25, 60, 74, 
151].  
Although the mean age of PTC patients with and without the BRAF V600E mutation was not significantly 
different in CPTC and FVPTC groups, we did not find a single patient younger than 20 years with a mutated 
BRAF tumour, thus confirming that BRAF mutation is rarely present in PTCs of young patients [52, 56, 74]. 
In most series, BRAF mutated PTCs tend to occur in older patients than PTCs without the BRAF mutation 
and to be rarely found in children or young adults. [56, 74] The inverse holds true for RET/PTC 
rearrangements which are frequently detected in PTC occurring in children and adolescents [175, 176].  
At variance with RET/PTC rearrangements that can be detected in cases of nodular goiters/follicular 
adenomas and Hashimoto thyroiditis displaying large, clear and irregular nuclei [36], BRAF mutations have 
not been detected in benign lesions of the thyroid [177] except in exceedingly rare cases [74, 148]. The 
reason for the absence of BRAF V600E mutation in benign lesions and in PTCs of children and adolescents 
remains unknown. It is tempting to speculate that BRAF mutation per se may induce senescence in thyroid 
cells as it has been observed in benign melanocytic lesions [178, 179]. Following this hypothesis, the 
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tumourigenic effect of BRAF mutation would only be seen whenever the mutation is accompanied by 
synergic mutations and/or epigenetic changes in other pathways [123, 179]. We are advancing that the BRAF 
mutation may be tumourigenic for the human thyroid only in relatively late stages of PTC development (in 
normal thyroid and in early neoplastic stages the mutation might induce a senescent phenotype). The results 
recently published by Franco et al [180] in a mouse model support the hypothesis that such synergies may be 
obtained in early stages of the neoplastic development and can be mediated by cooperation with the 
thyrotrophin receptor signaling pathway [180]. In vitro and in vivo studies are necessary to test the 
aforementioned hypotheses that are also important from a prognostic standpoint. 
The putative relationship between alterations of the TGF-beta/Smad-dependent pathway and BRAF mutation 
is difficult to evaluate in an observational study of human tumours like the present one. Despite 
acknowledging this limitation we think our findings suggest the existence of a synergic influence of TGF-
beta over BRAF mutated neoplastic cells in the periphery of the tumours.  
BRAF V600E mutation was more frequently detected in the subset of tumours with higher increment of 
TGF-beta expression at the periphery. This finding concurs with the results of Riesco-Eizaguirre et al [119] 
and suggests that, at the periphery of the tumours, the association of high levels of TGF-beta expression with 
BRAF mutation and invasiveness, as previously described in animal models [122], PTC cell lines and PTCs 
[119], reflects a synergic interaction that may potentiate the oncogenic effect of BRAF mutation. In the 
present series, the occurrence of BRAF mutation did not significantly alter, per se, the frequency of lymph 
node metastases, thus highlighting the complexity of the process and reinforcing the importance of growth 
pattern and invasion for the end result of the neoplastic development process. 
Considering that the increased expression of TGF-beta at the periphery of the tumours may functionally 
articulate with BRAF V600E mutation [122], it remains unclear the reason underlying this particular 
topographic immunoexpression of TGF-beta. Since BRAF mutation occurs, at least in most BRAF positive 
cases, in every tumour cell, the TGF-beta expression increment should be detected, in case it was a direct 
result of the BRAF mutation, throughout the whole neoplastic tissue. It is likely that this increment of TGF-
beta at the periphery of the tumours is influenced by the crosstalk between the neoplastic cells and cellular 
and non-cellular stromal elements, such as tumour-associated macrophages [117, 122], dendritic cells [115], 
lymphocytes [116] and/or basement membrane components [122]. A similar interaction with BRAF has been 
recently described with STAT3 which is highly expressed in the periphery of BRAF mutated PTCs and has 
been found to result from the crosstalk between neoplastic cells and stromal elements [Couto et al, 
unpublished results]. The aforementioned need of co-existing factors in the setting of BRAF oncogenic 
mutation provides an explanation for the low prevalence of BRAF positive PTCs in young patients [74], even 
if one assume that BRAF mutation may be an initiating event. 
In our series we also observed that FVPTCs with basal or underexpression of P-Smad2/3 tended to be more 
often BRAF mutated carcinomas, although the low number of BRAF mutated FVPTCs weakens any 
conclusions on these results. 
Other interactions between TGF-beta signaling pathways and MAPK pathway have been advanced, namely 
through oncogenic RAS that is thought to be required for the disruption of TGF-beta-growth suppressive 
effects in cell lines [60, 174, 181]. In our series, the N-RAS mutation was detected in 6% of the tumours, a 
prevalence that fits within the interval of previously reported data in other PTC series [25, 26, 31, 48, 83, 
148, 162, 163]. The N-RAS mutation was detected in the single case of the E-FVPTC group with 
intratumoural lymph vessels, but it does not seem appropriate to draw any conclusions on the putative 
relationship between N-RAS mutation and lymphangiogenesis from an anecdotic case. We found no 
significant association of N-RAS Q61R mutation with any other clinical or morphological feature, but these 
negative results may reflect the low number of mutated cases in our series.  
In one case (case 14 of the CPTC group) there was coexistence of BRAF and N-RAS mutation demonstrating 
that, although rarely, BRAF and RAS mutations can coexist in the same tumour [148]. It remains to be 
verified if the two mutations coexist in the same cells or correspond to distinct clones, as demonstrated in 
melanomas [182]. 
Our results confirm the prognostic prominence of staging over cytological and molecular features, and the 
major importance of architecture (encapsulated versus infiltrative growth pattern) and topography (different 
immunohistochemical characteristics of tumour cells according to their peripheral or central location) in the 
understanding of PTC development. 
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Taking into consideration all the data we have obtained we conclude that nodal metastases are associated to 
poorly circumscribed, locally invasive PTCs with high intratumoural lymph vessel density; such metastatic 
PTCs exhibit low levels of nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta 
overexpression, regardless of the occurrence of BRAF mutation. 
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The main conclusions of the Thesis, according to the proposed Aims, are the following: 
 
 
Structural aim To review all cases of thyroid tumours filed in the Cancer Registry of the 
Pathology Department of Centro Hospitalar de São João  
 
 
1. Selection of a representative series of PTC cases. 
 
• A series of 75 PTC cases was selected and considered representative of PTCs in the North of 
Portugal. We think that such cases are also representative of the general tendencies observed in 
other series on record. Despite this, we cannot rule out the possibility that our results and 
conclusions may reflect some uncontrolled geographic, institutional and/or sampling biases. 
 
 
2. Identification of problems in thyroid cancer diagnosis and prognosis that should be approached in 
future studies. A particular interest was devoted to the neoplastic components coexistent with PTC 
with influence over the patients’ outcome. 
 
• In the group of thyroid tumours displaying lymph node and/or blood borne metastases there was 
not a single case of well differentiated tumour of uncertain malignant potential, neither any case of 
minimally invasive, non angio-invasive follicular thyroid carcinoma, nor any case of encapsulated, 
non invasive follicular variant of PTC. In the future, studies regarding the role of the tumour 
capsule and the clarification of the malignant potential of encapsulated PTCs should be carried out. 
 
• The identification of poorly differentiated areas in PTCs and the identification of metastases over 
preexisting thyroid tumours constitute unusual settings with negative impact over the patients´ 
outcome. In the future, an attempt should be made to separate PTC cases that progress to poorly 
differentiated carcinomas from those that do not progress. The environmental conditions that 
favour the occurrence of metastatic disease in thyroid tumours should also be explored. 
 
• The identification of a basaloid component occasionally displaying solid cell nest features that may 
coexist with PTC constitutes an unusual finding with unknown impact over the patients’ outcome. 
In the future, an attempt should be made to clarify the putative role of solid cell nests in PTCs 
neoplastic development. 
 
 
Specific aims  
 
First specific aim    To evaluate the relative contribution of the clinico-pathological features of the 
tumours and of their molecular profiles to the development of PTC aggressive 
behaviour. 
 
 
1. Clarification of the differential contribution of the clinico-pathological features to the development 
of lymph node metastases in classic PTC (CPTC) and follicular variant of PTC (FVPTC). The role 
played by intratumoural and peritumoural lymph vessel density was particularly addressed. 
  
• The clinico-pathological features more closely associated to the occurrence of lymph node 
metastases, both in CPTC and FVPTC, are extra-thyroid extension and poorly circumscribed 
growth pattern.  
 
• Encapsulated, non angio-invasive FVPTCs carry an excellent prognosis even when the patients 
undergo partial thyroidectomy. This and the aforementioned conclusion justify the 
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recommendation of routine examination of the whole periphery of well circumscribed thyroid 
nodules with PTC nuclear features. 
 
• Intratumoural lymph vessel density correlates with the occurrence of extra-thyroid extension, 
lymph vessel invasion and lymph node metastases in PTC. 
 
• Peritumoural lymph vessel density is not significantly associated to any clinico-pathological or 
molecular feature of PTC. 
 
 
2. Clarification of the differential contribution of BRAF (V600E) and N-RAS (Q61R) mutations to the 
development of lymph node metastases in CPTC and FVPTC, and of the association of such 
mutations to other clinico-pathological features. 
 
• BRAF mutation is more frequent in CPTC than in FVPTC in contrast with N-RAS mutation which 
is more frequent in FVPTC than in CPTC. 
 
• Our results do not support the existence of an association between BRAF mutation and the 
development of lymph node metastases in CPTC nor in FVPTC. 
 
• Our results do not also support the existence of an association between N-RAS mutation and the 
development of lymph node metastases in CPTC nor in FVPTC but the series is too small to allow 
a definitive conclusion on this issue. 
 
• Our results do not support the existence of an association between BRAF mutation and poor 
circumscription, extra-thyroid extension, tumour size, lymph vessel invasion and vascular invasion. 
This and the aforementioned conclusion do not support the practical usefulness of preoperative 
routine detection of the BRAF mutation in order to predict an aggressive phenotype. 
 
• Our results do not support the existence of an association between N-RAS mutation and poor 
circumscription, extra-thyroid extension, tumour size, lymph vessel invasion and vascular invasion. 
This and the aforementioned results on N-RAS do not support the practical usefulness of 
preoperative routine detection of N-RAS mutations regarding the prediction of an aggressive 
phenotype but, again, the series is too small, with a low number of N-RAS mutated cases, to allow a 
definitive conclusion on this issue. 
 
 
3. Clarification of the morphological and molecular basis underlying the differences in the biological 
and clinical behaviour of encapsulated FVPTC (E-FVPTC) and poorly circumscribed FVPTC (PC-
FVPTC).  
 
• E-FVPTC differs from PC-FVPTC regarding the rarity of extra-thyroid extension, intratumoural 
lymph vessels, lymph vessel invasion and lymph node metastases, as well as regarding the scarcity 
of BRAF V600E mutation and prominence of RAS mutations; the latter features contribute to 
approach E-FVPTC to minimally invasive FTC. 
 
• PC-FVPTC shares most of the features of CPTC, particularly regarding the poorly circumscribed 
peripheral growth pattern, occasionally accompanied by vascular invasion and extra-thyroid 
extension, occurrence of BRAF V600E mutation, abundance of intratumoural lymphatic vessels, 
frequent lymph vessel invasion and frequent occurrence of lymph node metastases. 
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Second specific aim To identify genetic and epigenetic alterations of PTC that may be used as 
biomarkers of invasion and metastization in the daily practice of diagnostic 
Anatomic Pathology. 
 
 
1. Disclosure of the relationship between the expressions of TGF-beta, phosphorylated Smad2/Smad3, 
Smad4 and inhibitory Smad7 and some clinico-pathological features associated to PTC 
aggressiveness. 
 
• Lymph node metastases are not detected in well circumscribed PTCs (WC-PTCs) regardless the 
presence of immunoexpression for TGF-beta, phosphorylated Smad2/Smad3, Smad4 and Smad7. 
 
• Increased cytoplasmatic expression of TGF-beta at the periphery of poorly circumscribed PTCs 
(PC-PTCs) is associated to morphological features of invasiveness, featuring the so-called 
epithelial-to-mesenchymal transition (EMT), and to lymph node metastases. 
 
• The nuclear expression of Smad7 is more frequent in WC-PTCs than in PC-PTCs and is associated 
with unicentricity and absence of extra-thyroid extension, vascular invasion and nodal metastases. 
  
• Smad7 is a marker of favourable evolution that may be routinely used to predict the occurrence of 
lymph node metastases. Our results indicate that preoperative detection of Smad7 nuclear 
expression should be evaluated in a forthcoming study as it may constitute a valuable tool for risk 
stratification of patients with PTC.  
 
• Smad4 nuclear expression in WC-PTC is detected only in tumours without vascular invasion.  
 
 
2. Disclosure of the topographic differences of TGF-beta expression in CPTC and FVPTC cases with 
and without genetic alterations. 
 
• In PTC, there are signs of the dual role of TGF-beta regarding the co-existence, in the same 
tumour, of signs of activation and inhibition of TGF-beta/Smad-dependent pathway according to 
the location of the neoplastic cells. TGF-beta levels of expression in the neoplastic cells are related 
to topography and invasiveness, thus being better evaluated in tissue samples, where epithelial-
stromal relations are preserved, than in cell lines. 
 
• Increased cytoplasmatic expression of TGF-beta in the periphery of PC-PTC is associated with the 
occurrence of BRAF V600E mutation which does not significantly alter, per se, the frequency of 
lymph node metastases, thus highlighting the complexity of the process and reinforcing the 
prognostic importance of growth pattern and invasion. 
 
• The role of BRAF V600E mutation in PTC prognosis depends upon the synergic interactions with 
other factors, namely TGF-beta overexpression at the periphery of the tumours, and probably 
reflects the influence of the crosstalk between the neoplastic cells and cellular and non-cellular 
stromal elements. The need of co-existing factors interacting with BRAF mutation provides an 
explanation for the rarity of BRAF mutated PTCs in young patients. 
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A incidência do carcinoma papilar da tireoide (CPT) tem aumentado nos últimos anos, enquanto o carcinoma 
folicular da tireoide (CFT) tem sido cada vez menos diagnosticado em todo o Mundo. 
O CPT dá origem, frequentemente, a metástases ganglionares via invasão e disseminação através de vasos 
linfáticos, enquanto o CFT metastiza principalmente via vasos sanguíneos para os pulmões e para os ossos. 
A variante folicular do CPT (VFCPT) compreende o subtipo mal circunscrito/infiltrativo (VFCPT-MC), que 
partilha a maioria das características do CPT clássico (CPTC), e o subtipo encapsulado (VFCPT-E) que 
parece estar relacionado com o CFT minimamente invasor. 
Os fatores de prognóstico indicadores de agressividade clinico-patológica permanecem incompletamente 
estabelecidos, em parte devido à diferente constituição das séries publicadas no que se refere à proporção 
relativa de CPTC e dos subtipos de VFCPT. 
Algumas características clinico-patológicas do CPT, tal como a ocorrência de mutações dos genes BRAF e 
RAS, ainda não constituem marcadores de agressividade completamente aceites. Por outro lado, foi 
recentemente descrita uma associação entre a ativação da via Smad-dependente do TGF-beta e invasão local, 
metastização ganglionar e mutação do BRAF em CPT. 
No presente estudo clínico-patológico, recolhemos todos os casos de tumores da tireoide (tumores malignos 
e tumores de potencial maligno incerto) registados no Registo Oncológico do Serviço de Anatomia 
Patológica do Centro Hospitalar de São João, entre 1978 e 2006, e desse conjunto selecionámos uma série de 
75 casos de CPTC e VFCPT, incluindo VFCPT-E e VFCPT-MC, que foram divididos em casos de CPT bem 
circunscrito (CPT-BC) (n=22) e CPT mal circunscrito (CPT-MC) (n=53), de acordo com as características 
dos seus limites. Avaliámos as características morfológicas dos tumores, nomeadamente a densidade de 
vasos linfáticos (DVL) determinada pela expressão de D2-40, a expressão imuno-histoquímica de TGF-beta 
e dos elementos da via Smad-dependente do TGF-beta (Smad2/Smad3 fosforilado, Smad4 e Smad7), e o 
estado mutacional do BRAF e do N-RAS nos tumores, com o objetivo de procurar esclarecer a contribuição 
destas características para a ocorrência de metástases ganglionares. 
O número de casos com o diagnóstico de carcinoma bem diferenciado (CPT e CFT) registados no Registo 
Oncológico do Serviço de Anatomia Patológica do Centro Hospitalar de São João tem vindo a aumentar ao 
longo dos anos devido a um aumento do número de casos de CPT, enquanto o número de casos de CFT tem 
permanecido baixo. Identificámos 1043 casos de CPT que foram subclassificados, de acordo com os critérios 
da Organização Mundial de Saúde, independentemente do seu tamanho. A VFCPT foi a variante mais 
frequente (411 casos) seguida do CPTC (377 casos). Dos casos de CPTC, 23% desenvolveram metástases 
ganglionares, 2% desenvolveram metástases à distância e 6% tiveram recidivas. Dos casos de VFCPT, 3% 
desenvolveram metástases ganglionares, 1% desenvolveram metástases à distância e 3% tiveram recidivas.  
No período de 29 anos (1978 – 2006), identificámos cinco casos de doentes com CPT com componente de 
carcinoma pouco diferenciado que evoluíram de forma desfavorável, e dois casos de doentes com CPT que 
coexistia com um componente basaloide, cujo significado clinico a longo prazo permanece desconhecido. 
Na nossa série de 75 CPT, a mutação V600E do BRAF foi detetada em 29% dos tumores, 41% dos casos de 
CPTC e 16% dos casos de VFCPT, enquanto a mutação Q61R do N-RAS foi detetada em 6% dos tumores, 
3% dos casos de CPTC e 10% dos casos de VFCPT. A mutação V600E do BRAF foi detetada em 7% dos 
casos de VFCPT-E e 25% dos casos de VFCPT-MC. A mutação do BRAF foi significativamente mais 
frequente em CPTC e em mulheres, e foi detetada apenas em doentes com mais de 20 anos, sugerindo um 
efeito tumorigénico tardio no desenvolvimento do CPT. A mutação do BRAF não se associou a qualquer das 
outras características estudadas relacionáveis com agressividade. 
As características morfológicas mais relacionadas com a ocorrência de metástases ganglionares foram a 
extensão extra-tireoideia e o padrão de crescimento mal circunscrito, tanto em CPTC como em VFCPT. 
Outras características adicionais significativamente associadas a metástases ganglionares foram a 
multicentricidade no CPTC e a invasão vascular na VFCPT. Nenhum dos casos de VFCPT-E apresentou 
extensão extra-tireoideia, invasão vascular linfática, nem metástases ganglionares, ao contrário do sucedido 
com os casos de CPTC e VFCPT-MC. Apenas um caso de VFCPT-E (8%) apresentou vasos linfáticos 
intratumorais que expressavam D2-40, em contraste com a sua presença em 77% dos casos de VFCPT-MC. 
A DVL intratumoral determinada pela expressão de D2-40 correlacionou-se com a ocorrência de extensão 
extra-tireoideia, invasão vascular linfática e metástases ganglionares no CPT. Em oposição com a DVL 
intratumoral, a DVL peritumoral não se associou a nenhuma das características clinico-patológicas ou 
moleculares do CPT, sendo semelhante em CPTC, VFCPT-E e VFCPT-MC. 
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Não foram detetadas metástases ganglionares em nenhum dos casos de CPT-BC independentemente da 
presença de expressão de TGF-beta, Smad2/Smad3, Smad4 e Smad7, ou da ocorrência de mutação do BRAF. 
O aumento da expressão citoplasmática de TGF-beta na periferia dos CPT-MC associou-se a características 
morfológicas de invasão, configurando a chamada transição epitélio-mesenquimatosa, e à presença de 
metástases ganglionares, assim como à ocorrência de mutação do BRAF cuja presença não altera, por si, a 
frequência de metástases ganglionares. 
A expressão nuclear de Smad7 foi mais frequente em CPT-BC que em CPT-MC e associou-se a 
unicentricidade e ausência de extensão extra-tireoideia, invasão vascular e metástases ganglionares.  
Os nossos resultados demonstram a importância (e a absoluta necessidade) de uma amostragem tão extensa 
quanto possível (e de uma observação detalhada) da periferia das peças cirúrgicas de CPT. Demonstram 
também a maior importância do padrão de crescimento infiltrativo das neoplasias e dos sinais de invasão 
extra-tireoideia em relação à presença de mutações do BRAF no desenvolvimento de metástases ganglionares 
tanto em CPTC como em VFCPT. 
Os resultados do perfil de vasos linfáticos em CPT sublinham o papel dos vasos linfáticos intratumorais na 
metastização ganglionar do CPT e reforçam a importância em distinguir a VFCPT-E da VFCPT-MC no que 
diz respeito à invasão, padrão metastático e perfil molecular. 
Finalmente, concluímos que as metástases ganglionares estão significativamente associadas a CPT mal 
circunscritos com elevada densidade de vasos linfáticos intratumurais; os CPT com metástases ganglionares 
têm baixos níveis de expressão nuclear de Smad7 e uma transição epitélio-mesenquimatosa periférica com 
sobre-expressão de TGF-beta, independentemente da presença de mutação do BRAF. 
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The incidence of papillary thyroid carcinoma (PTC) has been rising in the last years while follicular thyroid 
carcinoma (FTC) is being diagnosed less and less frequently everywhere. 
PTC gives frequently rise to nodal metastases via lymphatic vessels while FTC metastasizes mainly via 
blood vessels to lung and bones. The follicular variant of PTC (FVPTC) encompasses the poorly 
circumscribed/infiltrative subtype (PC-FVPTC), which shares most of the features of classic PTC (CPTC), 
and the encapsulated subtype (E-FVPTC) which appears to be related to minimally invasive FTC. 
Prognostic factors indicative of PTC clinico-pathological aggressive behaviour remain incompletely 
established in part due to the different composition of the series on record regarding the relative proportion 
of CPTC and FVPTC subtypes. 
Several clinico-pathological features of PTC, together with the occurrence of BRAF and RAS mutations, are 
still not fully accepted as markers of aggressiveness. On the other hand, TGF-beta/Smad-dependent pathway 
activity has been recently associated with local invasion, nodal metastization and BRAF mutated PTCs. 
In the present clinico-pathological study we collected all cases of thyroid tumours (malignant tumours and 
tumours of uncertain malignant potential) from the Cancer Registry of the Pathology Department of Centro 
Hospitalar de São João, from 1978 to 2006, and selected a series of 75 CPTC and FVPTC cases, including E-
FVPTC and PC-FVPTC, which were divided into cases of well circumscribed PTC (WC-PTC) (n=22) and 
poorly circumscribed PTC (PC-PTC) (n=53), according to the characteristics of their borders. We evaluated 
the morphological features of the tumours, namely intratumoural and peritumoural lymph vessels density 
(LVD) determined by D2-40 immunoexpression, the immunoexpression of TGF-beta and TGF-beta/Smad-
dependent pathway elements (phosphorylated Smad2/Smad3, Smad4 and Smad7) and the BRAF and N-RAS 
mutational status of the tumours, in an attempt to clarify the contribution of these features for the occurrence 
of nodal metastases.  
The number of cases with a diagnosis of well differentiated carcinoma (PTC and FTC) recorded in the 
Cancer Registry of the Pathology Department of Centro Hospitalar de São João has increased over the years 
due to an increased number of PTC cases, while the number of FTC cases remained persistently low over the 
years. We identified 1043 PTC cases that were sub-classified, irrespective of size, accordind to the WHO 
criteria. The FVPTC (n=411) was the most frequent variant followed by CPTC (n=377). From the CPTC 
cases, 23% developed lymph node metastases, 2% developed distant metastases and 6% had recurrences. 
From the FVPTC cases, 3% developed lymph node metastases, 1% developed distant metastases and 3% had 
recurrences.  
In the 29 year period (1978 – 2006), we identified five cases of PTC with a poorly differentiated component 
that followed an aggressive clinical course and two cases of PTC coexisting with a particular basaloid 
component with unknown impact over the patients’ long term outcome. 
In our series of 75 PTCs, BRAF V600E mutation was detected in 29% of tumours, 41% of CPTC and 16% of 
FVPTC, whereas NRAS Q61R mutation was detected in 6% of tumours, 3% of CPTC and 10% of FVPTC. 
The BRAF V600E mutation was detected in 7% of E-FVPTC and 25% of PC-FVPTC. BRAF mutation was 
significantly more frequent in the CPTC group and in females, and it was detected only in patients older than 
20 years, suggesting a late tumourigenic effect in the development of PTC. BRAF mutation was not 
significantly associated to any of the other studied features related to aggressiveness.  
The morphological features most closely related to the occurrence of nodal metastases were extra-thyroid 
extension and poorly circumscribed growth pattern, in both CPTC and FVPTC. Additional features 
significantly associated to nodal metastases were multicentricity in CPTC and vascular invasion in FVPTC. 
None of the E-FVPTC cases presented extra-thyroid extension, lymph vessel invasion or nodal metastases, at 
variance with CPTC and PC-FVPTC cases. Only one case of E-FVPTC (8%) had intratumoural D2-40-
stained vessels in contrast to their presence in 77% of the cases of PC-FVPTC. Intratumoural LVD 
determined by D2-40 expression correlated with the occurrence of extra-thyroid extension, lymph vessel 
invasion and lymph node metastases in PTC cases. At variance with intratumoural LVD, peritumoural LVD 
was not associated with any clinico-pathological or molecular feature, being similar in CPTC, E-FVPTC and 
PC-FVPTC. 
Nodal metastases were not detected in any WC-PTC regardless the presence of immunoexpression for TGF-
beta, Smad2/Smad3, Smad4 and Smad7, and of the occurrence of BRAF mutation. 
Increased cytoplasmatic expression of TGF-beta at the periphery of PC-PTC was associated to 
morphological features of invasiveness, featuring the so-called epithelial-to-mesenchymal transition (EMT), 
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and presence of nodal metastases, as well as to the occurrence of BRAF mutation which did not significantly 
alter, per se, the frequency of nodal metastases. 
The nuclear expression of Smad7 was more frequent in WC-PTCs than in PC-PTCs and was associated with 
unicentricity and absence of extra-thyroid extension, vascular invasion and nodal metastases. 
Our results emphasize the importance of an extensive sampling and detailed observation of PTC surgical 
specimens; they also highlight the importance of infiltrative growth pattern and invasiveness over the 
presence of BRAF mutation in CPTC and FVPTC for the development of nodal metastases. 
The results on the lymph vessels profile of PTC stress the role of intratumoural lymph vessels in PTC nodal 
metastization and reinforce the importance of distinguishing E-FVPTC from PC-FVPTC regarding 
invasiveness, metastatic pattern and molecular profile. 
Finally, we conclude that nodal metastases are associated to poorly circumscribed, locally invasive 
PTCs with high intratumoural lymph vessel density; such metastatic PTCs exhibit low levels of 
nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta overexpression, regardless of 
the occurrence of BRAF mutation. 
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ABSTRACT   
 
Poorly circumscribed growth pattern, extra-thyroid extension and high intratumoural lymph vessel density are 
significantly associated to nodal metastatization in papillary thyroid carcinoma (PTC). It was also shown that TGF-
beta/Smad-dependent pathway activity is associated with local invasion, nodal metastatization and BRAF mutated 
PTCs. 
We analyzed the immunoexpression of TGF-beta, Smad2/Smad3, Smad4, and Smad7 in a series of 42 cases of classic 
PTC and 33 cases of follicular variant of PTC with known clinico-pathological and follow-up data, as well as BRAF and 
RAS status. The 75 PTCs were divided into poorly circumscribed (PCPTC) (n=53) and well circumscribed (WCPTC) 
(n=22) according to their borders.  
Nodal metastases were not detected in any WCPTC regardless the presence of immunoexpression for TGF-beta, 
Smad2/Smad3, Smad4 and Smad7, and occurrence of BRAF mutation (in 20% of WCPTCs). 
Increased cytoplasmatic expression of TGF-beta at the periphery of PCPTC was associated to morphological features of 
invasiveness, featuring the so-called epithelial-to-mesenchymal transition (EMT), and presence of nodal metastases, as 
well as to the occurrence of BRAF mutation which did not significantly alter, per se, the frequency of nodal metastases. 
The nuclear expression of Smad7 was more frequent in WCPTCs than in PCPTCs and was associated with unicentricity 
and absence of extra-thyroid extension, vascular invasion and nodal metastases.  
We conclude that nodal metastases are associated to poorly circumscribed, locally invasive PTCs that exhibit low levels 
of nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta overexpression, regardless of the occurrence 
of BRAF mutation. 
 
Key words: Papillary thyroid carcinoma; BRAF; TGF-beta; Smad7; prognosis. 
 
 
INTRODUCTION 
The large majority of papillary thyroid carcinomas (PTC) evolve favourably [1] although a subset of cases may progress 
adversely leading to the development of recurrences and/or metastases [1-3].  
Most cases of classic PTC (CPTC) are poorly circumscribed, display a peripheral invasive front and give frequently rise 
to lymph node metastases [1], whereas many cases of the follicular variant of PTC (FVPTC) are encapsulated, sharing 
some of the clinico-pathological features of follicular carcinoma such as vascular invasion and distant metastases, as 
well as its most frequent molecular alterations, RAS mutations and PAX8/PPARgamma rearrangements [4-7]. There is 
also a poorly circumscribed/ infiltrative subtype of FVPTC that, like CPTC, discloses a high intratumoural lymph vessel 
density and is prone to give rise to lymph node metastases [5,6,8]. 
It has been shown that BRAF V600E mutation is particularly prevalent in CPTC, as well as in PTC with a prominent 
papillary growth pattern such as Warthin-type and tall cell variant of PTC [9], in contrast to its low prevalence in 
FVPTC [9-11].  
In a recent clinico-pathological study of 75 cases of PTC (42 CPTC and 33 FVPTC) we observed that poorly 
circumscribed/ infiltrative growth pattern and extra-thyroid extension, rather than the presence of BRAF V600E, were 
significantly associated with the occurrence of lymph node metastases [11]. The infiltrative growth pattern of most non-
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encapsulated forms of PTC is mainly the result of increased motility and of tumour cell´s invasiveness [12-14] which 
are features related to the so called epithelial-to-mesenchymal transition (EMT). At PTC´s infiltrative periphery, the 
neoplastic cells display loss of polarity/cohesiveness [14], decreased expression of beta-catenin and E-cadherin at the 
cell membrane [14], increased nuclear expression of STAT3[Couto et al, unpublished results], increased cytoplasmatic 
expression of vimentin [15], fibronectin 1[12], met [16], ret [17], cytokeratin 5/6 [18] and galectin-3 [19], and increased 
nuclear expression of cyclin D1[20]. 
The above mentioned alterations at the infiltrative edge of the tumours reflect probably the cross-talk between tumour 
cells and cellular and non-cellular elements of the stroma, in part mediated by integrin-related epithelial-to-stromal 
connections which are enhanced at PTC´s periphery [21]. Dendritic cells were found to be located at the tumour´s 
invasion edge in a small series of PTC [22] and, together with lymphocytes, appear to be decreased in PTCs with distant 
metastases [23], while increased density of tumour-associated macrophages in poorly differentiated carcinomas 
correlate with invasion and decreased survival [24]. 
EMT is partially regulated by transforming growth factor beta (TGF-beta) in PTC cell lines [25-28] and in animal 
models [29]. TGF-beta is one of the members of the TGF-beta superfamily and occurs in 3 isoforms – TGF-beta1, TGF-
beta2 and TGF-beta3 – that function via the same membrane receptor signaling system [30]. In TGF-beta/Smad-
dependent pathway, the activated TGF-beta receptor complex propagates the signal inside the cell through the 
phosphorylation of receptor regulated Smad2 and Smad3 downstream proteins localized in the cytoplasm [30-32]. 
Phosphorylated Smad2 and Smad3 form heteromeric complexes with Smad4 and re-localize to the nucleus where they 
regulate gene transcription [30-32]. Inhibitory Smad7 acts in an opposite manner and antagonizes TGF-beta/Smad-
dependent signaling, inducing TGF-beta receptor degradation and thus preventing Smad2 and Smad3 phosphorylation 
[31, 32]. TGF-beta/Smad-dependent pathway activation induces major growth suppressive effects on epithelial cells in 
general [32], and on animal [33-35] and human [36, 37] thyroid cell lines, as well as on some PTC cell lines [25,28], in 
particular. TGF-beta is also related to inhibition of migration and invasiveness in some PTC cell lines [25]. 
The expression of TGF-beta, Smad2, Smad3 and Smad7 have been detected in multinodular goiters [38-40] and in 
follicular adenomas of some series [40,41], but not in other series of thyroid lesions where TGF-beta was the only 
element searched [42].  
In tumours, TGF-beta expression has been detected in 52-100% of PTC cases [38,40-43] and, whenever specifically 
studied at the tumour´s periphery, was associated to the occurrence of extra-thyroid extension and lymph node 
metastases [26]. Similarly, phosphorylated Smad2/Smad3(P-Smad2/3), has been detected in every case of PTC [40], 
while Smad4 is expressed in 75% of PTC cases [40] and in every PTC cell line [44,45]. Smad7 expression has been 
detected in 80% of PTCs and PTC cell lines [40,44]. 
In tumour cells, particularly when exhibiting an EMT phenotype characterized by mesenchymal-type features [12], the 
response to TGF-beta growth suppressive effect can be partially or totally abrogated via interferences in the signaling 
pathways that mediate its action [26,29,37,46-48]. TGF-beta anti-proliferative effects were reported as attenuated in 
cases of multinodular goiter [49], in anaplastic carcinoma cell lines [50], as well as in rat thyroid cell lines [51]. At the 
EMT, the TGF-beta altered cell response has been associated to the development of pro-oncogenic effects, namely 
through the inhibition of cell adhesion and enhancement of motility [32,52]. 
Besides playing a functional role in tumour cell migration, invasion and EMT in vitro, TGF-beta and high TGF-
beta/Smad-dependent pathway activity are associated with invasion, nodal metastasizing and BRAF mutated PTCs [26]. 
It has been reported that oncogenic BRAF stimulates TGF-beta secretion in vitro [26]. BRAF is thought to play a major 
role in extracellular matrix remodeling [52] and is required for TGF-beta-induced EMT during progression from PTC to 
poorly differentiated carcinoma in an animal model [29]. Finally, it has been shown that BRAF suppresses the 
expression of E-cadherin, which is a typical finding at the infiltrative edge of poorly circumscribed PTCs, and that this 
effect can be abrogated with both TGF-beta and MAPK inhibitors [26]. 
We decided to analyze the immunohistochemical expression of TGF-beta1 and TGF-beta2 and their downstream 
phosphorylated Smad2/Smad3 and Smad4 elements, and of the inhibitory Smad7, in well circumscribed and poorly 
circumscribed PTCs (WCPTC and PCPTC, respectively). The study was made using the previously analyzed series of 
75 carcinomas in which BRAF and N-RAS status had been characterized [11], in order to clarify the putative 
relationship between functioning TGF-beta/Smad-dependent pathway and BRAF mutation in the two PTC subtypes: 
WCPTC and PCPTC. 
 
MATERIAL AND METHODS 
Part of the clinico-pathological data of the 75 cases has been previously reported [8,11]. 
  
Tumour samples 
 
A series of 75 PTC cases was retrieved from the Cancer Registry of the Pathology Department of Hospital de São João: 
42 CPTC and 33 FVPTC.  Both groups (CPTC and FVPTC) included cases with lymph node metastases (+M) (mean 
follow-up of 5.9 years; range 1 to 14 years) and cases without metastases and long term follow-up (-M) (mean follow-
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up of 18.8 years; range 10 to 24 years). Three cases (two CPTC and one FVPTC) disclosed, together with lymph node 
metastases, lung metastases (Tables 1 and 2). Both groups included tumours larger than 1cm and small tumours, 1cm or 
less in diameter, that were classified according to their pattern of growth as CPTC or FVPTC. None of the patients died 
from the disease.  
All samples had been fixed in formalin and included in paraffin. Clinical data were collected from the pathology reports 
and clinical files. H&E slides were retrieved from the archives and reviewed independently by two pathologists (CE and 
MSS) and the tumours were classified using the WHO criteria [1]. Cases with doubtful PTC features were excluded. 
Due to their scarcity, variants of PTC such as tall cell, columnar cell and sclerosing diffuse variant were not included. 
Well circumscribed carcinomas (WCPTC) were those with expansive growth pattern along the whole periphery and 
those limited by a capsule with none or only minimal focal invasion. Poorly circumscribed carcinomas (PCPTC) were 
those with infiltrative growth pattern or with an extensively invaded capsule. Vascular invasion was considered to be 
present whenever one image of unequivocal venous vessel invasion was observed. 
 
Mutation screening 
 
The detection of BRAF (exon 15) and N-RAS (exon 2) mutations were performed as previously described [11] in 10 µm 
sections of 65 tumours: 34 CPTC and 31 FVPTC. The remaining 10 cases had insufficient available material for 
performing the molecular study. 
 
Immunohistochemistry 
 
Immunohistochemical staining was performed using streptavidin-biotin technique as previously described [8]. Briefly, 
slides were incubated overnight at 4ºC with TGF-beta1/2 rabbit polyclonal antibody (from here on designated as TGF-
beta) in a 1:50 dilution (TGF-beta1(V), Santa Cruz Biotechnology, CA) against a peptide in the C-terminus of precursor 
and mature human TGF-beta1 and TGF-beta2 ligands; P-Smad2/3 rabbit polyclonal antibody in a 1:100 dilution (P-
Smad2/3 (Ser 423/425), Santa Cruz Biotechnology, CA) against C-terminus of both phosphorylated Smad2 and Smad3; 
Smad4 monoclonal mouse antibody in a 1:100 dilution (Smad4 (B-8), Santa Cruz Biotechnology, CA) and Smad7 
mouse monoclonal antibody in a 1:100 dilution (Smad7 (Z8-B), Santa Cruz Biotechnology, CA). Then, slides were 
incubated with biotinylated secondary goat antibody and streptavidin-peroxidase complex (Lab Vision, Thermo 
Scientific) for 10 minutes at room temperature. Tissue microarrays with adequate positive and negative controls were 
used in every set of stainings. 
 
Semiquantitative assessment of TGF-beta and Smads expression 
 
The TGF-beta expression in the tumour cells was evaluated in the center and in the periphery of all carcinomas (CPTC 
and FVPTC) and in the respective remaining thyroid tissue, which was used as an internal control tissue, in order to 
reduce the influence of fluctuations of the physiological expression in each case. TGF-beta expression detected in cells 
of the control tissue was considered as the basal expression.  
TGF-beta expression in the tumour cells located in the center of each tumour was compared with the expression in the 
respective control tissue and the TGF-beta expression in the tumour cells located in the periphery of each tumour was 
compared with the expression in the respective center of the tumour. The mean expressions observed in each location 
were also compared. The center of the tumour comprised the bulk of the tumour, i.e., the whole neoplastic tissue except 
the subcapsular areas and/or the invasive front. The periphery of the tumour comprised the rim of tumour cells 
underneath the capsule or at the expansive periphery in WCPTC and in the invasive front in PCPTC.  TGF-beta 
expression was cytoplasmatic and was graduated in 4 categories that were considered to represent continuous and 
crescent immunostaining intensity: negative 0 (weak staining in less than 25% of cells), positive 1 (weak staining in at 
least 25% of cells or moderate intensity in less than 25% of cells), positive 2 (moderate intensity in at least 25% of cells 
or intense staining in less than 25% of cells) and positive 3 (intense staining in at least 25% of cells). 
The expression of P-Smad2/3, Smad4 and Smad7 was nuclear and cytoplasmatic and was evaluated in all CPTC and 
FVPTC tumours and in the respective remaining thyroid tissue, which was used as an internal control tissue and 
considered the basal expression. The expression of P-Smad2/3, Smad4 and Smad7 in the center of the tumour and at the 
periphery were considered too difficult to distinguish and, therefore, assumed as similar.  The expression was graduated 
in 2 categories: negative (weak staining in less than 25% of cells) and positive (weak, moderate or intense staining in at 
least 25% of cells), regarding each subcellular location (nuclear or cytoplasmatic) separately. 
 
Statistical analysis 
 
The results are expressed as absolute values, percentages and/or mean±standard deviation. The χ2 test with Yates 
correction and the Students‘t test (unpaired) were used in the statistical analysis. Two values were considered 
significantly different whenever p<0.05 and suggestively different whenever p<0.1. 
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RESULTS 
1. Clinico-pathological and molecular features  
CPTC and FVPTC groups displayed similar features except the prevalence of poorly circumscribed tumours (83.3% of 
CPTC and 54.4% of FVPTC, p=0.010), vascular invasion (26.6% of CPTC and 57.6% of FVPTC, p =0.018) and BRAF 
V600E mutation (41.2% of CPTC and 16.1% of FVPTC, p =0.032). A detailed description of the clinico-pathological 
and molecular features of the 75 cases has been previously reported [8,11]. 
 
2.  CPTC versus FVPTC 
2a. TGF-beta expression  
TGF-beta expression was observed in all but two FVPTC-M cases and was detected in the center of 88.0% of tumours 
(95.2% of CPTC and 81.8% of FVPTC), at the periphery of 94.7% of tumours (100% of CPTC and 87.9% of FVPTC) 
and in the control tissues in 73.0% of cases (78.6% of CPTC and 63.3% of FVPTC). 
In comparison with the respective control tissue, the center of the carcinomas disclosed basal or overexpression of TGF-
beta in 83.8% of cases.  The TGF-beta expression at the periphery of each tumour was similar or higher than the TGF-
beta expression in the center in all but one CPTC-M and three FVPTC-M cases (94.7%) (Tables 1 and 2) (Fig1). 
The mean intensity of TGF-beta expression in the center of the tumours, in comparison with the respective control 
tissue, was much higher in PTC-M than in PTC+M (p<0.0001).The mean intensity of TGF-beta expression at the 
periphery, compared with the respective center of the tumours, was significantly higher in PTC+M than in PTC-M 
(p=0.0001) and was also significantly higher in tumours with poorly circumscribed growth pattern (p<0.0007), extra-
thyroid extension (p=0.002) and BRAF V600E mutation (p=0.029). 
The supplemental table summarizes the result of the comparison between CPTC and FVPTC. 
 
2b. P-Smad2/3 expression  
P-Smad2/3 nuclear expression was observed in all tumours (Figs. 2A and 2B) and in all but two control tissues of the 
CPTC-M group (97.3%) (Fig. 2C).  
P-Smad2/3 cytoplasmatic expression was observed in 72.0% of tumours and in 18.9% of control tissues. In comparison 
to the respective control tissue, P-Smad2/3 had a basal level or was underexpressed in the cytoplasm of tumour cells in 
43.2% of the cases. Tumours with basal or underexpression of cytoplasmatic P-Smad2/3 belonged more frequently to 
the group of FVPTC than to the CPTC group (60.6% and 29.3%, respectively; p=0.010) and tended to have more often 
wild type BRAF than mutated BRAF (p=0.053) (Tables 1 and 2). P-Smad2/3 expression was not significantly associated 
to any other clinical, pathological or molecular features. 
 
 
2c. Smad4 expression  
Smad4 nuclear expression was observed in 26.7% of tumours and 85.1% of control tissues (Figs. 2D, 2E and 2F). 
Smad4 had a basal level or was overexpressed in the nuclei of tumour cells in 39.2% of the cases in comparison with 
the respective control tissue. Vascular invasion was significantly less frequent in tumours with basal or overexpressed 
nuclear Smad4 (p=0.004), particularly in the FVPTC group (p=0.003). 
Smad4 cytoplasmatic expression was observed in all tumours and in all but 2 control tissues of the PTC-M group 
(97.3%).  
 
2d. Smad7 expression  
Smad7 nuclear expression was observed in 69.3% of tumours and in all but two control tissues of the CPTC-M group 
(97.3%) (Figs. 2G, 2H and 2I). 
Smad7 had a basal level or was overexpressed in the nuclei of the tumour cells in 71.6% of tumours in comparison with 
the respective control tissue. There was a significant association between basal to overexpressed Smad7 in the nuclei of 
the tumour cells and well circumscribed growth pattern (p=0.0001), unicentric CPTC (p=0.048), absence of vascular 
invasion in FVPTC (p=0.013), absence of extra-thyroid extension in FVPTC (p=0.023) and absence of lymph node 
metastases in both CPTC and FVPTC (p<0.0001).  
Smad7 cytoplasmatic expression was observed in 66.7% of tumours and in 14.9% of the control tissues. Smad7 had a 
basal level or was underexpressed in the cytoplasm of the tumour cells in 48.6% of cases in comparison with the 
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respective control tissue, both in CPTC and FVPTC. Smad7 cytoplasmatic expression was not significantly associated 
to any clinical, pathological or molecular feature. 
 
3. WCPTC versus PCPTC 
None of the 22 WCPTC had lymph node metastases while 50.9% of the 53 PCPTC had given rise to lymph node 
metastases. 
Globally, the difference between the mean TGF-beta expression in the center of the tumours and in the control tissue 
was similar in WCPTC and in PCPTC (p=0.839) whereas the difference between the mean TGF-beta expression in the 
periphery of the tumours and in the center of the tumours was much higher in PCPTC than in WCPTC (p=0.0007).  
In 63.6% of WCPTC cases (14 out of 22) the TGF-beta expression was nearly homogeneous, absent or low/moderate, 
throughout the tumour. In PCPTC, the PTC-M cases disclosed a significantly more intense expression of TGF-beta in 
the center of the tumours than in the control tissue (p<0.0001), whereas in PTC+M cases the cells in the periphery of 
the tumours presented a significantly more intense expression of TGF-beta than those in the center of the tumours 
(p=0.017) (Table 3).  
The BRAF V600E mutation was detected in 20.0% of WCPTC including 4 WCPTC cases disclosing similar or higher 
TGF-beta expression in the periphery than in the center, while none of the 3 WCPTCs with a lower TGF-beta 
expression in the periphery than in the center were BRAF mutated tumours. The group of WCPTC cases with similar or 
higher TGF-beta expression at the periphery than in the center had similar clinico-pathological features and no lymph 
node metastases, independently of the BRAF mutational status (Tables 1 and 2). 
The BRAF mutation was detected in 15 PCPTCs (33.3%) disclosing similar or higher TGF-beta expression in the 
periphery than in the center. PCPTC cases with similar or higher TGF-beta expression at the periphery than in the 
center disclosed lymph node metastases in 40.0% of BRAF mutated tumours and in 56.7% of tumours with wild-type 
BRAF. 
Smad4 nuclear expression in WCPTC subgroup was detected only in tumours without vascular invasion (p=0.005) 
(Table 3), whereas in PCPTC, Smad4 nuclear expression was not significantly associated to any clinical, pathological or 
molecular features. 
 
DISCUSSION AND CONCLUSIONS  
The results we have obtained confirm the prognostic prominence of staging over cytological and molecular features, 
and the major importance of architecture (expansive versus infiltrative growth pattern) and topography (different 
immunohistochemical characteristics of tumour cells according to their peripheral or central location) in the 
understanding of PTC development. 
It is known that the neoplastic cells at the tumour periphery differ substantially from those in the bulk of the tumours 
regarding the expression of several structural and functional proteins (e.g. cytokeratins, vimentin, beta-catenin, E-
cadherin, fibronectin 1, TGF-beta) [12,15,18,26].  
The role of TGF-beta in thyroid cell signaling and in thyroid carcinogenesis, like in many other models, is very complex 
and profoundly influenced by the cellular and tissue context [26], thus being better evaluated in tissue samples than in 
cell lines.  In the present study, we observed signs of the dual role of TGF-beta regarding the co-existence in the same 
tumour of signs of activation and of inhibition of TGF-beta/Smad-dependent pathway according to the location of the 
neoplastic cells. 
The tumour suppressive effect of TGF-beta/Smad-dependent pathway that had been firmly established in thyroid cell 
lines [33-37] and in some PTC cell lines [25, 28], was found to be abrogated at the periphery of PTC [12,26], where 
increased vimentin expression and loss of E-cadherin with increased motility and invasiveness configure an EMT 
invasive phenotype [12]. We observed, particularly in the poorly circumscribed tumours, that TGF-beta expression was 
stronger in the invasive front than in the central regions of the tumours, and that an increased TGF-beta expression at 
the periphery of the tumours was associated to the occurrence of extra-thyroid extension and lymph node metastases, as 
previously reported by Riesco-Eizaguirre et al [26].  
Our subdivision of PTCs into well and poorly circumscribed carcinomas (WCPTC and PCPTC, respectively) goes 
further than the usual division into CPTC and FVPTC and provides interesting results: in WCPTC (no infiltrative 
features and no lymph node metastases) the mean increment of TGF-beta immunoexpression from the center to the 
periphery was very low in comparison with PCPTC, in line with the above mentioned association between TGF-beta 
expression at the periphery and invasiveness, also reported by other authors [26]. 
We detected TGF-beta and P-Smad2/3 expressions in the center of all cases of WCPTC and PCPTC and control tissues 
(except in nine TGF-beta negative cases), as it had been reported previously [38,40,42, 43], thus highlighting the 
existence of signs of functioning TGF-beta/Smad-dependent pathway in PTC.  
Smad4 nuclear expression is considered as indicative of a functioning TGF-beta/Smad-dependent pathway [40,44,45], 
but the nuclear translocation of phosphorylated Smad2 in response to TGF-beta, does not require the presence of Smad4 
[30], as our results also indicate. In the present study, all tumours expressed Smad4 in the cytoplasm of the neoplastic 
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cells, like it had been observed by Matsuo et al [40] and Cerutti et al [44], whereas Smad4 nuclear expression was 
detected in 27% of tumours. In WCPTC, Smad4 nuclear expression was detected only in cases without vascular 
invasion. The nuclear expression of Smad4 in PTC cells had not been detected previously to the best of our knowledge. 
The percentage of cases with Smad4 nuclear expression may be related with an impaired nuclear translocation of 
Smad2/3-Smad4 complexes as a sort of end result of Smad4 mutations that were detected in another series in 21% of 
PTCs [53]. Unfortunately, the absence of available material for the molecular search of Smad4 mutations in the present 
series did not allow the confirmation or the rejection of this hypothesis. Whatever the mechanisms involved in the 
process, we found that signs of functioning TGF-beta/Smad-dependent pathway in the center of the tumours, namely 
basal or overexpression of TGF-beta and nuclear Smad4, were associated to low vascular invasiveness and absence of 
lymph node metastases, respectively. 
Smad7 nuclear expression has been associated to loss of TGF-beta/Smad-dependent pathway inhibition [54] and was 
found to be at basal or overexpressed levels in 72% of the cases of the present series, a percentage similar to that 
reported in another series of PTC [40]. We found that Smad7 nuclear expression was associated to low neoplastic 
invasiveness, namely to well circumscribed growth pattern, and to unicentricity in CPTC and to absence of extra-
thyroid extension and vascular invasion, in FVPTC. More importantly, Smad7 nuclear expression was associated to 
absence of lymph node metastases both in CPTC and FVPTC. 
The encapsulated, non-angioinvasive FVPTC is the prototype of a carcinoma with an extremely benign course [55] and 
discloses a very low intratumoural lymph vessel density [8]. In the present series, and in almost every series on record, 
most WCPTCs display a capsule and are apparently protected from the cascade of TGF-beta oncogenic effects 
occurring at the periphery of PCPTC. The WCPTCs that do not disclose invasive front and EMT features 
(independently of the occurrence of BRAF mutation), nor lymph node metastases, present often a nearly homogeneous 
TGF-beta expression throughout the tumour.  
At variance with TGF-beta, BRAF mutation has been found to promote growth and cell invasiveness [56]. The putative 
relationship between alterations of the TGF-beta/Smad-dependent pathway and BRAF mutation is difficult to evaluate 
in an observational study like the present one. Despite acknowledging this limitation we think our findings suggest the 
existence of a synergic influence of TGF-beta over BRAF mutated neoplastic cells in the periphery of the tumours.  
BRAF V600E mutation was more frequently detected in the subset of tumours with higher increment of TGF-beta 
expression at the periphery. This finding concurs with the results of Riesco-Eizaguirre et al [26] and suggests that, at the 
periphery of the tumours, the association of high levels of TGF-beta expression with BRAF mutation and invasiveness, 
as previously described in animal models [29], PTC cell lines and PTCs [26], reflects a synergic interaction that may 
potentiate the oncogenic effect of BRAF mutation [11]. In the present series, the occurrence of BRAF mutation did not 
significantly alter, per se, the frequency of lymph node metastases, thus highlighting the complexity of the process and 
reinforcing the importance of growth pattern and invasion. 
Considering that the increased expression of TGF-beta at the periphery of the tumours may functionally articulate with 
BRAF V600E mutation [29], it remains unclear the reason underlying this particular topographic immunoexpression of 
TGF-beta. Since the BRAF mutation occurs, at least in most BRAF positive cases, in every tumour cell, the TGF-beta 
expression increment should be detected, in case it was a direct result of the BRAF mutation, throughout the whole 
neoplastic tissue. It is likely that this increment of TGF-beta at the periphery of the tumours is influenced by the 
crosstalk between the neoplastic cells and cellular and non-cellular stromal elements, such as tumour-associated 
macrophages [24,29], dendritic cells [22], lymphocytes [23] and basement membrane components [29]. A similar 
interaction with BRAF has been recently described with STAT3 which is highly expressed in the periphery of BRAF 
mutated PTCs and has been found to result from the crosstalk between neoplastic cells and stromal elements [Couto et 
al, unpublished results]. The aforementioned need of co-existing factors in the setting of BRAF oncogenic mutation 
provides an explanation for the low prevalence of BRAF positive PTCs in young patients [11]. 
Other interactions between TGF-beta signaling pathways and MAPK pathway have been advanced, namely through 
oncogenic RAS that is thought to be required for the disruption of TGF-beta-growth suppressive effects in cell lines 
[51]. In our series, N-RAS Q61R mutation occurred in 6% of cases without any significant association with pathological 
signs of invasiveness but the number of positive cases is too small to allow any definite conclusion on this issue. 
Summing up, the signs of functioning TGF-beta Smad-dependent signaling pathway in the central areas of the tumours 
are associated to low invasiveness and absence of lymph node metastases while, at the periphery, TGF-beta expression 
is associated to invasiveness and occurrence of lymph node metastases, both in CPTC and in cases of the poorly 
circumscribed form of FVPTC. Our findings support the assumption that TGF-beta acts synergically with BRAF and 
probably with other cellular and molecular stromal factors at the periphery of the tumours, leading to neoplastic 
progression and acquisition of invasive properties by cancer cells. 
Our results indicate that Smad7 nuclear expression in the center of the tumours appears to be a marker of favourable 
evolution, unrelated to the occurrence of BRAF mutation. We suggest that preoperative detection of Smad7 nuclear 
expression should be evaluated by fine-needle aspiration in a large series of PTCs with thorough clinical, imaging and 
follow-up data, as it may constitute a valuable tool for risk stratification of patients. 
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We conclude that nodal metastases are associated to poorly circumscribed, locally invasive PTCs that exhibit low levels 
of nuclear Smad7 and a peripheral EMT phenotype displaying TGF-beta overexpression, regardless of the occurrence 
of BRAF mutation. 
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Table1. Clinico-pathological, molecular and immunohistochemical features of the CPTC cases 
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3 F 31 21 3.5 PC + - - - - 3 3 2 +/+ +/- -/+ +/+ +/+ +/- - 
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10 F 30 21 0.6 PC + - - V600E - 2 3 2 +/+ +/- -/+ +/+ -/+ -/+ - 
11 F 40 20 2.2 WC - - - - - 1 2 2 +/+ +/- -/+ -/+ +/+ +/+ - 
12 F 50 20 3.0 WC - - - V600E - 1 1 0 +/- +/- -/+ -/+ +/- +/- - 
13 F 25 17 2.1 WC - - - V600E - 1 1 1 +/+ +/- -/+ +/+ +/+ +/- - 
14 F 45 22 4.5 WC + - - V600E Q61R 2 3 2 +/- +/+ +/+ -/+ +/+ +/- - 
15 F 23 24 2.5 PC - - - - - 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - 
16 M 65 24 2.3 PC - - - - - 3 3 2 +/+ +/+ -/+ +/+ +/+ +/+ - 
17 F 21 19 2.0 PC - - + V600E - 1 2 0 +/+ +/- -/+ +/+ +/+ +/- - 
18 F 79 23 2.8 PC - + - - - 3 3 1 +/+ -/- -/+ -/+ +/+ +/- - 
19 F 65 16 3.5 PC - + - V600E - 1 2 0 +/+ +/- -/+ +/- +/- +/- - 
20 F 28 24 2.5 PC - - + - - 3 3 0 +/+ +/+ -/+ +/+ +/+ +/- - 
21 F 28 20 2.0 PC - - + V600E - 3 3 0 +/+ +/- -/+ +/+ +/+ +/+ - 
22 F 43 18 1.5 WC + - + - - 1 1 0 +/+ +/- -/+ +/+ +/+ +/+ - 
23 F 47 16 4.5 PC - + + V600E - 1 3 1 +/+ +/- -/+ +/+ +/+ +/- - 
24 F 28 5 0.9 PC - - - V600E - 1 2 1 +/+ +/- +/+ +/+ +/+ +/- + 
25 F 21 6 1.2 PC - - - - - 1 2 2 +/+ +/+ +/+ +/+ -/+ +/- + 
26 F 22 14 1.9 PC + - - - - 1 1 1 +/+ +/- -/+ +/+ +/+ +/- + 
27 F 30 3 1.3 PC - + + - - 2 3 2 +/+ +/- -/+ +/+ -/+ +/- + 
28 F 56 3 0.7 PC + - - - - 3 3 2 +/+ +/- -/+ +/+ -/+ +/- + 
29 F 18 3 1.5 PC + + + - - 3 3 2 +/+ +/- +/+ +/+ -/+ +/- + 
30 M 22 4 1.1 PC + - - - - 2 3 2 +/- +/- +/+ +/+ -/- +/- + 
31 F 22 6 0.8 PC - - - ND ND 1 2 2 +/+ +/- -/+ +/+ -/+ +/- + 
32 F 56 3 0.8 PC + - - ND ND 1 2 1 +/+ +/- -/+ +/+ -/+ +/+ + 
33 M 42 5 1.6 PC + + - - - 2 3 3 +/+ +/- -/+ +/+ -/+ +/- + 
34 F 38 7 3.0 PC + - + V600E - 1 1 2 +/+ +/- -/+ +/+ -/+ +/- + 
35 F 35 5 1.7 PC - - + V600E - 0 2 2 +/+ +/- -/+ +/+ -/+ +/- + 
36 M 11 9 6.0 PC + + + - - 1 2 0 +/+ +/- -/+ +/+ +/- +/- +* 
37 F 56 4 2.4 PC - + - - - 1 2 2 +/+ +/- -/+ +/+ -/+ +/- +* 
38 F 83 1 7.5 PC - + - V600E - 0 3 ND +/+ ND -/+ ND -/+ ND + 
39 F 18 4 3.6 PC + - + - - 2 2 1 +/+ +/- +/+ +/+ -/+ +/- + 
40 M 14 4 2.5 PC + + - - - 1 2 1 +/+ +/- +/+ +/+ -/- +/- + 
41 F 32 9 1.1 PC - + - V600E - 0 2 1 +/- +/- -/+ +/+ +/- +/- + 
42 F 56 10 7.5 PC + + - ND ND 1 2 1 +/+ +/- -/+ +/+ -/+ +/- + 
M-male, F-female, + presence, - absence, WC-well circumscribed, PC-poorly circumscribed, ND-not determined, C-expression 
in  the center of the tumour, P-expression in the tumour periphery, CT-expression in the control tissue, n- nuclear, c-
cytoplasmatic, LNM-lymph node metastases. * Cases with concurrent distant metastases. 
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Table 2. Clinico-pathological, molecular and immunohistochemical features of the FVPTC cases 
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1 F 32 22 2.0 WC - - + - - 2 0 2 +/+ +/- -/+ +/+ +/+ +/- - 
2 F 26 21 1.8 PC + - + V600E - 2 3 1 +/+ +/- -/+ +/+ +/+ +/+ - 
3 F 59 19 0.5 WC - - - - - 0 0 0 +/- +/- -/+ +/- +/- +/- - 
4 F 51 18 1.4 WC - - - - - 2 3 1 +/+ +/- +/+ +/+ +/+ +/- - 
5 F 36 18 0.5 PC - - - V600E - 1 1 1 +/+ +/- +/+ +/+ +/- +/- - 
6 F 39 15 1.0 WC + - - - Q61R 1 1 0 +/- +/- +/+ +/+ +/+ +/- - 
7 F 48 13 0.6 WC - - - - - 1 0 0 +/+ +/+ +/+ +/+ +/- +/- - 
8 F 33 20 0.2 PC - - - - - 3 3 0 +/+ +/+ +/+ +/+ +/+ +/- - 
9 F 30 15 0.5 WC - - - - - 1 1 0 +/+ +/+ -/+ +/+ +/- +/- - 
10 F 21 21 0.6 PC - - - - - 1 3 1 +/- +/- -/+ +/+ +/- +/- - 
11 F 37 18 0.3 PC - - + - - 1 1 1 +/- +/- -/+ +/+ +/- +/- - 
12 F 28 21 2.8 WC + - + - - 2 3 0 +/+ +/- -/+ +/+ +/+ +/+ - 
13 F 34 20 3.5 WC - - - - - 0 0 0 +/- +/- +/+ -/+ +/- +/- - 
14 M 61 22 4.0 WC - - + V600E - 2 2 2 +/+ +/- -/+ +/+ +/+ +/- - 
15 M 35 20 3.5 WC - - + - Q61R 1 1 1 +/+ +/- -/+ +/+ +/- +/- - 
16 F 50 20 2.5 WC - - - - - 1 1 1 +/- +/- -/+ -/+ +/- +/- - 
17 F 47 23 3.0 PC - - - - Q61R 2 3 0 +/- +/- +/+ +/+ +/+ +/- - 
18 F 49 14 3.0 WC + - + - - 2 1 1 +/+ +/+ -/+ +/+ +/+ +/- - 
19 F 35 21 1.7 PC + - + ND ND 3 3 1 +/+ +/- -/+ +/+ +/+ +/- - 
20 F 32 13 4.7 PC + - + - - 2 3 2 +/+ +/- +/+ +/+ +/+ +/- - 
21 F 52 13 2.5 WC + - - - - 1 1 2 +/- +/- +/+ +/+ +/- +/- - 
22 F 66 13 2.5 WC + - - - - 1 1 0 +/+ +/- +/+ +/+ +/- +/- - 
23 F 58 13 1.5 PC + - + V600E - 0 1 1 +/+ +/- -/+ +/+ +/+ +/- - 
24 F 54 10 1.8 PC + - + - - 1 2 1 +/+ +/+ -/+ +/+ +/+ +/- - 
25 M 45 20 4.0 WC - - - - - 1 1 1 +/- +/- -/+ +/+ +/- +/- - 
26 M 57 3 9.5 PC - + + - - 2 2 1 +/+ +/+ +/+ +/+ -/+ +/- + 
27 F 56 3 0.8 PC + - + - - 1 2 2 +/+ +/- +/+ +/+ -/- +/- + 
28 M 21 4 2.5 PC - + + - - 1 2 0 +/+ +/- -/+ +/+ -/+ +/- + 
29 F 20 14 1.0 PC + - + ND ND 0 1 2 +/- +/- -/+ +/+ -/- +/- + 
30 F 49 4 2.2 PC - - + - - 0 1 0 +/- +/- -/+ +/+ -/- +/- + 
31 F 43 10 4.0 PC + + + - - 0 1 0 +/- +/- -/+ +/+ -/- +/- + 
32 F 43 10 1.5 PC + + + V600E - 1 3 1 +/- +/- -/+ +/+ +/- +/- + 
33 M 63 7 1.8 PC - - + - - 1 3 1 +/- +/- -/+ +/+ -/+ +/- +* 
M-male, F-female, + presence, - absence, WC-well circumscribed, PC-poorly circumscribed, ND-not determined, C-expression in  the 
center of the tumour, P-expression in the tumour periphery, CT-expression in the control tissue,  n-nuclear, c-cytoplasmatic, LNM-
lymph node metastases. * Case with concurrent distant metastases. 
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Figure 1. TGF-beta expression at the center and at the periphery of the tumours. A- Well circumscribed BRAF mutated FVPTC-M 
with similar expression at the center and at the periphery (case 14, 200x); B – Well circumscribed wild type BRAF FVPTC-M with 
increased expression at the periphery (case12, 200x); C – Poorly circumscribed wild type BRAF FVPTC+M with lung metastases and 
increased expression at the periphery (case 33, 200x); D – Well circumscribed wild type BRAF FVPTC-M with decreased expression 
at the periphery (case18, 200x); E – Poorly circumscribed wild type BRAF CPTC+M with increased expression at the periphery 
(case33, 40x) and F – Poorly circumscribed BRAF mutated CPTC-M with increased expression at the periphery  (case17, 40x). 
Table3. Comparison between the immunohistochemical patterns of expression at the center and at 
the periphery of the tumours in well and poorly circumscribed PTCs (WCPTC and PCPTC). 
          Features 
TGF-beta intensity of expression 
(mean±sd) 
Smad4 nuclear 
expression (%) 
Smad7 nuclear 
expression (%) 
C-CT p P-C p C-CT p C-CT p 
W
CP
TC
 
 
 
VI 
   Present 
   Absent 
0.7±0.8 
0.4±0.7 
0.376 
0.0±0.6 
0.1±0.5 
0.641 
0.0 
70.6 
0.005 
100.0 
100.0 
>0.999 
PC
PT
C 
 
Multicentricity 
   Present 
   Absent 
0.1±0.9 
0.8±1.3 
0.053 0.7±0.6 
0.7±0.9 
0.935 26.1 
39.3 
0.381 47.8 
67.9 
0.167 
 
EE 
   Present 
   Absent 
0.3±0.9 
0.6±1.3 
0.398 1.0±0.7 
0.6±0.7 
0.048 26.7 
50.0 
0.746 40.0 
66.7 
0.119 
 
LNM 
   Present 
   Absent 
-0.2±0.9 
1.2±1.1 
<0.0001 0.9±0.6 
0.4±0.8 
0.017 30.8 
36.0 
0.771 19.2 
100.0 
<0.0001 
EE-extra-thyroid extension, VI – vascular invasion, C - expression in the center of the tumour, P – expression 
in the tumour periphery, CT- expression in the control tissue, LNM-lymph node metastases.  
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Figure 2. Expression of P-Smad2/3: A – Papillary areas of the center of the tumour (case 26 of CPTC group, 200x), B –Follicular 
areas of the center of the tumour (case 28 of FVPTC group, 400x) and C – Control tissue (case 2 of CPTC group, 400x). Expression 
of Smad4: D – Papillary areas of the center of the tumour (case 39 of CPTC group, 200x), E – Follicular areas of the center of the 
tumour (case 27 of FVPTC group, 200x) and F– Control tissue (case 27 of FVPTC group, 200x). Expression of Smad7: G – Papillary 
areas of the center of the tumour (case 9 of CPTC group, 400x), H – Follicular areas of the periphery of the tumour (case 1 of FVPTC 
group, 100x) and I – Control tissue (case 1 of FVPTC group, 200x).  
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Supplementary table. Comparison between the immunohistochemical patterns of expression at the center and at 
the periphery of the tumours and the PTC features in CPTC and FVPTC. 
 
Features 
TGF-beta intensity of expression 
(mean±sd) 
Overexpression or basal expression in the 
nucleus of tumour cells (%) 
C-CT p P-C p Smad4 p Smad7 p 
CP
TC
+F
V
PT
C 
Growth pattern    PC 
                            WC 
0.5±1.2 
0.4±0.7 0.839 
0.7±0.7 
0.1±0.5 0.0007 
33.3 
52.2 0.198 
58.8 
100.0 0.0001 
Multicentricity    Present 
                            Absent 
0.3±0.9 
0.6±1.2 0.217 
0.5±0.6 
0.5±0.8 0.630 
35.5 
41.8 0.635 
61.3 
79.1 0.120 
EE                       Present 
                            Absent 
0.3±0.9 
0.5±1.1 0.409 
1.0±0.7 
0.4±0.7 0.002 
26.7 
42.4 0.377 
40.0 
79.7 0.008 
VI                        Present 
                            Absent 
0.4±1.2 
0.5±1.0 0.719 
0.6±0.8 
0.4±0.7 0.259 
19.4 
53.5 0.004 
61.3 
79.1 0.120 
BRAF                 V600E 
                           Wild type 
0.2±1.2 
0.5±1.0 0.295 
0.8±0.8 
0.4±0.7 0.029 
27.8 
43.5 0.273 
88.9 
67.4 0.117 
RAS                    Q61R  
                            Wild type 
0.8±1.0 
0.5±1.0 0.532 
0.5±0.6 
0.5±0.7 0.965 
75.0 
36.7 0.291 
100.0 
71.7 0.566 
LNM                   Present 
                            Absent 
-0.2±0.9 
0.8±1.0 <0.0001 
0.9±0.6 
0.3±0.7 0.0001 
30.8 
43.8 0.325 
19.2 
100.0 <0.0001 
CP
TC
 
Growth pattern    PC 
                            WC 
0.6±1.2 
0.5±0.8 0.787 
0.6±0.7 
0.3±0.5 0.362 
35.3 
57.1 0.401 
58.8 
100.0 0.075 
Multicentricity    Present 
                            Absent 
0.4±0.7 
0.7±1.3 0.393 
0.5±0.5 
0.5±0.8 0.757 
35.3 
31.7 0.753 
47.1 
79.2 0.048 
EE                       Present 
                            Absent 
0.2±1.0 
0.7±1.2 0.233 
1.0±0.6 
0.3±0.7 0.006 
27.3 
43.3 0.478 
45.5 
73.3 0.140 
VI                        Present 
                            Absent 
0.8±1.4 
0.4±1.0 0.449 
0.5±0.9 
0.5±0.6 0.945 
25.0 
44.8 0.305 
58.3 
69.0 0.719 
BRAF                 V600E 
                           Wild type 
0.3±1.3 
0.6±1.1 0.562 
0.8±0.8 
0.4±0.6 0.048 
30.8 
40.0 0.719 
84.6 
55.0 0.132 
RAS                    Q61R  
                            Wild type 
0.0 
0.5±1.2 0.694 
1.0 
0.5±0.7 0.525 
100.0 
34.4 0.364 
100.0 
65.6 >0.999 
LNM                   Present 
                            Absent 
-0.2±0.9 
1.1±1.0 <0.0001 
0.8±0.6 
0.3±0.7 0.009 
33.3 
43.5 0.540 
22.2 
100.0 <0.0001 
FV
PT
C 
Growth pattern    PC 
                            WC 
0.4±1.2 
0.4±0.7 0.812 
0.9±0.7 
0.0±0.5 <0.0001 
29.4 
50.0 0.296 
58.8 
100.0 0.007 
Multicentricity    Present 
                            Absent 
0.2±1.2 
0.5±0.8 0.383 
0.6±0.7 
0.4±0.8 0.310 
35.7 
42.1 >0.999 
78.6 
78.9 >0.999 
EE                       Present 
                            Absent 
0.5±0.6 
0.4±1.0 0.824 
1.0±0.8 
0.4±0.7 0.148 
25.0 
41.4 >0.999 
25.0 
86.2 0.023 
VI                        Present 
                            Absent 
0.2±1.0 
0.6±1.0 0.224 
0.7±0.7 
0.2±0.7 0.077 
15.8 
71.4 0.003 
63.2 
100.0 0.013 
BRAF                 V600E 
                           Wild type 
0.0±0.7 
0.5±0.9 0.255 
0.8±0.8 
0.4±0.8 0.324 
20.0 
46.2 0.368 
100.0 
76.9 0.553 
RAS                    Q61R  
                            Wild type 
1.0±1.0 
0.4±0.9 0.239 
0.3±0.6 
0.5±0.8 0.720 
66.7 
39.3 0.558 
100.0 
78.6 >0.999 
LNM                   Present 
                            Absent 
0.1±1.0 
0.6±1.0 0.091 
1.1±0.6 
0.3±0.7 0.004 
25.0 
44.0 0.431 
12.5 
100.0 <0.0001 
EE – extra-thyroid extension, VI – vascular invasion, LNM – lymph node metastases, PC – poorly circumscribed, WC – well 
circumscribed, C - expression in the center of the tumour, P – expression in the tumour periphery, CT- expression in the control 
tissue. 
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